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ABSTRACT OF THE DISSERTATION
A Thesis on the Ontogeny and Functions of Macrophages in Pancreatic Ductal Adenocarcinoma
by
Yu Zhu
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, 2017
Professor David G. DeNardo, Chair

The immune system plays an essential role in protecting the host organisms against both
foreign invaders and self-attacks arisen within the host, such as tumors. Instead of promoting the
long-term fitness of the organism, the immune system is often suppressed or hijacked by tumor
cells to accelerate the progression of malignancies. Among the key drivers of immune
suppression, macrophages are one of the most abundant immune cells present in tumor tissues.
High levels of macrophage infiltration in the malignant tissues correlate with negative patient
outcome in many types of cancers, including pancreatic ductal adenocarcinoma (PDAC), one of
the most lethal malignancies in human beings. Therefore, attempts have been directed towards
targeting tumor-associated macrophages (TAMs) to improve the efficacy of cancer treatment.
We attempted to target TAM responses in murine PDAC models through inhibiting the
colony stimulating factor-1 receptor (CSF1R) signaling pathway. CSF1R signal blockade not
only depleted half of the TAMs within the tumor microenvironment, but also functionally
reprogrammed the remaining TAM compartment to support anti-tumor T cell responses. More
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importantly, CSF1R signal blockade sensitized the tumors to T cell checkpoint-based
immunotherapies, which failed to achieve clinical efficacy as monotherapies. These findings
revealed the potential benefits of targeting TAMs to improve treatment of PDAC patients.
However, TAM-targeting strategies have limitations. Optimal TAM-based therapeutic
intervention requires in-depth understanding of the sources that supply macrophages to
malignant tissues. Towards that end, we investigated the ontogeny of TAMs in murine PDAC
models, and identified both inflammatory monocytes and tissue-resident macrophages as sources
of TAMs. Unexpectedly, significant portions of pancreas-resident macrophages originate during
embryonic development at the yolk sac stage. These cells undergo significant local expansion
through in situ proliferation during tumor progression. While monocyte-derived TAMs play
more potent roles in tumor antigen presentation, embryonically derived TAMs exhibit profibrotic transcriptional profiles and ex vivo fibrotic activities, indicative of their role in producing
and remodeling extracellular matrix molecules. Collectively, these findings uncovered the
heterogeneity of TAM origin and functions, and could provide insights into therapeutically
targeting different TAM subsets based on the different pathological features of the PDAC
microenvironment.
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Chapter 1: Introduction
1.1 Overview of Pancreatic Cancer
1.1.1 Pancreas and Pancreatic Cancer
Pancreas, named after the Greek words pan (all) and kreas (flesh), is a multi-modular
glandular organ that lies in the retroperitoneal position of the abdomen behind the stomach. It is
composed of exocrine glands and endocrine glands tightly organized together. Through these
glands, pancreas functions as a critical component of both the digestive system and the endocrine
system.
The pancreas predominantly consists of exocrine glands that play a central role in the
conversion of consumed foodstuff into “usable fuels” for cells in the body. These exocrine
glands accomplish their functions through the secretion of digestive enzymes and bicarbonate
ions into the duodenum of the gastrointestinal tract. The key components of the exocrine
pancreas are acinar cells and duct cells. The acinus, named after the Latin term meaning “berry
in a cluster”, are specialized in synthesizing, storing, and secreting digestive enzymes. The major
types of pancreatic enzymes are proteolytic enzymes (involved in protein digestion), pancreatic
amylase and chitinase (involved in carbohydarate digestion), and pancreatic lipase (involved in
fat digestion). The three principal types of proteolytic enzymes are trypsinogen,
chymotrypsinogen, and procarboxypeptide. These enzymes are stored in granules in inactive
forms, known as zymogens, in the apical region of acinar cells. The apical surface of the cells
also line up as microvilli, within which a filamentous actin network is organized to mediate the
exocytosis of zymogen granules. Hormones and neurotransmitters that mediate the stimulation of
enzyme secretion are mediated through receptors located in the basolateral membranes of these
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cells. As the zymogens get secreted into the duodenum under hormonal regulation, they are
cleaved into active forms through a cascade of proteolytic events initiated by enzymes secreted
by cells lining the luminal border of the duodenum mucosa. Duct cells, on the other hand, are the
main producers of bicarbonate ions. These ions are secreted to the duodenum to neutralize the
acidity of chyme. This process creates a neutral or alkaline environment that is not only optimal
for pancreatic enzymatic functions, but also minimizes acidic damages to duodenum mucosa.
On the other hand, the endocrine gland of the pancreas tightly regulates the digestive
procedures by secreting hormones to control blood sugar levels. The major components are
clusters of endocrine cells known as the islets of Langerhans, which are dispersed throughout the
pancreas between the exocrine cells. Beta cells are the most abundant components of the islets of
Langerhans, whose function is to produce and secrete insulin that regulates the blood glucose
level. In addition, alpha cells, delta cells, PP cells are also integral part of the endocrine pancreas;
these cells produce glucagon, somastatin, and pancreatic polypeptide respectively.
Given the importance of the pancreas in both the exocrine and the endocrine system,
disorders in this organ can have significant impacts on the fitness of an entire organism.
Common diseases in the pancreas include pancreatitis, type 1 diabetes mellitus, and pancreatic
cancer. Pancreatitis is inflammation of the pancreas, which comes in acute or chronic forms.
Type 1 diabetes mellitus results from the destruction of beta cells in the pancreas islets of
Langerhans that leads to compromised abilities to produce insulin in response to high blood
sugar levels. Pancreatic cancers are malignant tumors that arise within the organ. A small subset
of pancreatic cancer arises from the pancreatic islet cells. These cancers are called pancreatic
neuroendocrine tumors (PNETs) and account for 5% of pancreatic cancer cases. PNETs produce
excessive amount of hormones, such as insulin, glucogan, and gastrin, which disrupt systemic
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homeostasis. The vast majority of pancreatic cancers arise within the exocrine portion of the
organ. These tumors are called pancreatic ductal adenocarcinoma (PDAC).
PDAC leads to a series of disruptions to organismal homeostasis. As a consequence of
the destruction of acinar cells, the normal release of digestive enzymes is compromised. This
leads to incomplete digestion of consumed molecules, malabsorption, diarrhea, and increased
intestinal infections, among other consequences. Subgroups of patients develop uneven textures
of fatty issue under the skin, due to the release of pancreatic enzymes that digest fat. Tumors in
exocrine pancreas can also cause destruction or dysfunction of beta cells, leading to abnormal
insulin secretion. Patients could experience irregular changes in blood sugar levels, or diabetes in
some cases. Among all the abnormalities, liver dysfunction is most frequently observed. This
often results from the obstruction of the bile duct by the tumor, which frequently localizes to the
head of the pancreas close to the bile duct. Normally, the liver secretes bilirubin as part of the
bile liquid, and bile goes through the bile duct into the intestine. As tumors block the bile duct,
excessive amount of bilirubin builds up in the liver, causing liver dysfunction. In addition, liver
is the most common site of metastasis. Presence of tumor cells in the liver will alter the tissue
function. Moreover, increasing amount of evidence in mouse models suggests that before the
dissemination of tumor cells, pre-metastatic livers undergo tissue remodeling and inflammation,
which may well likely disrupt their functions.
PDAC is one the most lethal forms of solid cancers. Five-year survival rate of PDAC
patients between 2006 and 2012 is 7.7% (https://seer.cancer.gov/). As a point of reference, the 5year survival rate for breast cancer, prostate cancer, colorectal cancer, and skin melanoma
patients are 89.7%, 98.9%, 65.1%, and 91.5% respectively. The median survival of pancreatic
cancer patients is less than 6 months. Pancreatic cancer is the 4th most common cause of cancer	
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related death, despite being the 12th most type of cancer in the United States. The dismal
prognosis of pancreatic cancers is partially due to its late diagnosis, as the majority of pancreatic
cancer patients have already developed metastasis at the time of diagnosis. Only 9% of patients
demonstrate a confinement of the tumor at the primary site. An additional 29% of patients have
cancers spread to regional lymph nodes. Even for the 9% patients with local diseases, the 5-year
survival rate is only 29.3%, which contrasts with 98.8% in localized breast cancer patients.
Currently established treatment protocols do not confer significant clinical benefits in
PDAC treatment. Treatment options are very limited. Surgical resection is applicable only in
patients with local diseases. Traditional chemotherapies and radiation therapies are not effective
in restraining tumor progression. Importantly, development of new treatment regimens has been
very slow and relatively ineffective in comparison to other tumors. For example, the death rate
for colorectal cancer patients was dropping by 2.7% annually between the years of 2004 and
2013, which is reflective of improved efficacies in targeted therapeutics; the rates for new
colorectal cases have been dropping by 3.2% annually in the past decade as well. In comparison,
the rates for new pancreatic cancer cases have been rising by 0.6% each year; five-year survival
rate has been fluctuating between 3% and 7% since 1975 without significant improvement, all of
which reflect a lack of improvement in treatment strategies. Newer treatment options, such as
immune checkpoint-based therapies in particular, do not improve patient outcomes as
monotherapies. In comparison, checkpoint immunotherapies demonstrated impressive response
rates in many types of cancer, including metastatic diseases. Development of treatment strategies
is desperately needed for PDAC patients, which requires in-depth understanding of pancreatic
cancer biology.
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PDAC is driven by mutations altering genetic programs that govern cellular activities.
Oncogenic mutation in Kras is a signature of PDAC genetics, and is present in 90-95% of the
patients. Kras is also the earliest detected mutations found in preneoplastic lesions, such as
pancreatic intraepithelial neoplasia (PanINs). Tumor suppressor genes are also very frequently
mutated, including p16/CDKN2A, p53, and SMAD4, whose functions are lost in approximately
90%, 75%, and 55% of cancers, respectively. Initial genetic abnormalities include not only
oncogenic mutations, but also shortening of chromosomal ends, i.e. telomeres. Epigenetic
regulation is also severely disrupted. Collectively, these cell autonomous aberrations lead to the
transformation of PDAC cell of origin, causing disease to initiate and progress.
PDAC is believed to arise from a series of non-invasive precursor lesions. These include
pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasm (IPMN),
and mucinous cyctic neoplasm (MCN). The risk of patients with these lesions to develop
pancreatic cancer is increased by more than 20-fold (Hruban et al., 2007). PanINs are the most
common among these lesions. They harbor many of the same genetic mutations found in PDAC,
even within the same patients. This adds strengths to the hypothesis that PDAC arises within
these pre-neoplastic lesions.
The precise nature of cellular origin of PDAC is still under debate. PDAC obtained its
name due to the ductal-like morphological features of the neoplastic cells. However, induction of
oncogenic mutations in mature pancreatic ductal epithelial cells does not efficiently induce
tumorigenesis. Instead, acinar cells are dramatically more prone to Kras-induced transformation
(Kopp et al., 2012), suggesting the possibility that the cell of origin for PDAC may be acinar
cells instead. Indeed, one of the early events during tumorigenesis in genetic mouse models is
acinar-to-ductal metaplasia (ADM), an event where acinar cells change their identity to ductal
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epithelial cells (Schmid, 2002). ADM is commonly observed in PanIN lesions, further
suggesting the possibility that acinar cells may be the tumor-initiating cells. In addition to acinar
cells and ductal epithelial cells, it also remains to be seen if there are pancreatic stem or
progenitor cells in adults that could be the “tumor-initiating cells” for PDAC. Understanding the
properties of cell of origin could help addressing sell-autonomous mechanisms by which PDAC
evades cancer surveillance and therapeutic targeting.
Genetic mutations not only drive a series of cellular activities that govern proliferation,
metabolism, and invasiveness, but also alter the way the cells shape their tissue
microenvironment to promote tumor progression through non-sell-autonomous mechanisms.
This will be discussed in the following sections.

1.1.2 Cancer and Cancer Microenvironment
Cancers are characterized by uncontrolled growth of transformed cells with genetic
mutations. While encompassing a wide range of diseases covering almost all mammalian organs,
cancers share some common features that help us understand the biology of these diseases. They
acquire several biological traits that confer advantages of tumor cells at the expense of host
fitness; these traits include self-sufficiency in growth signals, insensitivity to growth inhibition,
resistance to programmed cell death, and unlimited replication potential.
First, cancer cells are self sufficient in growth signals. Normal cells require exogenous
growth factors in order to exit a quiescent state and enter active proliferation. Such signals are
transduced usually through transmembrane receptors, which trigger downstream signaling
pathways that promote cell division. This way, cell division is orchestrated within a larger tissue
context that enables optimal organ functions by meeting various cellular needs within different
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tissue components. However, cancers generate their own growth signals independently of the
extracellular milieu. Their altered oncogenic program takes over the proliferative system, usually
making cells constitutively cycling, thereby reducing their dependence of stimulation from the
external microenvironment.
On the other hand, multiple inhibitory signals are usually able to maintain tissue
homeostasis by inhibiting cell proliferation within normal tissues. These signals could block the
potential of the cells to proliferate, or force cells out of active division cycles back into quiescent
states. Cancer cells can often disrupt the elements that mediate these negative regulatory
pathways. This mechanism, coupled with growth signal autonomy, contributes to the hyperproliferative features of neoplastic cells.
Fundamentally, tumor growth is the net result of cell production and cell loss. Abilities to
proliferate autonomously and to evade growth inhibition are not sufficient to drive tumor growth,
because higher rates of cell death can also compromise the ability of the cancer cell population to
expand. Programmed cell death, or apoptosis, is essential to the homeostasis of most
multicellular organisms due to its importance in eliminating unnecessary or harmful cells and
cellular debris. Normal cells have sensors to detect apoptosis-inducing signals, either from
intracellular molecules that indicate irreversible cellular damages, or from extracellular sources.
However, cancer cells often develop strategies that render them resistant to programmed cell
death, which is a hallmark of most types of tumors. They become resistant to apoptosis through
several mechanisms, such as upregulating pro-survival effector molecules, downregulating
“death receptors” that can engage apoptosis signals, and inhibiting the production or activities of
pro-apoptotic effector molecules, such as caspases.
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Moreover, cancer cells have limitless replication potential. Normal cells have limited life
span, i.e. they could undergo a finite number of cell division cycles before entering a crisis state
and undergo senescence. This phenomenon is termed “Hayflick limit”. Genetic mutations within
cancer cells often allow them to evade the Hayflick limit. Under homeostatic conditions, normal
cells undergo senescence often due to the shortening of telomeres, regions of repetitive
nucleotides at the end of a chromosome. Cancer cells often utilize alternative programs to
replicate their chromosome ends, such as upregulating telomerase that promotes telomere
lengthening, which could dramatically or indefinitely delay the occurrence of senescence.
While a lot of initial attention in cancer research was directed towards the transformed
cells themselves, in the past decade or so it has become well appreciated that tumors are not
malignant cells growing in isolation. Instead, cancer cells are embedded within a very complex
organ system that is composed of a wide range of cellular and non-cellular components.
Fibroblasts, blood vessels, neurons, and immune cells are examples of key cellular components
of the tumor microenvironment.
Fibroblasts are essential stromal components of the tumor microenvironment. One of the
major functions of fibroblasts is to produce, deposit, and remodel the extracellular matrix (ECM),
which in normal tissues ensures the integrity of the organ system. While cancer-associated
fibroblasts (CAFs) carry out the same functions as their normal fibroblast counterparts, their
activities are severely disrupted. Tumor cells recruit fibroblasts, promote fibroblast proliferation,
and induce an activated myofibroblast phenotype. Activated fibroblasts in tumors could produce
ECM molecules in an unrestrained fashion, therefore laying out excessive amount of ECM that
leads to tissue fibrosis. The growth of fibrous part of the tissue, or desmoplasia, was originally
considered to a protective mechanism by encapsulating, constraining, or even rejecting the tumor.
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However, accumulating amount of evidence suggests a strong correlation between desmoplasia,
tumor progression, and poor patient outcome. Excessive amount of ECM in the tissue activates
cancer cell proliferation, suppresses apoptosis, and promotes the invasion and metastasis of
tumor cells. Fibrosis also increases interstitial pressure and leads to poor tumor vascularization.
These altogether lead to hypoxia and pose a barrier to effective therapy delivery. In parallel to
ECM remodeling, CAFs can secrete a large amount of inflammatory cytokines that can further
modulate the local environment through the recruitment of immune cells and modulation of
tumor vasculature.
Blood vessels are also abundant in many kinds of tumor tissues. Despite their selfsufficiency in growth signals, tumor cells still require oxygen and nutrients to sustain their
metabolic activities. As tumors reach the size of a few millimeters in diameter, tumors would
experience low oxygen tension, known as hypoxia, and nutrient deprivation. To meet their
metabolic needs, tumor cells would trigger vasculature generation and remodeling, a series of
events collectively called “angiogenesis”. In addition to hypoxia, other events during tumor
expansion, such as the buildup of extracellular matrix and inflammation, are also able to trigger
angiogenesis. These players in the tumor stroma could trigger sprouting/branching of preexisting blood vessels by promoting the protrusion of a selected endothelial cell. Alternatively,
endothelial progenitor cells could be recruited from the circulation system to the tumor site,
differentiate to new endothelial cells that line up blood vessels; this process is called
“vasculogenesis”. Moreover, a subset of cancer cells could differentiate and adopt an endothelial
cell-like phenotype and form bona fide blood vessels. Tumor cells can also line up blood vessels
by mimicking, rather than differentiating into, endothelial cells. Tumor neo-vasculature is often
morphologically and functionally distinct from normal vasculature. They appear disorganized
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and tortuous. They are more leaky than normal blood vessels. Endothelial cells can demonstrate
abnormal cell morphologies, such as aneuploidy, multiple chromosomes, and multi-centrosomes.
The generation and remodeling of vasculature in the tumor not only allows the transport of
oxygen and nutrients, but also produces or allows the supply of growth factors that further
enhance tumor cell proliferation.
Nerves are also important components of the tumor stroma. Cancer cells can attract
nearby nerves through the secretion of axon guiding molecules, thereby increasing the number
and extensions of axons. Such process is called “axonogenesis”, which is very similar to
angiogenesis. Adrenergic signals from sympathetic nerve cells can directly stimulate cancer cells,
rendering resistance to apoptosis, promoting invasive potential and migratory capacity. Neural
activation of tumor cells can also lead to increased secretion of angiogenesis promoting
cytokines. Cholinergic signals from parasympathetic nerve cells have also been shown to
promote “cancer stem cell” properties. In addition, the nervous system can also act on other
stromal components in the tumor, including vasculature and immune cells.
It is important to note that reorganization or disruption of the tissue microenvironment
not only is a consequence of tumor development, but also occurs prior to malignant
transformation and contributes to tumorigenesis. For example, while tumor cells secrete a wide
range of inflammatory cytokines to recruit immune infiltration, chronic inflammation during
premalignant stages can cause cell damages and facilitates tumorigenesis. Similarly, while tumor
cells activate fibroblasts to promote fibrosis and inflammation, aberrant fibroblast activation can
secrete factors that promote inflammation and facilitate cancer cell transformation. In addition,
human beings that have chronic depression or have suffered traumatic life events are more likely
to develop cancers, which suggests the possibility that neural deregulation may promote cancer
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transformation. Indeed, adrenergic signaling in tumor stroma was shown to be essential for
tumor initiation in murine transplantation models.
Taken together, tumors are malignant cells with aberrantly regulated proliferative
programs that reside within a complex tissue microenvironment. Cancer cells remodel various
aspects of the tissue environment, which in turn facilitate tumor progression. This dissertation is
focused on understanding how tumors, in particular pancreatic ductal adenocarcinoma (PDAC),
interact with the immune components of the stroma.

1.2 Overview of the Immune System
1.2.1 Overview of the Innate Immune System
The immune system plays an essential role in both defending organisms against pathogen
invasion and protecting against abnormalities that rise within the host. It is a tightly regulated
system composed of several lines of defense.
Anatomical barriers form the first line of defense that includes the skin, tears, and mucus.
These are the initial sites of encounter as pathogens attempt to enter the body. Physical,
biological, and chemical components exist in these sites to maintain barrier integrative in order
to minimize the penetrance of pathogens into host organisms. For example, epidermal cells in the
skin form a waterproof and airtight keratinized layer that is impermeable to most foreign
organisms. Sweat glands in the skin also secrete bactericidal peptides such as dermicin to kill
microbes. Cells in sebaceous glands also produce oily substances such as sebum to cover hair
and the keratinized layer, preventing the cracking and drying of the barrier. Similarly, in other
barriers, such as the digestive tract and the respiratory system, different components also
function to deter ingested or inhaled pathogens.
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External barriers are not perfect. As pathogens pass through and penetrate into the host
organisms, innate immune system constitutes the second line of defense. The major functions of
the innate immune cells are to (1) quickly recognize, contain, inactivate, and eliminate invaders,
(2) remove debris, and (3) prepare the body for subsequent events that bring the organisms back
to homeostatic conditions. Innate immunity can be further classified into cellular immune
responses and humoral immunity, which are immune responses mediated by macromolecules
present in the humors, or body fluid.
The major cellular components of the innate immunity are phagocytic cells, including
macrophages, neutrophils, and dendritic cells. They recognize foreign materials by binding to
pattern-associated molecular patterns (PAMP), which are molecules associated with pathogens
but not host cells. Examples of PAMPs include lipopolysaccharides, double-stranded RNA, and
unmethylated CpG motifs, all of which signal to the phagocytes the presence of “non-self”. In
addition, phagocytes can detect pathogens by sensing damage-associated molecular patterns
(DAMP), which are host molecules expressed or released during inflammatory responses.
Examples of DAMPs include heat shock proteins, extracellular matrix (ECM) proteins, DNA,
and ATP, which signal cellular damages or cell death caused by infectious or non-infectious
inflammation. PAMPs and DAMPs are recognized by pattern recognition receptors (PRRs),
whose engagement on phagocytes lead to the activation of these cells. Upon activation,
phagocytes could engulf pathogens or pathogen-infected cells, and subsequently eliminate
pathogens through several mechanisms. For example, phagocytes would increase oxygen
consumption upon phagocytosis, causing a respiratory burst, which produces reactive oxygen
species that could effectively kill the microbes. Alternatively, phagocytes could eliminate
pathogens through lysozymes, proteases, lactoferrins, among others, to destroy the key
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components of the microbes. In addition, phagocytes could release chemicals such as nitric oxide
to eliminate microbes in adjacent locations. Moreover, certain types of phagocytes, such as
macrophages and dendritic cells, could transport specific fragments of the engulfed antigens to
their cell surface, and present these molecules to lymphocytes, a key component of the adaptive
immune system that could initiate specific defense reactions against pathogens of interest.
In addition to phagocytosis, certain innate immune cells could kill pathogens through
other mechanisms. A class of innate immune cells called granulocytes (such as neutrophils,
eosinophils, and basophils) and mast cells could undergo a process called degranulation, during
which antimicrobial and cytotoxic molecules, such as myeloperoxidase, cathepsins, and
histamines, are released to the extracellular space to combat infection. Neutrophils are also
known for their abilities to secrete neutrophil extracellular traps (NETs), fibers composed of
chromatin and proteases, that participate in the trapping and killing pathogens.
A third kind of innate immune cells are natural killer (NK) cells. Instead of directly
killing the invading pathogens, NK cells target a type of infected cells that lack major
histocompatibility complex (MHC) I, whose expression on the cell surface labels the cell as
“self”. NK cells kill by (1) natural killing, (2) antibody-dependent cellular cytotoxicity, (3)
redirected lysis, and (4) lectin facilitated killing. They can also produce cytokines to amplify the
immune responses by recruiting and/or activating other leukocytes.
In addition, a recently discovered class of immune cells, called innate lymphoid cells
(ILCs), also constitute another key cellular component of the innate immune system (Klose and
Artis, 2016). Unlike many other innate immune cells, ILCs lack pattern recognition receptors
(Robinette et al., 2015). Instead, they sense cytokines and inflammatory mediators secreted by
parenchymal cells or myeloid cells. Upon engagement, ILCs promote immune responses by
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secreting soluble factors, such as classic T helper cytokines including IFNγ and TNF for type 1
ILCs (ILC1s), IL-5, IL-9, and IL-13 for ILC2s, and IL-17, IL-22, and GM-CSF for ILC3s. In
addition, some previously unknown “ILC-specific” effector molecules are also secreted, such as
amphiregulin (Monticelli et al., 2011; Robinette et al., 2015) and methionine-enkaphalin
(Brestoff et al., 2015), which mediate epithelial cell repair and adipocyte beiging respectively.
In addition to the cellular components discussed above, the complement system is also a
key component of innate immunity that, together with B lymphocytes of the adaptive immunity,
forms the humoral immune system (Dunkelberger and Song, 2010). It is composed of more than
30 proteins circulating in the plasma that initiate a sequence of events on the surface of the
pathogen to help eliminate the infection. The complement system can be engaged either upon
identification of pathogen surface molecules, such as certain polysaccharides, or upon
recognition of antibodies that bind to the pathogen surface. Upon activation, protein components
will initiate a cascade of proteolytic cascades that eventually lead to the production of active
opsonin and assembly of membrane attack complexes (MACs). Opsonins coat the pathogen
surface, allowing either the phagocytosis of pathogens or membrane permeabilization by MACs
that kill the invading bacteria. During the proteolytic events, a series of proinflammatory
mediators are produced, leading to the amplification of immune responses by recruiting other
effector cells.
Collectively, phagocytes, granulocytes, natural killer cells, and innate lymphoid cells
altogether build up the cellular arm of the innate immune system. These innate immune cells,
along with humoral components such as the complement system, initiate immediate responses
against invading pathogens in order to maintain the fitness of host organisms.
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The innate immune system is evolutionarily conserved from vertebrate animals to plants.
It relies on germline-encoded receptors to recognize microbes bearing conserved surface
molecules that are shared by many organisms. Therefore, the innate immune system does not
require an extended phase to initiate responses and could elicit rapid responses to combat
pathogens. However, the range of pathogens that can be recognized by the innate immune system
is limited, due to the restricted diversity of recognition machinery. Moreover, the efficiency of
the innate immune system to eliminate recognized pathogens is constrained because microbial
organisms could evolve more rapidly than the infected hosts and develop strategies to evade
these defense mechanisms. For example, many bacteria adopted strategies that allow them to
hide pattern recognition molecules from being recognized by the immune system. To address the
limitations of the innate immune system, vertebrates developed the adaptive immunity with
higher levels of specificity and diversity.

1.2.2 Overview of the Adaptive Immune Responses
Similar to the innate immune system, the adaptive immune system is also composed of
both cellular and humoral immunity. The major components of the cellular arm of adaptive
immunity are T lymphocytes, whereas B lymphocytes are the central players of the humoral
immune system. “T” designates “thymus”, named so based on the observation that T cells
undergo the maturation process in the thymus. “B” stands for “bursa of Fabricius”, the site of B
cells production in birds. Mammals do not have the organs equivalent of bursa of Fabricius;
instead, B cells in mammals are produced in the bone marrow.
Unlike innate immune cells that can recognize a wide range of molecules commonly
expressed by multiple pathogens, T and B lymphocytes recognize epitopes that are usually
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unique to specific antigens. Both types of lymphocytes rely on their unique membrane receptors,
termed T cell receptors (TCRs) and B cell receptors (BCRs) in the respective cell types, for this
recognition. T cell receptors in most T cells are heterodimers of two chains designated alpha (α)
and beta (β). Though a small fraction of T cells express TCR composed of gamma (γ) and delta
(δ) chains. B cells express BCRs that are composed of cell surface-bound antibodies and signal
transduction moieties. Each antibody is a Y-shaped molecule consisting of two identical
polypeptide heavy chains and two identical light chains. Each heavy chain or light chain contains
constant regions and variable regions. To generate TCRs and BCRs, a series of genetic
recombination, known as V(D)J recombination, occurs in developing T cells and B cells
respectively. The process involves somatic recombination events that occur at the locus of TCR
genes and immunoglobulin genes, generating highly diverse products of TCRs and
immunoglobulins that specifically recognize certain unique amino acid sequences. Therefore,
both T and B cell responses are highly antigen-specific, which is one of the hallmarks of the
adaptive immune system.
T cells are present in several categories and accomplish their defense responses through
different mechanisms. Broadly speaking, T cells can be classified into effector T cells, regulatory
T cells, and memory T cells. Effector T cells are activated cells that are relatively short-lived.
These cells are responsible for eliminating pathogens upon activation by the innate immune
responses. Memory T cells do not immediately become active, even though they are usually
produced at the same time as effector T cells. Instead, they are long-lived, persist after the
resolution of inflammation, and could mount quicker immune responses upon secondary
exposure to the same antigen. On the other hand, the role of regulatory T cells (Tregs) is to
modulate and prevent excessive immune responses. Tregs ensure the balance between effective
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immunity that damages the invaders and immunopathology that damages the host, keeping other
immune cells at bay so that effectors do not cause unnecessary tissue damages as they control or
eliminate infections.
T cells activation is a tightly regulated process that requires multiple signals integrated
together. First signal is initiated when TCRs recognize pathogen-specific peptides that are
presented by MHC molecules on antigen presenting cells. It is important to note that T cells do
not recognize free-floating antigens, but can only recognize peptide-MHC (pMHC) complex.
This TCR-pMHC binding requires co-receptors that include at least CD3 along with either CD4
or CD8. In addition, T cell activation requires a second “co-stimulatory” signal, without which T
cells would be rendered “anergic”, or non-functional, by TCR-pMHC engagement alone. One of
the best-characterized co-stimulatory molecules on T cells is CD28, which binds to CD80 or
CD86 on antigen presenting cells and then triggers downstream signaling pathways to enable T
cell expansion and differentiation. To ensure a proper T cell differentiation program that caters to
the need of the pathogenic challenge, a third signal is triggered by inflammatory cytokines within
the local environment. The cytokine milieu not only has a key influence on the kind of T cells
being produced, but also determines if the first two signals lead to tolerance, effector T cell
activities, or immune memory. The three signals are highly integrated to ensure proper T cell
activation.
Effector T cells are predominantly composed of cytotoxic T cells and helper T cells.
While other less abundant populations, including natural killer T cells, gamma delta T cells, and
mucosal associated invariant T cells, are also subclasses of effector T cells. Cytotoxic T cells
express CD8 molecules on their cell surface; they are activated by antigen presenting cells that
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present antigens on surface MHC class I molecules (MHCI). Helper T cells express CD4 on their
surface and are activated by peptides on MHC class II molecules (MHCII).
Cytotoxic T cells, or CD8+ T cells, kill pathogen-infected cells mainly through two
mechanisms. When confronting infected cells, CD8+ T cells can release a series of cytotoxic
granules including perforin, granzymes, and granulysin. Perforin and granulysin could form
pores on the target cells, allowing granzymes, a family of serine proteases, to enter and initiate a
cascade of apoptotic events. CD8+ T cells can also upregulate Fas ligand upon encounter with
and recognition of infected cells. Fas ligand can bind to Fas molecule of the target cells and
initiate receptor-mediated extrinsic apoptosis pathways.
T helper cells, or CD4+ T cells, do not directly kill pathogen-infected cells. Instead, their
functions are mainly carried out through the release of cytokines that help the activities of other
immune cells. These include mediating class switching in B cells, activating cytotoxic T cells,
and modulating phagocytosis in macrophages. The type of cytokine milieu has a direct influence
on what type of T helper cells are generated during CD4 activation, and different types of CD4+
T cells are able to produce different kinds of cytokines to respond to the challenges brought forth
by various pathogens. The major classes of T helper cells are Th1 and Th2 cells. Th1 cells are
mainly responsible for combatting against intracellular bacteria and protozoa. They are activated
by IL-12 and IL-2 that trigger downstream signaling that converge to transcription factors
STAT4 and T-bet. Th1 cells predominantly produce IFN-γ, which triggers macrophage
phagocytosis and activates iNOS to produce bactericidal radicals. Th1 cells are also potent at
activating CD8+ T cells to produce cytotoxic molecules to kill compromised cells. Th2 cells are
responsible for defending against extracellular parasites, including helminthes. They are
activated by IL-4, through STAT6 and GATA3, and produce IL-4, IL-5, IL-9, and IL-13 as
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effector cytokines. These effectors activate eosinophils, basophils, and mast cells to attack
parasites. IL-4 also stimulates B cell to produce immunoglobulin E (IgE) that further stimulates
mast cells to produce inflammatory mediators. IL-4 also acts in an autocrine fashion to enhance
Th2 responses. Th2 cells can also produce IL-10 that suppresses Th1 differentiation. In addition
to Th1 and Th2 cells that make up the majority of the CD4+ effector T cell populations, there are
also other T helper cell types. Th17 cells play a role in clearing extracellular bacteria and fungi
mostly at the skin and mucosal surfaces. Th22 cells are involved in wound healing responses in
the skin by acting on keratinocytes, myofibroblasts, and epithelial cells. Folicular helper T cells
(TFH) regulate the development of antigen-specific B cells in secondary lymphoid organs. There
are also other less well-established helper T cells, such as Th9 cells, which may constitute their
own distinct lineages.
Responses by effector T cells are tightly regulated to ensure that the system could
discriminate between self and non-self and that the adaptive immune responses do not overshoot
to cause autoimmunity. Regulatory T cells, or Tregs, play a critical role in regulating effector T
cell activities. These cells are characterized by high level of IL-2 receptor and glucocorticoidinduced TNFR family related gene (GITR) on their surface, and unique expression of the
transcription factor FoxP3. Tregs regulate or suppress effector T cells (and potentially other
immune cells) through several possible mechanisms. First, Tregs have high levels of IL-2 receptor
expression on their cell surface, which could serve as a reservoir that deprives the other T cells of
this activating cytokine. In addition, Tregs are potent producers of transforming growth factor
beta (TGFβ) and IL-10, which could either suppress the abilities of antigen presenting cells to
activate effector T cells or downregulate T cell effector activities. Cell-cell contact-based
mechanisms could also mediate Treg-based immune suppression.
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In addition to effector T cells and regulatory T cells, a third class of T cells constitute
memory T cells, which are long lived T cells generated during primary immune responses and
respond to cognate antigens during secondary encounters. Memory is the second hallmark of the
adaptive immune system.
The principal function of B cells is to generate antibodies against soluble antigens. Unlike
T cells that can only recognize peptides presented on MHC molecule, antibodies can recognize
free-floating antigens. Antibody functions are several fold: first, antibodies can block and
neutralize parts of the pathogen surface, rending the pathogen incapable of effective attacks.
Second, antibodies can perform agglutination, a process in which invading cells are glued into
clumps that are processed for phagocytosis. Similarly, antibodies can precipitate serum-soluble
antigens out of solution, rendering them recognizable by phagocyte. In addition, antibodies that
bind to foreign microbes can activate the complement system, allowing the formation of
membrane attack complexes that lead to the lysis of the invaders. In a similar process, antibodybound pathogen can also be recognized by cellular immune components, such as NK cells.
Like T cells, B cells are activated by several signals. First signal comes when BCRs bind
to antigens. B cells then endocytose the antigen along with BCR, process the antigen that is then
presented onto surface MHCII molecules, which subsequently act as antigen presenting cells and
interact with cognate CD4+ T cells. These T cells would then provide the second signal to B
cells for further activation. Upon activation, B cells would proliferate and form germinal centers
in secondary lymphoid organs. In the germinal centers, activated B cells would differentiate into
antibody-secreting plasma cells and memory B cells. Similar to the T cell counterpart, plasma
cells would serve as immune effectors and carry out their functions by secreting antibodies,
while memory B cells would persist for future infections.
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In conclusion, T and B lymphocytes constitute the cellular and humoral aspects of the
adaptive immune system. With unique features of antigen specificity and memory, adaptive
immunity cooperates with innate immune players to form a tightly regulated defense system.
This system not only plays a key role in defending the host organisms against foreign pathogens,
but also protects the organisms against attacks arisen within the “self”. Cancer is a classical
example of such self-attacks.

1.2.3 Immune Responses in Cancer
The presence of immune cells in cancer was observed a long time ago, with the earliest
known report by Rudolf Virchow in the 19th century. Ever since, the immune system was
postulated to play a role in protecting organisms against malignant diseases. In the last two
decades, these postulations were corroborated by experimental evidence in mouse models, as
mice deficient in various aspects of the immune system are more prone to develop carcinogen- or
oncogene-induced tumors or even spontaneous tumors. These pieces of evidence led to the
generation of the “immune surveillance” theory, which proposes the protective role of the
immune system. Indeed, mice deficient in the generation of functional T and B lymphocytes
have higher chances of developing tumors upon induction (Shankaran et al., 2001). This is
exacerbated when natural killer cells are also depleted, suggesting the involvement of innate
immunity in cancer surveillance (O'Sullivan et al., 2012). Deficiencies of certain molecules in
myeloid cells, as exemplified in CD80 and CD86 double knockout mice that lack co-stimulatory
signals, are also more susceptible to carcinogen-induced sarcoma development (Loser et al.,
2005), which further illustrates an integrated defense mechanism that involves interactions
between innate and adaptive immune components. Cytokines likely play an important role
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during this coordination, especially type I cytokines. Mice lack interferons (Dunn et al., 2005;
Kaplan et al., 1998), interferon receptors (Kaplan et al., 1998), and certain type 1 interleukins,
such as interleukin (IL)-12 and IL-23 (Langowski et al., 2006; Liu et al., 2004), are all prone to
tumorigenesis. While being supported by a large number of mouse studies, the surveillance
theory adopts a one-dimensional and static view of the role of the immune system. Later
evidence suggested that the interactions between cancer and the immune system are rather
dynamic. Therefore, a newer “immune editing” theory was developed, which adds the dimension
that the immune system also sculpts the tumors. The immunoediting process is composed of
three distinct phases: elimination, equilibrium, and escape. The elimination phase is evidenced
by the experimental approaches that corroborate the “surveillance” mechanisms. Equilibrium
phase occurs when the immune system fails to eliminate cancer cells but is able to suppress their
outgrowth. This phase was mostly inferred from clinical observations, but later supported by a
number of experimental animal models. The first piece of evidence came from a lose dose
carcinogen treatment, where the majority of the mice do not develop tumors. However, if T cells
were depleted after a prolonged tumor-free period after carcinogen treatment, mice would
develop malignant diseases (Koebel et al., 2007). This suggests the capabilities of the immune
system to suppress the outgrowth of tumor cells for an extended period of time. This equilibrium
regulates both the primary tumor development and the occurrence of metastasis (Eyles et al.,
2010). Unlike the elimination phase, in which both the innate and adaptive immune systems are
important, equilibrium seems to rely mostly on adaptive immunity, which likely contains tumor
cells in an antigen-specific manner. As tumors exit the equilibrium phase, they would escape
immune regulation. Cancer patients present diseases that are in the “escape” phase.
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Tumors escape immune attacks through both the suppression of anti-tumor immunity and
the augmentation of pro-tumor immune responses. To negatively suppress inhibition by the
immune system, tumor cells can suppress dendritic cell activities through the secretion of a series
of cytokines and factors, such as adenosine (Novitskiy et al., 2008) and prostaglandin E2 (Lee et
al., 2002). They can also evolve strategies that evade the recognition or phagocytosis by
dendritic cells or macrophages. For example, multiple types of tumors have upregulated level of
CD47, a molecule that delivers “do-not-eat-me” signals to phagocytes. These disruptions in
myeloid cell activities lead to the prevention of antigen processing. As a consequence, antigen
presentation becomes compromised in secondary lymphoid tissues. Therefore, anti-tumor T cells
do not become activated or traffic to the tumor site. Even when confronting the activated and
infiltrated T cells, tumor cells also have strategies to avoid attacks. They could downregulate
MHCI molecules on their cell surface or alter their own antigen presentation machinery, both of
which help hiding tumor antigens from T cell recognition. They can suppress lymphocyte
activities through paracrine mechanisms, such as the upregulation of PD-L1 or shedding of
NKG2D ligands, which renders anergy and suppress T cell/NK cell effector functions (Nausch
and Cerwenka, 2008).
On the other hand, tumors often augment the myeloid compartment and the inhibitory
arm of the adaptive immune system to allow immune escape. One of the hallmarks of many
types of cancers is the extensive infiltration of immune cells. These include cells from both the
myeloid lineage (such as macrophages, neutrophils, immature dendritic cells (DCs)) and the
lymphoid lineages (such as regulatory T cells). Myeloid cells, including macrophages and
neutrophils, have plastic phenotypes. Even though they could be equipped with cytotoxicity and
anti-tumor activities, they are polarized in the tumor microenvironment to promote cancer
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progression through various mechanisms. They do so by secreting growth factors that sustain the
proliferation and survival of cancer cells, promoting angiogenesis, and metabolically inhibiting
anti-tumor adaptive immune responses. Similarly, the dendritic cell compartment is
reprogrammed. Conventional dendritic cells that are able to functionally activate CD8+ T cells
are scarce in many tumors, due to a combination of defects in DC recruitment and tumor-induced
DC apoptosis (Ma et al., 2013). Instead, tumors could recruit DCs with immature phenotype
characterized by low MHC molecules and co-stimulatory molecules, such as CD80 and CD86,
and inefficient motility (Kim et al., 2006; Mahnke et al., 2002; Palucka and Banchereau, 2012).
Activation by these DCs lead to tolerogenic T cell activation, as evidenced by the induction of
regulatory T cell responses (Jonuleit et al., 2000) instead of antigenic activation. Cancers often
upregulate the infiltration of regulatory T cells to suppress the functions of CD8+ cytotoxic and
Th1 T cells, thereby rendering the tumor cells tolerated by the immune system.
One of the corollaries of the immunoediting theory is that the immune system only
attempts to sequester tumor initiation. While this may truly be the function of effector CD4+ and
CD8+ T cells, other components of the immune system could promote the growth of nascent
tumor cells instead. This is evidenced the demonstration of chronic inflammation as a significant
risk factor for cancer (Hussain and Harris, 2007). During inflammation, tissue-infiltrating
leukocytes could produce a large number of inflammatory mediators, such as reactive oxygen
species, reactive nitrogen species, and cytokines, which could disrupt the environment that is
suitable for the homeostasis of parenchymal cells. Possible disruptions include tissue damage,
fibrosis, angiogenesis, and hypoxia (Mantovani et al., 2008; Multhoff et al., 2011). Inflammatory
mediators, along with tissue disruptions caused by these factors, could promote genome
instabilities and genetic alterations that lead to the initiation of tumorigenesis (Grivennikov and
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Karin, 2010). In addition, epigenetic changes could be induced in premalignant cells. Stress
could also disrupt proteostasis, by stimulating the over-production of heat shock proteins for
example, that overwhelms the healthy cellular activities. While surveillance mechanisms exist to
eliminate transforming cells, inflammation could supply pro-survival factors and nutrients that
even overcome transformation-induced stress, such as oncogene-induced senescence. Moreover,
a number of inflammatory cytokines could promote epithelial-to-mesenchymal transition, which
upregulates the invasiveness and mobility of transformed or transforming cells.
In conclusion, the interactions between the tumor and the immune system are dynamic
and complex. The immune system could restrain and eliminate nascent tumor cells, while
chronic inflammation could participate in the promotion of tumorigenesis. Established tumors
could evade immune recognition, while the immune system could also be utilized to target tumor
cells. In order to better target the immune system to treat cancer, it is imperative to have a better
understanding of how the immune system could function and how these processes could go awry
in cancer-bearing organisms. This dissertation focuses on one of the most abundant innate
immune cells in many types of tumors, macrophages.

1.3 Overview of Macrophage Biology
1.3.1 Macrophages in Pathogen Infection
Macrophages were originally discovered by Ellie Metchnikoff. Named after Greek words
“makro” (large) and “phagein” (eat), these cells are known for their abilities to engulf and digest
pathogens, cellular debris, and infected or transformed host cells. As a key component of the
innate immune system, macrophages play important roles in the clearance of pathogen during
infections by bacteria, viruses, fungi, and parasites.
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Macrophages are present in almost all mammalian organs, including the sites that are
susceptible to the initial attacks of invading pathogen. Because of their locations, tissue resident
macrophages are often a key player in the initial phase of the combat against pathogens.
However, tissue resident macrophages alone may not be sufficient to mount a sufficient defense.
To ensure a sufficient number of defense effector cells, affected tissues would also send signals
to recruit more inflammatory monocytes from circulation that differentiate into macrophages
upon infiltration into affected tissues. In most infectious diseases, recruitment provides the major
source of macrophages. The C-C motif chemokine ligand 2 (CCL2) and CCL2 receptor 2
(CCR2) signaling pathway is essential for monocyte recruitment (Pierce et al., 1990). Other
cytokines and chemokines also demonstrated monocyte-attracting activities. These include
macrophage colony-stimulating factor (M-CSF, also known as CSF-1), granulocyte-macrophage
colony-stimulating factor (GM-CSF, or CSF-2), CCL3, CCL5, CCL8, vascular endothelial
growth factor (VEGF), placental growth factor (PlGF), and CXC-motif ligand-12 (CXCL12)
(Coffelt et al., 2009), although their relevance in vivo is less well established. Deficiency in
monocyte recruitment compromises immune responses against bacteria including Listeria
monocytogenes, Toxoplasma gondii, and Mycobacterium tuberculosis, viruses including
influenza, and fungi infections (Serbina et al., 2008; Shi and Pamer, 2011; Zhang and Wang,
2014). On the contrary, during helminth infections, macrophages undergo proliferation at the site
of infection independently of blood recruitment (Jenkins et al., 2011). However, in certain
helminth infection models, such as Schistosoma mansoni infection, in situ proliferation occurs in
monocyte-derived macrophages instead of tissue resident macrophages (Nascimento et al., 2014).
These data suggest that recruitment and local proliferation may occur sequentially or
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simultaneously to supply sufficient quantities of macrophages for defense against foreign
pathogens.
At the infection site, macrophages become activated and contribute to the clearance of
pathogens by a range of effector mechanisms. To recognize pathogens or pathogen-affected cells,
macrophages are equipped with pattern recognition receptors (PRRs) to recognize pathogenassociated molecular patterns and damage-associated molecular patterns. These PRRs include
membrane-bound toll-like receptors (TLRs) and C-type lectin receptors (CLR2), and
cytoplasmic NOD (nucleotide-binding oligomerization domain)-like receptors (NLRs) and RIG
(retinoid acid-inducible gene)-I-like receptors (RLRs) (Takeuchi and Akira, 2010). Altogether,
these pattern recognition receptors recognize molecules associated with microbes (such as
lipopolysaccharides, flagellin, and single-stranded or double-stranded RNA), and molecules
associated with cellular damages that represent the “danger” signal (such as extracellular
adenosine triphosphate (ATP) and high motility group box 1 protein, both of which are released
by injured cells). Upon the engagement of PPRs, the intracellular signaling pathways triggered
downstream will lead to transcriptional activation of inflammatory mediator genes followed by
the production and secretion of these factors. In addition to PRRs, macrophages are also armed
with a wide range of receptors for immunomodulatory cytokines. Engagement of different
cytokine receptors could lead to differential activation of macrophages (Mosser and Edwards,
2008). An over-simplistic classification categorizes macrophage activation status into M1 and
M2, corresponding to classically activated macrophages and alternatively activated macrophages.
This nomenclature was proposed to parallel the classification of T cell differentiation into Th1
and Th2 cells. Cytokines such as interferon gamma (IFNγ) and tumor-necrosis factor (TNF)
activate M1 macrophages, which then produce pro-inflammatory cytokines, promote Th1
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responses, and cause extracellular matrix (ECM) destruction and apoptosis. Exposure to
cytokines such as interleukin (IL)-4 leads to the activation of M2 macrophages, which promote
Th2 responses, ECM construction, and wound healing. However, this simplistic scheme
underestimates the variety of cytokines available in the tissue environment; macrophages are
usually exposed to a large number of factors of different flavors at the infection sites. Indeed,
increasing amount of data demonstrate a large spectrum of activation status that fits between and
beyond the M1 and M2 dichotomy (Murray et al., 2014; Xue et al., 2014), which allows
macrophages to carry out different functions tailored to the needs of specific pathogenic
challenges.
To clear pathogens, activated macrophages perform phagocytosis, engulfing not only
microbes but also microbe-infected cells. As discussed earlier, macrophages could initiate a
series of microbicidal activities following phagocytosis, such as producing ROS during
respiratory burst and synthesizing proteolytic enzymes to digest microbial components. Other
than killing engulfed microbes, macrophages could kill extracellular pathogens or infected cells
in proximity through the secretion of metabolites that have microbicidal activities. These
metabolites include indoleamine-pyrrole 2,3 dioxygenase (IDO) and nitric oxide. Macrophages
could also upregulate apoptosis-inducing molecules, such as Fas ligand, which gets rid of
infected cells in a paracrine manner. In addition to direct microbicidal mechanisms, macrophages
also secrete various proinflammatory cytokines and chemokines that recruit other effector
leukocytes to the infection sites to clear pathogens. For example, CXC-motif ligand-10 (CXCL10) and CXCL-11 secretion induces the infiltration of CD8+ T cells and Th1 cells to control
virus and intracellular bacteria infections. Secretion of IL-17 could attract Th17 cells to fight
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fungus infections at certain sites. IL-4 and IL-13 could attract granulocytes such as eosinophils to
combat parasites.
During the clearance of infection, immune responses cause tissue damages due to the
release of cytotoxic molecules and metabolites. A functional immune response dictates the
inevitable consequence of immunopathology, compromising the short-term health of the host in
exchange for long-term fitness of a pathogen-free organism. However, upon elimination of
invading pathogens, uncontrolled inflammation needs to be avoided. Macrophages play a critical
role in the resolution of immune responses against infections. They engulf effector immune cells
that have accomplished their microbicidal functions. They adopt the “M2” activation state and
secrete immunosuppressive cytokines that inhibit potentially excessive cytotoxic activities. They
can also initiate the wound-healing process through actions on non-hematopoietic cells. For
example, macrophages secrete factors such as transforming growth factor-beta (TGFβ) and
metalloproteinases to activate fibroblast cells, which in turn lay out ECM molecules to serve as a
scaffold for tissue repair (Ortega-Gomez et al., 2013).

1.3.2 Macrophages in Development and Homeostasis
In addition to defending the host against pathogen infections, another important function
of macrophages is to maintain tissue integrity of an organism. First, they are necessary in
embryonic and neonatal development, during which organs develop into functional units that
perform designated activities of an organism. In adult organisms, macrophages are also involved
in the maintenance of homeostasis.
The necessity of macrophages during development was manifested by a series of tissue
abnormalities in mice that have a deficiency in macrophage colony-stimulating factor (MCSF,
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also known as CSF1). Abnormalities cover a wide range of tissues, including the bone,
mammary gland, kidney, and pancreas (Pollard, 2009). More dramatically, PU.1 deficient mice
that lack macrophages are embryonically/neonatally lethal, which further suggests the
importance of macrophages during development.
Macrophages regulate proper tissue development through several mechanisms. First, they
provide factors that sustain the survival and proliferation of tissue parenchymal cells during
development. This is best studied in brain development, where neuron viability relies on the
presence of macrophages. In addition to supplying pro-survival factors, macrophages are also
involved in fine-tuning and promoting the functions of parenchymal cells. Brain resident
macrophages, called microglia, have also been indicated to modulate neuron activities, prune
synapses during development, and maintain neural circuits and brain structure (Erblich et al.,
2011). In addition to the regulation of terminally differentiated cells, microglia may also regulate
neural stem cells during development (Nandi et al., 2012). Similarly, macrophages are also
important in maintaining the viability and functions of mammary gland stem cells (Gyorki et al.,
2009) during development.
In addition to its actions on parenchymal cells and/or tissue stem cells, macrophages are
also important for remodeling the tissue structure. They do so through modifications of the
extracellular matrix and vasculature. Moreover, processing cell death and cellular debris is
another key mechanism by which macrophages oversees proper development. Development is
accompanied by constant tissue remodeling, during which a lot of cells and structures that form
temporarily will need to be recycled. These cells would receive signals to undergo apoptosis.
Macrophages play a critical role at clearing apoptotic cells, both to avoid unnecessary or
detrimental inflammation, and to clear space for further construction/reconstruction. A best	
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known example is the disappearance of interdigital webs that formed during limb development,
in which macrophages have been shown to actively scavenge the apoptotic cells (Gregory and
Devitt, 2004). Not only are macrophages necessary for the recycling of apoptotic cellular debris,
they are also active inducers of apoptosis. For example, during eye development, macrophages
induce apoptosis through Wnt-dependent pathways in order to optimize the patterning of
vasculature in the developing eye (Lobov et al., 2005).
Even though the vast majority of data defining the functions of macrophages were
obtained from development and pathological conditions, these cells are also essential for the
maintenance of organismal homeostasis. Homeostasis is not a static condition, but instead
involves various events occurring in a very dynamic manner. Maintenance of hair is a great
example, in which hair follicles undergo various phases to allow hair to grow. Hair follicle
cycling not only happens in response to hair loss but is also involved during the homeostatic hair
turnover. Macrophages can be activated to secrete factors that stimulate the active cycling of hair
follicle stem cells to promote hair growth (Castellana et al., 2014). In the hematopoietic system,
depletion of macrophages led to impaired generation of erythroblasts and caused peripheral
blood anemia (Chow et al., 2013). This suggests that macrophages are important for the
maintenance of the blood system that provides oxygenation to all organs, potentially through
interactions between bone marrow resident macrophages and hematopoietic progenitor cells. In
extramedullary hematopoietic sites, macrophages were shown to retain hematopoietic stem cells
(HSCs) in the splenic niche, which is essential for maintaining HSC functions (Dutta et al., 2015).
Macrophages have also been reported to interact with tissue stem cells in various organs,
including the liver (Boulter et al., 2012), heart (Ben-Mordechai et al., 2013), mammary gland
(Gyorki et al., 2009), colon (Pull et al., 2005), and intestine (Saha et al., 2016). More
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experimental evidence is needed to define to what extent are these interactions involved in the
regulation of tissue homeostasis needs.
In addition to activating cellular activities, macrophages can also participate in
homeostasis by maintaining immune quiescence, i.e. inhibiting the activation of immune cells. A
classic textbook example is the participation of macrophages in clearing out apoptotic cell
products in a process called “efferocytosis”. Apoptotic cells undergo membrane flipping, where
the inner leaflet of the cell membrane becomes exposed to the outside. Inner membrane
phosphatidylserine was also translocated to the outer membrane, which is recognized by
macrophages. Upon the receipt of this “eat me” signal, macrophages engulf apoptotic cells,
which limits the non-discriminatory release of cellular materials that could trigger unnecessary
inflammation (Arandjelovic and Ravichandran, 2015). Efferocytosis is essential for maintaining
the non-phlogistic (not causing inflammation) nature of apoptosis, which is distinguished from
necrosis. In a similar fashion, macrophages also get rid of senescent cells, as exemplified by the
clearance of senescent red blood cells by splenic macrophages (Kohyama et al., 2009). In
addition, macrophages can secrete other immune dampening factors, such as complement
component 1q, resolven E1, protectin D1, and galectin, among others, to alleviate unnecessary
immune responses (Pinto et al., 2014).
Moreover, macrophages are important for maintaining metabolic homeostasis in response
to environmental changes, such as temperature decrease and caloric intake. Brown adipose tissue
(BAT) is the primary thermogenic organ upon exposure to low temperature. BAT resident
macrophages are required for metabolic adaptation to cold. Upon alternative “M2” activation,
these macrophages secrete norepinephrine that stimulates sympathetic nerve cells to activate the
thermogenic programs within the BAT (Nguyen et al., 2011). White adipose tissue is responsible
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for long-term storage of nutrients and regulates systemic metabolic activities through hormone
release. In lean animals, alternatively activated macrophages maintain insulin sensitivity in
adipocytes, partially through the secretion of IL-10 (Odegaard and Chawla, 2013). As mice
develop from lean into fat physique under the influence of high fat diet, classically activated
macrophages infiltrate WATs and remodel these tissues during their enlargement (Lumeng et al.,
2007). High fat diet also causes increased lipid storage in hepatocytes; liver resident
macrophages, or Kupffer cells, participate in this process by regulating fatty acid oxidation in
hepatocytes. Disruption in the alternative activation of Kupffer cells led to insulin resistance and
steotosis (Kang et al., 2008). During the increased uptake of fatty acid mentioned above,
macrophages act as lipid sensors and trigger the corresponding responses through the activation
of peroxisome proliferator activator receptors (PPAR) (Jantsch et al., 2014). Similarly,
macrophage activation is also altered to respond to changes glucose levels (de Souza et al., 2008).
Another critical aspect of homeostasis is the balance in body fluids. While kidney is the
principal organ that regulates salt and water in an organism, the skin does not equilibrate readily
with the plasma, and therefore is less susceptible to renal homeostatic control (Titze, 2014).
Interestingly, macrophages infiltrate to hypertonic sites of the skin where sodium and chloride
levels are above the normal threshold. These macrophages sense interstitial electrolytes, possibly
through the engagement of pattern recognition receptors, which trigger inflammasome activation
(Ip and Medzhitov, 2015). Consequently, nuclear factor of activated T-cells 5 (NFAT5) is
activated to initiate essential transcription programs in response to the osmotic stress (Muller et
al., 2013).
In conditions where homeostasis is disrupted, macrophages are important for restoring
the normal functions of a tissue, in processes such as tissue regeneration. This is evidenced by
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delayed tissue repair upon macrophage depletion. A key mechanism relies on the ability of
macrophages to clear senescent cells and cellular debris through phagocytosis, which is believed
to create an environment that is permissive to regeneration (Yun et al., 2015). For example, in a
non-inflammatory lung injury model that mimics damages caused by respiratory stress,
macrophages selectively deplete the dysfunctional type II lung epithelial cells, therefore
alleviating the consequences of injury (Miyake et al., 2007). In addition, angiogenesis can also
compensate for the lack of oxygenation at the injury site and facilitate tissue repair; macrophages
have been shown to provide critical signals for angiogenesis. This has been shown in multiple
pathophysiological processes, such as the repair during myocardial infarction (Aurora et al.,
2014) and peripheral nerve damage (Cattin et al., 2015).
	
  
1.3.3 Macrophages in Malignant Diseases
Macrophages can promote the initiation of tumorigenesis by promoting chronic
inflammation as discussed in Section 1.2.3. Chronic inflammation may cause DNA damages,
lead to genome instabilities, and generate a hostile tissue environment. In addition, depletion of
macrophages in pancreatic ductal adenocarcinoma correlated with significantly reduced number
of cells with tumor-initiating properties, suggesting that macrophages could also promote tumor
development through actions on “cancer stem cells” (Yang et al., 2013). Such activities could be
executed through the activation of the signal transducer and activator of transcription 3 (STAT3)
signaling pathway within the neoplastic compartment (Mitchem et al., 2013).
Beyond the inception of tumorigenesis, macrophages can also promote the progression of
established tumors. They are highly abundant in tumor tissues in many types of cancers. High
levels of macrophage infiltration in the tumor tissue, also called “tumor-associated macrophages”
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(TAMs), correlate with worse patient outcome in most types of cancers. One exception is
colorectal cancers, where contradictory roles of macrophages have been reported (Khorana et al.,
2003; Lackner et al., 2004; van Netten et al., 1993). These inconsistencies could be due to
variations in the timing of the disease progression and the location of macrophages that were
examined in different studies. Other than colorectal cancer, TAMs tends to play pro-tumorigenic
roles through various mechanisms that facilitate tumor progression.
First, TAMs can produce growth or survival factors that enhance the proliferation and
viability of tumor cells. A classic example came from studies looking at the MMTV-PyMT
breast cancer mouse model, in which macrophages recruited in a CSF1-dependent manner
secrete epidermal growth factor (EGF) that stimulates the division of neoplastic cells. In this
model, EGF also enhances the invasiveness of the cancer cell (Goswami et al., 2005; Patsialou et
al., 2009).
Second, macrophages can remodel the stromal components that are normally present in
the tissue to support organ functions, and skew their activities to facilitate tumor development.
Two examples are blood vessels and fibroblast cells, whose activations by TAMs lead to
angiogenesis and fibrosis respectively. The involvement of TAMs in promoting angiogenesis has
been demonstrated in mice deficient in macrophage recruitment, which have reduced vasculature,
increased hypoxia and reduced tumor growth and metastasis (De Palma et al., 2005; Pucci et al.,
2009). TAMs secrete an extended list of cytokines, such as VEGF, CXCL12, which promote
angiogenesis

and

vascularization

through

several

mechanisms:

they

could

trigger

sprouting/branching of pre-existing blood vessels by promoting the protrusion of a selected
endothelial cell. Alternatively, endothelial progenitor cells could be recruited from the
circulation system to the tumor site and differentiate to new endothelial cells that line up blood
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vessels; this process is called “vasculogenesis”. In a fashion similar to angiogenesis, TAMs can
also remodel the lymphatic vessels through lymphangiogenesis, which will not be discussed here.
As tumor vasculature is remodeled, basement membranes underlining the endothelial cells also
need to be remodeled. TAMs can accomplish this remodeling function through the secretion of
metalloproteinases (MMPs), such as MMP-9 (Coussens et al., 2002).
TAMs, especially the “M2” polarized macrophages, are well known for their abilities to
promote fibrosis through the secretion of profibrotic cytokines that activate fibroblast cells.
Quiescent fibroblasts would then become myofibroblasts and lay down extracellular matrix
molecules. The best-studied cytokine involved in this process is TGFβ, which induces fibroblast
proliferation and upregulates the transcription of profibrotic genes, including collagens and
fibronectin (Border et al., 1990; Haberstroh et al., 1993), through the phosphorylation of Smad
molecules (Meng et al., 2016). In addition to inducing the differentiation of fibroblasts into
myofibroblasts, macrophages also play a role in sustaining myofibroblast survival through the
stimulation of nuclear factor kappa B (NF-κB) activities (Pradere et al., 2013). In a similar
mechanism, macrophages can produce factors that promote epithelial-to-mesenchymal transition,
during which epithelial cells lose their identity and adopt a fibroblast phenotype and lay down
ECMs (Usunier et al., 2014). Surprisingly, TAMs could also promote fibrosis by directly
producing ECM molecules without involving the activation of fibroblasts. A recent proteomic
study in colorectal cancer models demonstrated that TAMs produced a wide range of collagens,
peoteoglycans, glycoproteins, and ECM modulators (Afik et al., 2016). It remains to be seen if
TAMs in other cancers can also directly lay down ECM molecules. As a side note, though the
angiogenic and pro-fibrotic functions of macrophages have been shown in multiple tissue
contexts, it is not clear if all macrophages have the same potential to execute these activities, or
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if only a subset of macrophages are capable of doing so. Characterization of angiogenic TAMs
led to the identification that these cells represent a TIE2-expressing subset of macrophages (De
Palma et al., 2005; Lewis et al., 2007). More recently, an atypical progenitor-like
monocyte/macrophage population was identified to be necessary for fibrosis (Satoh et al., 2017).
It remains to be seen to what extent in vivo are different macrophage subsets involved in these
processes.
The third tumor-promoting mechanism involves the suppression of anti-tumor immune
responses. Macrophages can secrete anti-inflammatory cytokines to inhibit the recruitment of
CD8+ and Th1-biased CD4+ T cells. They can metabolically suppress the activities of antitumor T cells, by depleting the L-arginine in the environment that is necessary for T cell
functions, through the secretion of L-arginine processing enzymes, nitric-oxide synthase and
arginase I. TAMs could also chemically modify T cell receptors to inhibit their recognition of
tumor antigens through molecules such as peroxynitrite. TAMs can also engage with T cells in a
paracrine manner through surface markers such as co-stimulatory molecules. Upon engagement
with macrophages, T cells could activate signaling pathways downstream of cytotoxic T
lymphocyte antigen-4 (CTLA4) and programmed death-1 (PD1), which drive the cells towards
an anergic or exhausted phenotype, rendering T cells non-functional. Macrophages also produce
chemokines to recruit immunosuppressive regulatory T cells, through the secretion of CCL-17
and CCL-22 for example.
Through these integrated actions on tumor cells, fibroblasts, endothelial cells, and
adaptive immune cells, macrophages create an environment that facilitates tumor growth and
invasion but deters effective immune responses, thereby facilitating tumor progression.
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Macrophages not only promote primary tumor growth but also accelerate metastasis. This
could occur during both the intravasation process at the primary tumor site and the extravasation
process at the metastatic/pre-metastatic site. TAMs at the primary tumor site promote the
invasion of tumor cells through the secretion of factors such as EGF and vascular endothelial
growth factor (VEGF) (Qian et al., 2011), thereby allowing tumor cells to enter circulation and
home to distant organs. Metastasis-associated macrophages (MAMs) can capture circulating
tumor cells and retain them at the pre-metastasis site, which extends the duration at which newly
arrived tumor cells could interact with the pre-metastatic niche. This extended duration could
allow further modifications to the tissue, and increases the possibilities of neoplastic cell
extravasation to form a metastatic site (Kitamura et al., 2015). Similar to TAMs, MAMs can also
produce growth factors to accelerate the expansion of tumor cells (DeNardo et al., 2009). In
addition, even before the arrival or disseminated cells, macrophages can already contribute to the
creation of a pre-metastatic niche, in part through the downregulation of dendritic cells and antitumor T cell infiltration (Sharma et al., 2015) and the induction of fibrosis at the pre-metastatic
site (Nielsen et al., 2016).
Macrophages not only participate in the natural courses of tumor initiation and
progression, but also affect how tumors respond to therapeutic interferences. This is usually
accomplished through (1) secretion of pro-survival factors that blocks the apoptosis pathways
induced by chemotherapies, (2) production of molecules involved in the metabolism of
chemotherapeutic drugs, which are converted to a form that is less toxic to tumor cells, and (3)
modulation of other stromal cells, such as dendritic cells (Ruffell et al., 2014), to suppress
chemotherapy-induced activation of anti-tumor immune responses.
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Taken together, macrophages infiltrating primary tumors and metastatic or pre-metastatic
tissues promote tumor progression, metastasis, and therapy resistance through various
mechanisms, therefore posing a significant barrier to effective anti-cancer treatments.
Understanding the biology of TAMs and MAMs is essential for the development of trials that
target these myeloid cells. While a lot of research has been done to elucidate the mechanisms by
which macrophages regulate tumor growth, available strategies to target these cells are very
limited, with the majority of the approaches focused on depleting these cells. Improving the
clinical efficacy in these strategies requires in-depth understanding of the sources that supply
macrophages to the tumor tissue. However, ontogeny of tumor-associated macrophages is not
well defined.

1.3.4 New Paradigm of Macrophage Ontogeny
As part of the mononuclear phagocytes system (MPS), macrophages in tissues were
considered to originate from the adult hematopoietic system. A four-decade-old dogma of
macrophage ontogeny held that hematopoietic stem cells in the bone marrow give rise to
monocytes through stepwise lineage specification; monocytes then enter circulation and further
differentiate into macrophages upon extravasation into tissues. In other words, this paradigm
proposed that monocytes in circulation constitute a mobile pool of intermediately differentiated
progenitors that are on their way between their origin (bone marrow) and their destination
(tissue). This dogma was proposed based on the initial observation that adoptively transferred
monocytes differentiate into macrophages as they circulate into the inflamed peritoneum. It was
later supported by a large number of similar observations in various tissues under different
pathological conditions (Ginhoux and Guilliams, 2016).
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This paradigm has been challenged in the past decade. As this model was based solely on
observations under inflammatory conditions, several lines of evidence looking at the homeostasis
of macrophages in non-pathological conditions raised discrepancies with the concept that the
adult hematopoietic system provides the only source of tissue macrophages. For example,
irradiation causes the ablation of the hematopoietic stem cells but does not wipe out tissue
resident macrophages, which can be minimally affected, as is the case with skin Langerhans cells
(Merad et al., 2002) and brain microglia (Ginhoux et al., 2010). Furthermore, patients who have
severe monocytopenia could have normal numbers of macrophages in many tissues (Collin et al.,
2006), a phenotype also recapitulated in mouse models. In addition, monocyte-derived cells tend
to have a shorter life span and high turnover rate, which does not explain the long half-life of
tissue resident macrophages. Moreover, the original MPS ontogeny paradigm views monocytes
as a cell type with transition roles but little other functionality; differentiation in macrophages is
their fate by default. This view has also been challenged. Monocytes were shown to be able to
traffic out of the blood into multiple tissues constitutively without contributing to the
macrophage pool. Instead these monocytes can sample antigens in a similar fashion as dendritic
cells (Jakubzick et al., 2013). These observations led to the rewriting of the paradigm of MPS
ontogeny.
An extensive list of parabiosis studies investigated the contribution of circulating Ly6CHi
monocytes to the turnover of tissue resident macrophages. Some tissues, including the colon and
intestine (Bain et al., 2014), dermis (Tamoutounour et al., 2013), and pancreatic islets (Calderon
et al., 2015) rely on monocyte infiltration for macrophage maintenance. On the other hand,
macrophages in a wide range of organs, including the lung, red pulp, pancreatic stroma, and
brain, do not show significant exchange with the blood for even after up to 5 months of
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parabiosis (Hashimoto et al., 2013). These data uncoupled the adult hematopoietic system with
the maintenance of tissue resident macrophages in many organs, suggesting the existence of an
alternative source that sustains these cells.
In addition to maintenance, the development of macrophages could also be independent
of HSCs. One of the first pieces of evidence to uncouple the ontogeny of tissue resident
macrophages with HSCs was based on the observation that macrophage development and
hematopoiesis had differential transcriptional requirements. Hematopoietic stem cell
differentiation requires the transcription factor c-Myb for proliferation and differentiation
(Sandberg et al., 2005). However, subsets of tissue resident macrophages in a wide range of
organs still develop in mice that lack this transcription factor (Schulz et al., 2012). This suggests
that HSCs are not the only developmental source of macrophages. Moreover, Flt3-based lineage
tracing experiments added further confirmation. Flt3 is a receptor tyrosine kinase that is
expressed in multipotent hematopoietic progenitors. Its expression is activated during early
stages of HSC differentiation (Boyer et al., 2011). Therefore, all hematopoietic cells in
circulation are labeled by Cre recombinase. However, macrophages in a number of tissues,
including epidermis Langerhans cells, liver Kupffer cells, spleen and kidney resident
macrophages, and brain microglia, demonstrated low levels of recombination. These data
suggested that an alternative hematopoietic source is responsible for the development of tissue
resident macrophages.
A series of tamoxifen-inducible lineage tracing models provided crucial data that helped
defining the origin of tissue resident macrophage: transgenic or knock-in mouse models that
have the Cre recombinase genes driven by various promoters took advantage of the early
expression of these promoter genes that precedes the emergence of HSC-initiated hematopoiesis,
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also called “definitely hematopoiesis”. Before the appearance of HSCs and the occurrence of
definitive hematopoiesis, the embryo undergoes several waves of blood production (Franklin and
Li, 2016; Ginhoux and Guilliams, 2016). First wave is called “primitive hematopoiesis”, in
which blood cells arise from the blood islands of extra-embryonic yolk sac. In mice this occurs
around embryonic day 7.0. During primitive hematopoiesis, a progenitor population called
“erythro-myeloid progenitors” (EMPs) arises around E7.25 and produces nucleated erythrocytes
and macrophages, which respectively provide oxygenation and participate in tissue structuring.
Following primitive hematopoiesis, a second wave of hematopoiesis occurs. During this period,
a slightly larger variety of leukocytes could be produced. In addition to EMPs, a population of
progenitors with lympho-myeloid potential is also produced. This wave of blood production
occurs in the hemogenic endothelium of the yolk sac; therefore the EMPs produced during this
wave are named “late EMPs” which distinguishes them from the EMPs that arise within the yolk
sac blood islands. “Early” EMPs express CSF1R but is c-Myb independent, while the “late”
EMPs appear to express c-Myb. Before the formation of the circulatory system, yolk sac serves
as the primary site of blood production for the embryo. Concomitant with the emergence of late
EMPs, a third wave starts within the hemogenic endothelium of the embryo proper around E8.25.
Coinciding with this, the embryo develops a functioning circulation system by E8.5. During this
wave of hematopoiesis, immature hematopoietic stem cells are generated within the para-aortic
splanchnopleura (P-Sp) region. Subsequently, HSCs were observed in the aorta gonads and
mesonephris (AGM) region at E10.5, and then in the fetal liver. Though still controversial, the
immature HSCs observed in the P-Sp region were considered to be the progenitors of HSCs that
later migrate to the AGM region and then ultimately settle in the fetal liver (Cumano and Godin,
2007). Fetal liver becomes the major site of hematopoiesis starting at E12.5 and peaks at E16.5
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in mice, before bone marrow takes over the hematopoietic function at perinatal stages (Orkin and
Zon, 2008).
Despite the agreement on the embryonic contribution to tissue resident macrophages,
controversies still exist regarding the precise nature of the embryonic progenitors that give rise to
these cells. This is partially due to differences in the mouse models used for lineage tracing and
the labeling variations by promoters driven by different genes. Runx1-CreER took advantage of
the early expression of Runx1 starting at E6.5. Tamoxifen pulse at E7.0 specifically labeled up to
30% of brain microglia while sparing hematopoietic stem cells (Ginhoux et al., 2010). CSF1RCreER has also been used, whose expression comes later than Runx1, therefore allowing a
longer time window for labeling. E8.5 tamoxifen treatment leads to the labeling of various tissue
macrophages, including those in brain, epidermis, liver, and spleen (Schulz et al., 2012), and
subsets of macrophages in the pancreas and heart (Calderon et al., 2015; Epelman et al., 2014;
Gomez Perdiguero et al., 2015). These findings, along with the presence of these cells in Myb
knockout mice, led to the model in which yolk sac EMPs differentiate into macrophages that
persist into adulthood.
However, whether these data above supports this “yolk sac exclusive” ontogeny model is
questionable. Persistence of macrophage populations in Myb knockout mice only suggests the
ability of progenitors to contribute to these cells when HSC differentiation is deficient, but does
not suggest that this is what actually happens in unperturbed situations. These observations could
be the mechanisms by which “early” EMP differentiation compensates for the deficiencies of
hematopoiesis induced by Myb-dependent “late” EMPs or HSCs. Along the same lines,
depletion of yolk sac-derived macrophages, through the treatment of CSF1 receptor depleting
antibodies on E6.5, did not lead to irreversible reductions in fetal macrophages in most organs.
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The only tissue resident macrophages that were irreversibly depleted were macrophages. Indeed,
kinetics studies using CSF1R- and Runx1-CreER fate mapping models demonstrated the
replacement of yolk sac derived macrophages as hematopoiesis progresses to the fetal liver stage.
In a novel S100A4-Cre model that specifically traces fetal monocytes, Cre labeling started to be
observed at E12.5 in macrophages in lung, liver, spleen, and skin, and the labeling efficiency
progressively increased to an average of 60% in neonates, which was maintained into adulthood.
Going back to the Runx1-CreER model, tamoxifen treatment at a later time point (E8.5) led to
the labeling of a myb-expressing EMP population that entered circulation and colonized the fetal
liver. These “late” EMPs were distinct from the “early” EMPs, which lack Myb expression and
differentiate into macrophages without going through the monocyte stage (Hoeffel et al., 2015).
These data suggest that fetal liver progressively replace yolk sac derived cells, and led to the
proposal of a new model in which late EMP-derived fetal liver monocytes are the major sources
of most tissue resident macrophages, while early EMPs in the yolk sac provide the source for
microglia.
In addition to early EMPs in the yolk sac and late EMPs in the fetal liver, fetal HSCs
were also proposed to contribute to the generation of resident macrophages. This was based on
the c-Kit-CreER model. In this model, E7.5 tamoxifen treatment led to significant amount of
labeling in brain microglia but not in the resident macrophage populations from other major
organs (Sheng et al., 2015). On the other hand, pulsing at later time points (E8.5 and E9.5)
labeled macrophages that are resident in the liver, lung, spleen, kidney, dermis, and peritoneum.
Because the kinetics of the labeling coincides with the occurrence of HSCs, these data led to the
proposal of fetal HSCs as sources of resident macrophages other than microglia. Moreover, the
labeling of other hematopoietic cells, including neutrophils and lymphocytes, led to the
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hypothesis that c-Kit+ cells pulsed at E8.5 or E9.5 are HSCs. However, further confirmations of
the identity of these cells are still needed to validate this model. Moreover, these data are still
consistent with the EMP model.
In addition to embryonically derived populations, regardless of the precise nature of the
progenitors, HSCs are also shown to be a significant contributor to many tissue resident
macrophages shortly after birth. For example, infiltration of monocytes replenished macrophages
in the colon during weaning. This was shown by the decrease of macrophages labeled on E8.5 by
CSF1R-CreER concomitant with an increase in Flt3-Cre labeled cells (Bain et al., 2014). This
replenishment was stimulated by microbiota in the neonates, suggesting that environmental
stimuli could interact with the tissue to shape the ontogeny of local macrophages. While the
contribution of perinatal hematopoiesis is best studied in organs that are exposed to the
environment, such as the lung and colon, it can also happen in internal tissues, such as the
arteries. Unlike the mouse models mentioned above, CX3CR1-CreER does not label significant
amount of inflammatory monocytes, therefore allowing the investigation into the contribution of
embryonic hematopoiesis to macrophages that do not express CX3CR1. E18.5 labeling in
CX3CR1-CreER reporter mice led to the labeling of most macrophages in neonatal arteries.
Interestingly, two weeks after birth, a significant portion of artery associated macrophages are
replaced by unlabeled monocytes, suggesting the contribution of HSCs to cardiarc macrophages
at the neonatal period (Ensan et al., 2016). Similarly, the MHCII+ macrophages in the
peritoneum also develop within the first week after birth, in a CCR2-dependent manner,
suggesting the perinatal contribution of HSCs to the development of this population (Kim et al.,
2016).
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Unlike the differentiation of macrophages from adult HSCs, embryonic macrophage
differentiation before the formation of fetal liver HSCs does not appears to involve monocyte
intermediates (Ajami et al., 2007). A question raised by this model is the mechanisms by which
tissue macrophages generated their phenotypic and functional diversity across various organs.
One possibility is that the diversity could be generated already upon differentiation at the
hematopoietic sites. Variable “clones” of macrophages could be armed with differing repertoire
of chemokine receptors that drive their unique migration pathways towards different organs or
even different sites within an organ. This “pre-determinism” model resembles the generation of
the homing of tissue resident memory T cells, which are activated uniquely in secondary
lymphoid sites and home to unique tissues. An alternative but related possibility is that
heterogeneous EMP populations give rise to different macrophages that home to their target
organs. This model might be unlikely, because the generation of a diverse progenitor population
may be costly. However, characterization of EMPs is relatively simplistic. We may
underestimate the heterogeneity of the “primitive” progenitors that may exist. Moreover, in all
lineage-tracing models mentioned above, the labeling of various mature macrophages
populations by a single promoter does not mean they share the same progenitor. E8.5 tamoxifen
pulse may label various CSF1R+ progenitors, each of which later gives rise to different resident
populations. This “progenitor heterogeneity” model also implies the concept of pre-determined
diversity and pre-determined destination.
Alternatively, progenitors such as EMPs could directly differentiate into macrophages,
which then settle into embryonic organs or organ primordial, and quickly achieve organ-specific
program upon the receipt of tissue specific niche signals. However, to accomplish this “fast
maturation”, macrophages may also need to develop unique receptors or signaling machineries
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that allows them to respond to environmental signals. Another possibility involves the
differentiation of embryonic progenitors into intermediate precursors, similar to monocytes in
adult hematopoiesis, which then differentiate into macrophages and obtain organ-specific
transcriptional program upon tissue entry. This “step-wise diversification” model was supported
by the profiling of a CD45+cKit-Lin-F4/80- population, whose surface markers and
transcriptional profiles are intermediary between EMPs and mature macrophages (Mass et al.,
2016). While these transition-state “pre-macrophages” could explain the generation of
phenotypic diversity among tissue macrophages, further studies are needed to validate their
existence and contribution to the macrophage ontogeny.
The contribution of multiple progenitors to macrophage ontogeny raised an important
“nature vs. nurture” debate. Multiple studies demonstrated a wide range of diversity among
various tissue macrophages. Macrophages resident in each tissue seem to demonstrate a distinct
signature in terms of transcriptional activities (Gautier et al., 2012), enhancer landscape
(Gosselin et al., 2014; Lavin et al., 2014), and chromosome modification profiles. A common
theme of these studies is a focus on the importance of environment in the regulation of
macrophage activities. To what extent does ontogeny contribute to the shaping of macrophage
functionality? Answer to this question requires investigations into macrophages of different
origins that co-exist within the same tissue. A number of studies used artificial systems by
partially depleting the tissue resident population to induce their replacement by monocytes,
followed by profiling the transcriptional signature of monocyte-derived macrophages and
remaining tissue resident macrophages. In the lung and peritoneal cavity, macrophages derived
from newly recruited monocytes acquired the majority of the majority of the gene signature of
their endogenous counterparts. On the other hand, monocyte-derived liver macrophages differ
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significantly from Kupffer cells in terms of enhancer signature (Lavin et al., 2014). Similarly,
monocyte-derived microglia also had more than 2,000 differentially expressed genes compared
from yolk sac-derived microglia (Bruttger et al., 2015). These studies suggest that ontogeny
could be one of the determining factors that shape the functional properties of macrophages.
However, these data should be taken with caution, because the depletion strategies involve
genotoxic irradiation, which could cause alterations in the activities of the endogenous
populations, even though tissue resident macrophages may be radiation-resistant. Indeed, several
studies have made similar attempts to enforce the recruitment and differentiation of monocytes
into tissue resident macrophages, either through shielded irradiation that protects the endogenous
population, or through transgenic diphtheria toxin receptor-mediated depletion. In both the lung
and the liver, monocyte-derived macrophages resemble their endogenous counterparts, with very
little distinction in transcriptional activities that may suggest most overlapping functionalities
between cells from different origins (Gibbings et al., 2015; Scott et al., 2016). These contrasted
results in how monocyte-derived liver macrophages resembled endogenous Kupffer cells
demonstrated how differences in experimental systems could lead to different conclusions, and
remind us of interpreting these studies with caution. Another important note is that a lot of these
studies looked at macrophages in the tissue as one homogeneous entity. However, each organ is
an intricate system with a complicated anatomy; therefore, cells located in different parts of the
tissue may behave differently. In the pancreas, monocyte-derived macrophages infiltrate the
islets, while embryonically derived macrophages are enriched in the exocrine stroma. Moreover,
various subsets of stromal macrophages, as distinguished by the expression of CD206, have
different gene expression profile (Calderon et al., 2015). These data suggest the possibility that
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ontogeny and signals from different environmental niches may interact with each other to shape
the properties of resident macrophages.
It is important to note that the ontogeny of tissue resident macrophages is not static.
While embryonically derived macrophages are abundantly populated in almost all organs at birth,
many cell populations are replaced by monocyte at various rates. On one end of the spectrum,
brain microglia are the first tissue macrophages derived from yolk sac progenitors, and they
persist long-term with very minimal contribution from blood monocytes. On the other end of the
spectrum, macrophages in the colon and intestine are short lived, and rely on constant
replenishment from the blood. The life spans of epidermis Langerhans cells, lung alveolar
macrophages, and liver Kupffer cells are more like that of the microglia; dermis MHCII+
macrophages are more like colon macrophages. Macrophages in other organs mostly fall into the
middle of the spectrum, including pancreas and heart. How do various tissue resident
macrophage populations possess different life span? How do those in the brain, lung alveoli, and
liver self-maintain through adulthood and aging? These unanswered questions are also worth
addressing.
Another important question is whether ontogeny plays a role in determining the fates of
macrophages during various pathological conditions. Macrophages undergo extensive
proliferation in Helminth infection, which implies the involvement of tissue resident
macrophages in Th2 inflammatory responses against pathogens (Jenkins et al., 2011). Local
proliferation also characterizes macrophages within visceral adipose tissues, suggesting that
resident macrophages may play a role in the regulation of metabolic diseases (Amano et al.,
2014). Not only can resident macrophages participate in the regulation of these pathological
conditions, they can also interact with the blood system to promote the infiltration of monocytes
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to expand the local macrophage pool. In a Listeria monocytogenes infection mode, Kupffer cells
undergo necroptosis to recruit monocytes that later differentiate into macrophages (Bleriot et al.,
2015). What is the fate of tissue resident macrophages during tumor development? How do they
contribute to tumor progression and metastasis? These questions are poorly addressed. In a breast
cancer model, mammary gland resident macrophages seemed to disappear while monocyte influx
gave rise to tumor-associated macrophages (Franklin et al., 2014). On the other hand, microglia
appeared to persist in glioblastoma (Chen et al., 2017) and brain metastasis (Bowman et al.,
2016). The limited number of studies suggests that the involvement of tissue resident
macrophages in tumor development may be organ- and tumor- specific. One organ of particular
interest to us is the pancreas. Pancreatic cancers can arise within either the exocrine or the
endocrine portions of the organ; meanwhile, stroma and pancreatic islets are infiltrated with
macrophages derived from different sources. It would be interesting to see if different
macrophage sources supply TAMs to different kinds of pancreatic cancers. In addition, cancer
occurrence in the heart is rare. Since the heart is infiltrated with macrophages of different
ontogeny, it is also worth asking if these cells contribute differently to cancer
immunosurveillance in this organ.

1.4 Scope of This Dissertation
1.4.1 Outstanding Needs for Improvement of Immunotherapies
Our knowledge of cancer biology is growing at unprecedented speed. In particular, we
are increasingly appreciative of the role that the tumor microenvironment plays in the regulation
of cancer development and in the utilities of cancer treatment. In parallel, advancement in the
development of therapeutics also demonstrates a promising future of cancer treatment by
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targeting the tumor stroma. A lot of attention has been paid to the immune components of the
cancer environment, with a focus on targeting the adaptive immune system. The advantage is
that: (1) the adaptive immune system is capable of combatting cancer in an antigen specific
manner, thereby allowing the minimization of side effects due to attacks on healthy cells in the
organisms that are necessary for host fitness; (2) memory is the second hallmark of the adaptive
immune system, which could build a long lasting anti-cancer arsenal that suppresses tumor
reoccurrence. Immunotherapies that activate adaptive immune responses have demonstrated
promising potential in multiple types of malignant diseases; in some cases these therapies even
showed impressive efficacy at treating late-stage patients with metastasis.
However, these immunotherapies do not work in all types of cancer. For example,
checkpoint therapies do not improve patient outcome in pancreatic ductal adenocarcinoma.
Moreover, even in responsive cancers such as skin melanoma, large cohorts of patients still do
not sufficiently benefit. Therefore, we need a much better understanding of the tumor
microenvironment unique in different kinds of tumors and metastasis in order to expand
treatment benefits to a much larger group of patients.
Activation of the adaptive immunity is reliant on the innate immune system, in particular
myeloid cells. Myeloid cells compose the overwhelming majority of leukocytes and far
outnumber the anti-tumor adaptive immune cells. However, tumor-infiltrating myeloid responses
are heavily skewed in the tumor to adopt a suppressive phenotype that promotes tumor growth
instead of inducing effective anti-tumor responses. Therefore, we need to change myeloid
responses in order to optimize therapies that are targeted towards boosting the adaptive immune
system. Targeting myeloid components of the tumor stroma is not a new concept in the
development of cancer immunotherapies. The prevailing strategy is directed towards reducing
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the amount of immune suppression by reducing the quantity of cells. However, such depleting
strategies have their own limitations. First, lower quantity of suppressive myeloid cells does not
equal higher quality of immune responses. Second, without understanding the sources of these
myeloid cells, depletion of these cells from the tumor stroma could simply induce a positive
feedback loop that further enhance their production and recruitment to the tumor site. Therefore,
as we develop therapeutic strategies, we may need to change our thinking from depleting these
cells to reprogramming these cells. In addition, we need to better understand the cellular origin
that provides these myeloid cells to the tumor tissue, and cut the supply from the source.
Furthermore, we can combine the knowledge in both aspects, and design an alternative strategy:
first depleting pre-existing suppressive myeloid cells to create vacancies that can later be
occupied by new comers, and then programing or conferring these new comers with anti-tumor
functions.

1.4.2 Central Questions of This Dissertation
We choose pancreatic ductal adenocarcinoma (PDAC) as a cancer model due to the high
lethality and the desperate need for effective immunotherapies. PDAC has a very rich stromal
environment, which is very scarce in CD8+ T cells but very extensively infiltrated with myeloid
cells that could be utilized for treatment. Our long-term goal is to understand how neoplastic
cells in PDAC tissues interact with their microenvironment. The scope of this dissertation
focuses on macrophages, one of the most abundant immune cells in PDAC tissue. The quantity
and quality of macrophages in PDAC correlate with patient outcome; therefore we aim to
develop strategies to reprogram macrophage functions to enable anti-tumor responses. Towards
that end, we want to understand: (1) how tumor-associated macrophages (TAMs) polarize
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toward pro-tumor or anti-tumor phenotypes, (2) what tumor-derived signals are responsible for
programming TAM activities, (3) where do TAMs come from, and (4) how we can utilize the
sources of TAMs to alter the myeloid compartment and the adaptive immune responses in PDAC.
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Chapter 2: CSF1/CSF1R Blockade Reprograms
Tumor-Infiltrating Macrophages and Improves
Response to T Cell Checkpoint Immunotherapy in
Pancreatic Cancer Models.

Reference:
Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West B, Luo J, Wang-Gillam A,
Goedegebuure SP, Linehan DL, DeNardo DG. CSF1/CSF1R blockade reprograms tumorinfiltrating macrophages and improves responses to T cell checkpoint immunotherapy in
pancreatic cancer. Cancer Research, 2014, 74 (18): 5057-5069. PMID: 25082815
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2.1 Summary
Cancer immunotherapy generally offers limited clinical benefit without coordinated strategies to
mitigate the immunosuppressive nature of the tumor microenvironment. Critical drivers of
immune escape in the tumor microenvironment include tumor-associated macrophages (TAM)
and myeloid-derived suppressor cells (MDSC), which not only mediate immune suppression but
also promote metastatic dissemination and impart resistance to cytotoxic therapies. Thus,
strategies to ablate the effects of these myeloid cell populations may offer great therapeutic
potential. In this report, we demonstrate in a mouse model of pancreatic ductal adenocarcinoma
(PDAC) that inhibiting signaling by the myeloid growth factor receptor CSF1R can functionally
reprogram macrophage responses that enhance antigen presentation and productive anti-tumor T
cell responses. Investigations of this response revealed that CSF1R blockade also upregulated T
cell checkpoint molecules, including PDL1 and CTLA4, thereby restraining beneficial
therapeutic effects. We found that PD1 and CTLA4 antagonists showed limited efficacy as single
agents to restrain PDAC growth, but that that combining these agents with CSF1R blockade
potently elicited tumor regressions, even in larger established tumors. Taken together, our
findings provide a rationale to reprogram immunosuppressive myeloid cell populations in the
tumor microenvironment under conditions that can significantly empower the therapeutic effects
of checkpoint-based immunotherapeutics.
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2.2 Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies.
Current therapies are ineffective at treating late stage disease. The few durable responses to
therapy seen in PDAC patients are often associated with significant cytotoxic lymphocyte (CTL)
infiltration into tumor tissue, suggesting that effective immunotherapy would hold promise to
improve patient outcome (1, 2). However, attempts to use immunotherapeutics as single agents
have achieved only limited clinical success (3, 4). While multiple factors can contribute to the
resistance of PDAC to immunotherapies, one dominant player is the presence of a suppressive
immune microenvironment. Critical drivers of this immunosuppressive microenvironment
include tumor-associated macrophages (TAMs), monocytic myeloid-derived suppressor cells
(Mo-MDSCs), and granulocytic MDSCs (G-MDSCs). These leukocytes can also promote tumor
cell proliferation, confer resistance to cytotoxic stress, and facilitate metastatic dissemination (5,
6). Therefore, high numbers of tumor-infiltrating myeloid cells often correlate with early local or
metastatic relapse, leading to poor survival in pancreatic cancer patients (7-9). Therapeutics that
can reprogram these myeloid responses might overcome immunosuppression to enhance
responses to immunotherapy. Previous work by our group and others demonstrated that
combining cytotoxic chemotherapy with the blockade of colony-stimulating factor 1 receptor
(CSF1R), which is prominently expressed by monocytes, Mo-MDSCs, and macrophages, results
in improved anti-tumor T cell responses (10-12). These data suggest that CSF1R blockade could
be effective at alleviating local tumor-induced immune suppression and bolstering the response
to immunotherapy.
In this report, we investigate the mechanisms by which inhibition CSF1R signaling
alleviates immune suppression. We demonstrate that CSF1/CSF1R blockade not only decreases
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the number of TAMs, but also reprograms remaining TAMs to support antigen presentation and
bolster T cell activation within the tumor microenvironment. This in-turn leads to reduced
immune suppression and elevated interferon responses, which restrain tumor progression.
However, in response to reduced immune suppression programmed death 1 ligand 1 (PDL1) is
up-regulated on tumor cells and cytotoxic T lymphocyte antigen 4 (CTLA4) on T cells. These
checkpoint molecules limit the potential of CSF1R inhibition to stimulate anti-tumor immunity.
While both programmed cell death protein 1 (PD1) and CTLA4 antagonists demonstrate limited
ability to restrain PDAC growth in this mouse model, similar to reported efficacy as single
agents in PDAC patients (3, 4). However, CSF1R blockade overcomes these limitations to
achieve regression in even well-established tumors. These data suggest that reprogramming
myeloid cell responses via CSF1/CSF1R blockade could improve the efficacy of checkpointbased immunotherapeutics.
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2.3 Methods and Materials
Pancreatic cancer tissue microarray cohort and analysis
Tissue microarray (TMA) studies were conducted on surgically resected PDAC specimens from
60 patients diagnosed in the Department of Pathology at Washington University. Patients
underwent pancreaticoduodenectomy followed by adjuvant chemotherapy. Fifty-nine of the sixty
patients did not receive neoadjuvant therapy. To assemble TMAs, clearly defined areas of tumor
tissue were demarcated and two biopsies (1.0-mm diameter) were taken from each donor block.
The Washington University School of Medicine ethics committee approved this study. Fully
automated image acquisition was performed using an Aperio ScanScope XT Slide Scanner
system with a 20× objective (Aperio Technologies) to capture whole-slide digital images.
Fluorescent staining analysis was performed using MetaMorph software.

Immunohistochemistry (IHC)
Tissues were fixed in 10% formalin, embedded in paraffin, and dehydrated in 70% ethanol.
Five-mm-thick sections were deparaffinized in xylene, rehydrated in graded ethanol, and
subjected to antigen retrieval by steam heating in Citra™ antigen retrieval solution (BioGenex).
CSF1 was stained with clone 2D10 at 1:100 (Thermo) and detected using indirect
immunofluorescence.

Cell lines and constructs
KC cells were derived from PDAC tumor tissue obtained from p48-CRE/LSL-KRas/p53flox/flox
mice (backcrossed C57/B6, n=6 by speed congenic) by our laboratory. Kras-INK (KI) cells were
obtained from Dr. Hanahan’s laboratory (Collisson et al., 2011; Roy et al., 2011). All cell lines
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were negative for MAP and mycoplasma. Subsets of these cells were labeled with a polycistronic
click beetle red luciferase-mCherry reporters.

Orthotopic model and preclinical animal cohorts
Syngeneic orthotopic PDAC tumors were established by surgical implantation, as previously
described (Aaltonen et al., 2009). Briefly, we injected 200,000 cells in 50 µl Matrigel (BDBiosciences) into each mouse’s pancreas. Cohorts of mice were randomized into different
treatment groups by either bioluminescence imaging on day 12 or gross palpation of the
pancreas. Mice were treated with 50 mg/kg Gemcitabine (GEM; Hospira) by intravenous (i.v.)
injection into the right retro-orbital sinus every 4–5 days. Preclinical studies were conducted with
10–15 10-week-old female mice per group. Tumor burden was measured by establishing gross
wet weight of the pancreas/tumor and comparing it to that of five parallel mice sacrificed at the
beginning of treatment. All studies involving animals were approved by the Washington
University School of Medicine Institutional Animal Studies Committee.

CSF1R inhibitors, CSF1 neutralizing antibodies, and checkpoint antagonists
CSF1 neutralizing antibody (clone 5A1, BioXCell) was administered via intraperitoneal (i.p.)
injection every 4–5 days, with the 1st injection containing 1 mg and subsequent injections 0.5 mg.
CSF1R inhibitors (CSF1Ri) were provided by Plexxikon Inc. PLX3397 is a selective bispecific
inhibitor for c-Fms and the c-Kit receptor tyrosine kinases (Artis et al., 2005; DeNardo et al.,
2011; Tsai et al., 2008). GW2580 has been described in detail previously (Conway et al., 2005).
Both GW2580 and PLX3397 were administered at 800 mg/kg in chow. CTLA4 and PD1
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antagonists (clones UC10-4F10 and RMP1-14, BioXCell) were given every 4–5 days at 250 and
200 mg/dose, respectively.

Flow cytometry analysis
Single-cell suspensions were prepared from dissected pancreatic tumors by manual mincing
using a scalpel, followed by enzymatic digestion with 3.0 mg/ml collagenase A (Roche) and
DNase I (Sigma) for 30 min at 37°C with constant stirring. Digestion mixtures were quenched by
10% fetal bovine serum (FBS), and filtered through 40-µm nylon strainers (Fisher Scientific).
Cells were incubated for 10 min at 4°C with rat anti-mouse CD16/CD32 mAb (eBiosciences) at
1:200 dilution. Cells were washed twice in PBS/BSA and incubated for 20 min with 100 µl of
fluorophore-conjugated anti-mouse antibodies (CD3e (145-2C11), CD4 (6K1.5), CD8a (53-6.7),
CD11b (M1/70), CD11c (N418), CD19 (MB19-1), Ly6C (HK1.4), CD45 (30-F11), CD115
(AFS98), F4/80 (BM8), MHCII (M5/114.15.2), FoxP3 (FJK-16s), CD44 (IM7), CD69 (H1.2F3),
PD1 (J43), PDL1 (MIH5), PDL2 (122), CTLA4 (UC10-4B9), IgG2α/κ (eBR2a), (all from
eBioscience) and/or Ly6G (1A8, BioLegend), and CD206 (MR5D3, AbDSerotec) using the
manufacturers’ recommended concentrations. Data acquisition was performed on the LSR-II
system (BD Biosciences), and FlowJo software version 9.2 (Tree Star) was used for analysis.

Quantitative reverse transcription-polymerase chain reaction (RT-PCR)
Total tissue RNA was extracted from snap-frozen tumor tissue or lysed tissue culture cells using
the E.Z.N.A. RNA Kit (Omega). cDNAs were synthesized using qScript cDNA SuperMix
(QuantaBio). Quantitative real-time PCR Taqman primer probe sets specific for TBP, HPRT,
GAPDH, CSF1R, CSF1, CCR2, CCL2, CCL5, CCL22, CXCL10, interferon (IFN)-α, IFNβ,
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interleukin (IL)-1b, IL10, IL12p35, NOS2, ARG1, TGFβ, EGF, PDL1, PDL2, PD1, and CTLA4
(Applied Biosystems) were used, and the relative gene expression was determined on a StepOne
PlusTM Real Time PCR System (Applied Biosystems) using Taqman Gene Expression Master
Mix (Applied Biosystems). The comparative threshold cycle method was used to calculate fold
changes in gene expression, which were normalized to the expression of TBP, HPRT and/or
GAPDH as reference genes.

Flow cytometry analysis
Single-cell suspensions were prepared from dissected pancreatic tumors by manual mincing
using a scalpel, followed by enzymatic digestion with 3.0 mg/ml collagenase A (Roche) and
DNase I (Sigma) dissolved in Dulbecco’s modified Eagle medium (DMEM; Gibco) for 40 min at
37°C with constant stirring. Digestion mixtures were quenched by adding DMEM containing
10% fetal bovine serum (FBS), and filtered through 40-µm nylon strainers (Fisher Scientific).
Cells were incubated for 15 min at 4°C with rat anti-mouse CD16/CD32 mAb (eBiosciences) at
1:200 dilution in phosphate-buffered saline (PBS) containing 1.0% bovine serum albumin (BSA;
Sigma) to prevent nonspecific antibody binding. Cells were washed twice in PBS/BSA and
incubated for 20 min with 100 µl of fluorophore-conjugated anti-mouse antibodies (CD3e (1452C11), CD4 (6K1.5), CD8a (53-6.7), CD11b (M1/70), CD11c (N418), CD19 (MB19-1), Ly6C
(HK1.4), CD45 (30-F11), CD115 (AFS98), F4/80 (BM8), MHCII (M5/114.15.2), FoxP3 (FJK16s), CD44 (IM7), CD69 (H1.2F3), PD1 (J43), PDL1 (MIH5), PDL2 (122), CTLA4 (UC104B9), IgG2α/κ (eBR2a), (all from eBioscience) and/or Ly6G (1A8, BioLegend), and CD206
(MR5D3, AbDSerotec) using the manufacturers’ recommended concentrations. This was
followed by two washes with PBS/BSA. Either 7-AAD (BD Biosciences) or Live/Dead Blue
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(Invitrogen) was used to identify dead cells. Data acquisition was performed on the LSR-II
system (BD Biosciences), and FlowJo software version 9.2 (Tree Star) was used for analysis.

Fluorescence-Activated Cell Sorting (FACS)
Cell suspension and antibody staining were prepared as described above. Sorting was performed
using the FACSAria-II cell sorter (BD Biosciences) at the FACS Core of Washington University
Department of Pathology and Immunology. For gene expression analysis, cells were directly
sorted into the TRK lysis buffer (Omega). For all sorting experiments, post-sort analyses were
performed to ensure >90% purity.

Gene Signature Survival Analysis
The full gene lists were matched for human-mouse ortholog by the provided gene symbols for
human genome annotation (gene symbol and entrez ID); some genes are missing the annotation.
The genes with human genome annotation were matched in the public datasets and their
expression was matched with outcomes. We used GSE1501 for survival analysis. For each
individual gene, the Kaplan-Meier survival curves on the binary gene expression (dichotomized
by median as low/high) were generated with log-rank test p-values. Top significant individual
genes log rank p-value included ZBP1, OAS3, PTPN6, SFPI1, IRF9, CDH13, SIGLEC1, STAT1,
SLC11A1, SH2D2A etc. The up- regulated genes and the down-regulated genes were each
centered by mean and scaled by standard deviation. The averaged expression of down-regulated
genes (all available genes or the significant genes only from the previous individual gene
analysis based on either log-rank test p or Wald test P<0.05) were separately calculated. Each
sample was categorized into one of the two groups (low, high by median averaged gene
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expression), then into one of the three groups (low, medium, high by the 33.33% and 66.67%
quantile of the averaged gene expression). The resulting 2 groups and 3 groups classification was
each associated with overall survival (OS).
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2.4 Results
2.4.1 CSF1 is overexpressed by human PDAC cells.
Previously, we reported that inhibition of CSF1/CSF1R signaling could improve the
efficacy of chemotherapy in murine PDAC models by enhancing chemotherapy-induced antitumor immunity (Mitchem et al., 2013). However, the mechanisms by which inhibition of
CSF1/CSF1R signaling regulates anti-tumor immunity are not well understood. To determine the
cellular sources of CSF1 and CSF1R in human pancreatic cancer patients, we analyzed TMAs
constructed from 77 cases of invasive PDAC and 4 samples of normal pancreatic tissue. IHC
staining showed that CSF1 is frequently, but not exclusively, expressed by malignant PDAC
cells (Figure 2.1A). In addition, tumors frequently had elevated expression of CSF1 compared to
normal tissue. PDAC cells in 70% of tumor specimens exhibited moderate to high levels of
CSF1 expression (Figures 2.1A–C). By contrast, CSF1R was frequently detected in the tumor
stroma, while only ~10% of the tumors examined had CSF1R expression in the epithelial
compartment (Figures 2.1A and D). These observations are consistent with other reports (Jiao et
al., 2012; Pyonteck et al., 2011) and suggest that PDAC tumor cells frequently produce high
levels of CSF1.

2.4.2 Inhibition of CSF1R signaling reprograms the tumor microenvironment.
In order to understand the impact of CSF1R signaling on the tumor microenvironment,
we compared the gene expression profile of PDAC tumor tissue following treatment with either
CSF1R inhibitors (CSF1Ri) or vehicle. Towards this end, we orthotopically implanted KI PDAC
tumor cells into syngeneic mice. This cell line produces high levels of CSF1 but does not express
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CSF1R (Mitchem et al., 2013). Starting on day 14 post-implantation, we treated mice with either
vehicle or the CSF1R tyrosine kinase inhibitor, PLX3397. Additional details on PLX3397 can be
found in the Methods section and published elsewhere (Artis et al., 2005; Conway et al., 2005;
Schubert et al., 2007; Tsai et al., 2008). Eight days of CSF1Ri treatment resulted in a significant
reduction

in

macrophages

the
and

number

of

tumor-infiltrating

CD11b+Ly6G−Ly6CHi

CD11b+Ly6G−Ly6CLoF4/80HiMHCII+

monocytes/

Mo-MDSCs,

but

not

CD11b+Ly6G+Ly6C+MHCIILow G-MDSCs (Figure 2.2A, Figure 2.8). Microarray analyses of
whole tumor tissue mRNA expression revealed 204 downregulated and 158 upregulated genes
following CSF1Ri treatment (Figure 2.2B, Table S1). As expected, expression of genes
indicative of macrophage infiltration, including Cd68, Mrc1, Msr1, and Csf1r, were decreased in
CSF1Ri-treated tumors (Figure 2.2D). The list of downregulated genes was enriched for
molecules involved in “inflammatory responses, chemotaxis, myeloid leukocyte-mediated
immunity, and proteolysis,” consistent with the decreased number of infiltrating macrophages
(Figures 2.2C–D). The list of upregulated genes was enriched for molecules involved in
“antigen presentation, allograft rejection, interferon responses, and TH1 immunity” (Figure
2.2C). This is consistent with the idea that CSF1R blockade can overcome immune suppression.
Corresponding to these altered pathways, genes indicative of cytotoxic T lymphocyte (CTL)
responses (Ifng, Cd3e, Cd8a, and Prf1), T cell recruitment (Cxcl10, Ccl3, and Ccl4), and
interferon responses (e.g. Ifng, Stat1, Irf1, and Irf9) were upregulated (Figure 2.2E). Array
results were also validated by quantitative real-time PCR (qRT-PCR) on a second set of samples
(Figure 2.2F). To determine the impact of these alterations, we applied these gene lists to
existing gene expression datasets from PDAC patients (Stratford et al., 2010) and found that the
core elements of the downregulated gene list were indicative of poor clinical outcomes (Figure
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2.2G). Taken together, these results suggest that: (1) inhibition of CSF1R signaling in the
stromal compartment decreases myeloid responses and reprograms the tumor microenvironment
to support T cell-mediated anti-tumor immunity and (2) these changes could improve patient
outcomes.

2.4.3 CSF1/CSF1R signal blockade selectively kills CD206Hi TAMs.
To determine how inhibition of CSF1/CSF1R signaling impacts myeloid responses, we
treated tumor-bearing mice with CSF1 neutralizing antibodies for 6, 12, 24, or 48 hours or 8 days
and analyzed tumor-infiltrating myeloid cell composition and cell death at these time points.
Within the first 6 hours of aCSF1 treatment, total TAM numbers began to decrease. By 8 days,
TAM numbers had decreased by ~60% (Figure 2.3B). TAMs are a heterogeneous population of
macrophages with diverse biological activities (Mantovani, 2008; Mantovani and Sica, 2010;
Martinez et al., 2008; Movahedi et al., 2010; Qian et al.). While classical activation of
macrophages can restrain cancer development, alternative activation often plays a protumorigenic role (Martinez et al., 2009; Mosser and Edwards, 2008). Distinct surface markers
have been used to distinguish between classically and alternatively activated macrophages.
Murine PDAC tumors contain a distinct subset of CD206Hi TAMs (Figures 2.3A, 2.8), and their
counterparts in human pancreatic cancer have been associated with poor clinical outcomes (Ino
et al., 2013). Quantification of CD206Hi and CD206Low TAM subsets revealed that aCSF1
treatment for 8 days led to a >90% depletion of CD206Hi TAMs, while CD206Low TAMs
decreased by only ~45% (Figures 2.3C-D). Similar results were seen following CSF1Ri
treatment (Figure 2.3G). The loss of CD206Hi TAMs could result from either preferential killing
of this TAM subset or altered CD206 expression. To distinguish between these possibilities, we
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analyzed the kinetics of macrophage cell death. We found that in PDAC tumors, CD206Hi TAMs
experienced significantly higher levels of cell death following aCSF1 treatment than CD206Low
TAMs (Figures 2.3C-E). These data suggest that CD206Hi TAMs are more sensitive to the
CSF1R signal blockade. Consistent with this differential sensitivity, we found that CD206Hi
TAMs express higher levels of CSF1R (Figure 2.3F). In addition, while total Mo-MDSCs
(CD11b+/Ly6G-/Ly6C+) did not demonstrate decreased infiltration until after 8 days of aCSF1
treatment, CD206Hi Mo-MDSCs were markedly reduced as early as 12 hours after CSF1
neutralization (Figure 2.9A). By contrast, the number of CD206Low Mo-MDSCs,
CD11b+/Ly6G+/Ly6C-/MHCII+ mature granulocytes, and CD11b+/Ly6G+/Ly6C+ G-MDSCs
remained unaffected until after 8 days of CSF1/CSF1R blockade (Figure 2.9B). Taken together,
these data suggest that the blockade of CSF1/CSF1R signaling preferentially, but not exclusively,
depletes CD206Hi TAMs and CD206Hi Mo-MDSCs in pancreatic tumors.

2.4.4 CSF1/CSF1R signal blockade reprograms TAMs.
Despite extensive loss of macrophages and Mo-MDSCs, 40-50% of TAMs remain after
αCSF1 or CSF1Ri treatment. To determine whether CSF1 blockade reprograms the remaining
macrophages to support anti-tumor activities, we FACS sorted TAMs from 8-day vehicle or
aCSF1-treated mice bearing established KI tumors and compared their gene expression profiles.
TAMs from aCSF1-treated tumors displayed reduced expression of immunosuppressive
molecules, including Pdcd1lg2, Il10, Arg1, Tgfb1and Ccl22. By contrast, anti-tumor immunity
genes, such as Il12a, Ifna, Ifnb1, Ifng, Cxcl10, and Nos2, were upregulated (Figure 2.3H). We
also observed markedly increased surface expression of MHCII after CSF1 or CSF1R inhibition
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(Figure 2.3I). Taken together, these data suggest that the CSF1/CSF1R blockade reprograms
remaining TAMs to support anti-tumor interferon responses and T cell activities.

2.4.5 CSF1/CSF1R signal blockade alters the function of TAMs and dendritic cells.
Based on the observed differences in cytokine profiles among TAMs, we predicted that
CSF1/CSF1R blockade might also alter the ability of macrophages to suppress T cell functions.
To address this hypothesis, we assessed the immunosuppressive activity and antigen presentation
capacity of macrophages in PDAC tumors from mice following CSF1 blockade. Consistent with
the reduced expression of immunosuppressive factors (Figure 2.3H), we found that
fluorescence-activated cell sorted TAMs from 8-day aCSF1-treated mice had significantly
reduced ability to block CD8+ T cell activation in ex vivo assays (Figure 2.4A). These data
suggest that the TAMs that remain after CSF1 blockade have reduced immunosuppressive
activity.
We also analyzed how CSF1 blockade might impact the number and function of antigen
presenting cells (APCs) in the tumor microenvironment. To identify potential APCs in PDAC
tumors, we orthotopically implanted mCherry-labeled KI tumor cells. This model allowed us to
identify potential APCs by their uptake of tumor antigens, based on their mCherry fluorescence
(Figure 2.4B, (Engelhardt et al., 2012)). We were able to detect tumor-derived mCherry signal
in granulocytes, monocytes, TAMs, and dendritic cells (DCs) (Figure 2.4B). The highest levels
of mCherry uptake were observed in TAMs and a subset of CD11blow/-/Ly6G/C-/CD19/CD11c+/MHCII+ cells, presumably lymphoid-like DCs (LyDCs). CSF1/CSF1R blockade did not
affect mCherry uptake. Interestingly, unlike in TAMs, CSF1/CSF1R blockade significantly
increased the number of tumor-infiltrating LyDCs and their surface expression of MHCII
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(Figure 2.4C, and Figures 2.9C-E). Because of the high level of tumor antigen uptake by
TAMs and LyDCs, we tested the ability of these two cell types to present antigen to naïve CD8+
T cells and stimulate their proliferation. We isolated TAMs and LyDCs from orthotopic KC
tumors obtained from mice treated with either vehicle or aCSF1 for 8 days. These leukocytes
were then loaded with SIINFEKL peptide and assessed for their ability to activate OT1 T cells.
While macrophages and LyDCs isolated from vehicle-treated tumors had very limited ability to
activate T cells, aCSF1 treatment significantly enhanced the capacity of these two cell types to
induce CD8+ T cell proliferation (Figure 2.4D). Taken together, these data suggest that CSF1
blockade alleviates immunosuppressive activities and enhances APC potential in both TAMs and
tumor-infiltrating LyDCs.

2.4.6 CSF1/CSF1R blockade modestly increases anti-tumor T cell activity.
To further understand how the blockade of CSF1/CSF1R signaling might reprogram the
tumor microenvironment to regulate tumor progression, we assessed alterations in tumorinfiltrating T lymphocytes and tumor growth following CSF1 or CSF1R blockade in established
murine PDAC tumors. Mice bearing established (12 days, ~1cm) orthotropic KI or PAN02
tumors were treated with aCSF1 IgGs or CSF1Ri. Tumor progression was modestly reduced by
aCSF1 or CSF1Ri treatment as a single agent (Figures 2.5A–C). This reduction in tumor growth
correlated with increases in CD3+CD8+ CTLs and CD3+CD4+ effectors T cells, decreases in
CD4+ Foxp3+ T regulatory cells (TRegs), and significantly improved effector-to-TReg ratios
(Figures 2.5D–E). While the majority of tumor-infiltrating CD8+ CTLs had a CD69+, CD44+,
and CD62L- activated phenotype, CSF1R blockade led to a modest increase in both the number
of CD69+ CD8+ T cells (65% to 76%) and the level of CD44 expression (Figure 2.5F). The
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observed increase in T cell numbers and enhancement of activation status correspond to our
results from gene expression profiling in Figure 1.2.

2.4.7 CSF1/CSF1R signal blockade alters T cell checkpoint signaling.
Although the CSF1/CSF1R blockade enhanced T cell infiltration, we hypothesized that
anti-tumor immunity might be limited via the engagement of T cell checkpoints. We found that
approximately 70% of activated CTLs had a high level of PD1 expression, which was unaffected
by CSF1R blockade. By contrast, CTLA4 expression on CD8+ CTLs was significantly
upregulated by CSF1R inhibition (Figure 2.5F). Along these lines, our array analysis (Figure
2.2) showed that Cd274 (PDL1) was significantly upregulated following CSF1R blockade. We
verified these results using qRT-PCR, and found that both Cd274 and Ctla4, but not Pdcd1lg2
(PDL2), are upregulated in tumor tissues following CSF1 or CSF1R blockade (Figures 2.6A–B).
These data suggest that while CSF1 blockade reprograms the tumor microenvironment to
enhance effector T cell infiltration, engagement of T cell checkpoints is also enhanced.
To determine the cellular sources of these molecules, we analyzed PDL1, PDL2, and PD1
expression on tumor cells and tumor-infiltrating myeloid cells from vehicle- or CSF1Ri-treated
mice. We found that TAMs expressed high levels of PD1, PDL1, and PDL2, but consistent with
a decreased immunosuppressive capacity, tumor-infiltrating macrophages from CSF1Ri-treated
mice had markedly decreased PDL2 and PD1 expression (Figures 2.6C, 2.6F). CSF1Ri
treatment also decreased the total number of PD1- and PDL2-positive TAMs (Figure 2.6D).
Similar effects were also seen with aCSF1 treatment (data not shown). Neither Mo-MDSCs nor
G-MDSCs expressed significant levels of PDL2. While CSF1R blockade did not alter PD1 or
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PDL1 expression in G-MDSCs, PDL1 expression was modestly elevated in Mo-MDSCs
following CSF1Ri treatment.
Expression of PDL1, PD1, and PDL2 has been reported on human PDAC tumor cells,
potentially allowing them to evade immune surveillance by suppressing T cell function. To
determine if CSF1R blockade affects the expression of these molecules on PDAC cells, we used
mCherry-expressing KI or KC cells to identify tumor cells in vivo. We found that both KI and
KC cells express PDL1 at modest levels in vivo, but neither cell line expresses PDL2 or PD1
(Figures 2.6C, 2.6F, and not shown). However, following CSF1 or CSF1R blockade, the
number of PDL1+ tumor cells and overall expression level of PDL1 was markedly upregulated
on PDAC tumor cells (Figure 2.6C, 2.6E). These observations correspond with the increased
mRNA levels of Cd274 identified by array analysis and qRT-PCR validation (Figure 2.2, 2.6A).
Taken together, these results suggest that while CSF1/CSF1R blockade reprograms macrophage
responses to bolster CTL responses, this reprogramming also leads to upregulation of PDL1 on
tumor cells and CTLA4 on T cells. These checkpoints will likely limit the efficacy of observed
anti-tumor immune responses.

2.4.8 CSF1/CSF1R blockade enhances responses to checkpoint immunotherapy.
Based on the above data, we hypothesized that CSF1 or CSF1R blockade could enhance
PDAC responses to PD1- and/or CTLA4-antagonist based immunotherapy. To assess this
hypothesis, we treated mice bearing established KI tumors with aPD1 or aCTLA4 with or
without CSF1Ri in combination with gemcitabine (GEM). PD1 and CTLA4 antagonists in
combination with GEM had only limited efficacy at blunting the progression of established
tumors (Figures 2.7A–B). By contrast, the combination of CSF1R blockade with either PD1 or
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CTLA4 antagonists reduced tumor progression by more than 90%. Since combined PD1 and
CTLA4 antagonist therapy is being tested clinically for the treatment of both melanoma and
PDAC, we also tried this combined therapeutic approach. In the absence of chemotherapy, even
combined aPD1/aCTLA4 treatment only limited tumor progression by ~50%. However, the
addition of CSF1R blockade to aPD1/aCTLA4 treatment completely blocked tumor progression
and even regressed established tumors by 15% (Figure 2.7C). When CSF1 blockade was
combined with aPD1/aCTLA4 and GEM treatment, we observed complete tumor regression in
30% of animals and an average tumor regression of ~85% (Figure 2.7D). Similar results were
seen in orthotopic KC tumors, and when the less potent CSF1R inhibitor, GW2850, was used
(Figures 2.7B, 2.10A-B). Analysis of T cell responses following combined therapy with aCSF1
and aPD1/aCTLA4 antagonists demonstrated increased CD8+ CTL and CD4+ effector T cell
infiltration and decreased CD4+ Foxp3+ TReg numbers (Figure 2.7E). In addition, the number of
TAMs, Mo-MDSCs, and G-MDSCs decreased following this combined therapeutic regimen
(Figure 2.7F).
To determine if alterations in tumor burden in CSF1Ri treatment mice were due to
increased T cells responses we conducted CD4 and CD8 T depletion studies and found that
CSF1R blockade no longer improved checkpoint-based therapy (Figure 2.7G). Taken together,
these results suggest that CSF1/CSF1R blockade improve checkpoint immunotherapy by
enhancing CD4+ and CD8+ T cell activities.
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2.5 Discussion
In this report, we show that blockade of CSF1/CSF1R signaling in pancreatic tumors
depletes CD206Hi TAMs and reprograms remaining macrophages to support anti-tumor
immunity. The blockade alone modestly enhances anti-tumor interferon responses, promotes
CTL infiltration, and slows tumor progression. However, the therapeutic effect is limited by the
induction of T cell checkpoint molecules, including PDL1 on tumor cells and CTLA4 on T cells.
Addition of the CSF1/CSF1R blockade markedly improved the efficacy of aPD1 and aCTLA4
checkpoint immunotherapy and led to the regression of even well-established PDAC tumors.
These data suggest that CSF1/CSF1R signaling may be an effective therapeutic target to
reprogram the immunosuppressive microenvironment of human PDAC tumors and enhance the
efficacy of immunotherapy.
Recent data from several groups suggest that inhibition of CSF1R signaling alters the
immunologic responses of tumor-infiltrating macrophages in several cancer types (DeNardo et
al., 2011; Mitchem et al., 2013; Mok et al., 2013; Priceman et al., 2010; Pyonteck et al., 2013;
Strachan et al., 2013). Mok et al. targeted CSF1R signaling using the compound PLX3397 in a
murine melanoma model; PLX3397 treatment depleted >80% of TAMs, leaving behind a small
population of MHCIIHi macrophages (Mok et al., 2013). These effects led to increased efficacy
of adoptively transferred T cell based therapies. These data agree with our report here. In
addition, recent work by Pyonteck et al. has shown that blockade of CSF1R signaling, using the
small molecule inhibitor BLZ945, significantly blunts murine glioma tumor growth by
reprogramming macrophage responses (Pyonteck et al., 2013). In contrast to pancreas,
melanoma and breast models, macrophage numbers in these murine glioma studies were not
reduced. Instead, TAM survival was sustained by tumor-derived factors. However, in glioma,
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CSF1R blockade impairs the tumor-promoting functions of TAMs and regresses established
tumors. Taken together, these results suggest that CSF1/CSF1R signaling can regulate both the
number and the function of TAMs, but these activities may be highly dependent on tumortype/tissue-specific factors.
One possible mechanism by which CSF1Ri reprograms the remaining TAMs is that
CSF1R signaling may promote tumor-promoting macrophage phenotypes, while its blockade
polarizes TAMs into the anti-tumor phenotype. In a study by Fleetwood et al. , macrophages
cultured in CSF1 or CSF2 demonstrated different cytokine profiles and transcription
activity(Fleetwood et al., 2007). For example, in response to lipopolysaccharide, CSF2-derived
macrophages preferentially produce IL-6, IL-12, and TNFα, while CSF1-derived macrophages
produce IL-10 and CCL-2, but not IL-12. These data suggest that the exact cytokine milieu
differentially program macrophages to play diverse roles. Intriguingly PDAC tumors can also
produce high levels of CSF2 (Bayne et al., 2012; Pylayeva-Gupta et al., 2012), which could
reprogram TAMs toward DC-like phenotypes when unopposed by CSF1R signaling.
Alternative to TAMs being reprogrammed by CSF1Ri, another possible mechanism is
that CSF1R signaling blockade selects for a subset of tumor-restraining macrophages that are
insensitive to the CSF signal kills-off a subset of TAMs that have a pro-tumor phenotype. In
many physiological and pathological settings, including cancers, macrophages are composed of
heterogeneous subsets of populations with distinct functions (Movahedi et al., 2010). These
subsets may depend on different factors for their survival, proliferation, and effector functions.
Selection pressure due to CSF1 signal blockade may have enriched for subsets of anti-tumor
macrophages in PDAC tissue that are less dependent on CSF1 signaling for their survival. Our
analysis of cell death in CD206HiMHCIILow vs. CD206LoMHCIIHi TAM sensitivity to aCSF1 IgG
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supports this hypothesis (Figure 2.3B). While both CD206Hi and CD206Low TAM populations
had detectable cell death upon CSF1 neutralization, the CD206Hi populations were preferentially
depleted. The CD206Hi TAM subset had significantly higher CSF1R expression levels,
suggesting that this population may be more dependent on the CSF1 signal. Taken together, the
heterogeneity of macrophages within the tumor tissue suggests that subsets of TAMs can be
targeted to modulate the tumor microenvironment and enhance tumor elimination.
CD206 is expressed in many subsets of myeloid cells other than macrophages, including
immature dendritic cells and monocytes (Van Dyken and Locksley, 2013). Whether CD206
expression is correlated to differential activation status in these cell types is not known.
Interestingly, Tie2+ monocytes almost uniformly express CD206 (Pucci et al., 2009). It remains
to be seen whether the loss of CD206Hi tumor-infiltrating monocytes upon αCSF1 treatment
(Figure 2.9A) involves the Tie2+ monocytes and/or affects tumor vasculature.
Although CSF1/CSF1R blockade enhances the anti-tumor activity of myeloid cells and T
cell responses, its efficacy can be blunted by upregulation of immune checkpoint molecules,
especially PDL1. While tumor intrinsic pathways have been reported to drive PDL1 expression
in tumor cells (Le et al., 2013), multiple lines of evidence suggest that PDL1 expression by
epithelial tumors is an adaptive response to interferon signaling from tumor stroma. Several
groups have reported that IFNγ and IFNα directly lead to the upregulation of PDL1 (Chen et al.,
2012; Rowe et al., 2012; Spranger et al., 2013; Terawaki et al., 2011). Consistent with these
studies, in vitro treatment with recombinant IFNγ markedly upregulated PDL1 expression in our
PDAC cell lines (not shown). Given the elevated expression of interferons and interferon
response genes in CSF1Ri-treated PDAC tumor tissue, we reason that CSF1Ri-mediated
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interferon production might drive the upregulation of PDL1 in PDAC cells, an inherent
limitation of this therapy.
Even though T cell checkpoint inhibitors alone have achieved impressive clinical benefits
in some other cancers, particularly melanoma (Hamid et al., 2013; Wolchok et al., 2013), their
application in pancreatic cancer as single agents has had limited efficacy (Royal et al., 2010).
This is potentially due to the immunosuppressive microenvironment of PDAC tissue, which
could be alleviated by therapeutic strategies that reprogram dominant myeloid responses to allow
for effective checkpoint therapy.
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2.6 Figures

	
  
Figure 2.1. PDAC tumors overexpress CSF1.
A–B) Immunohistochemical analysis of CSF1 expression in normal pancreas and PDAC tissue.
Representative immunofluorescent images are shown. C–D) Stratification of patient PDAC
samples based on expression levels of CSF1 and CSF1R (n=4 normal and 77 PDAC).
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Figure 2.2. CSF1/CSF1R blockade reprograms the tumor immune microenvironment.
A) Leukocyte infiltration in KI tumors from mice treated with vehicle or CSF1Ri (PLX3397) for
8 days. The frequency of CD11b+CD3/19−Ly6G−Ly6CLoF4/80HiMHCII+ macrophages,
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CD11b+Ly6G−Ly6CHi Mo-MDSC, and CD11b+Ly6GHiLy6C+MHCIIlow/- G-MDSC subsets is
depicted as the mean percentage over total live cells.
B) Cluster analysis of differential gene expression (Table S1) in vehicle- and CSF1Ri-treated
tumors.
C) Table of biologic processes enriched in “upregulated” or “downregulated” genes (DAVID
analysis).
D–E) Selected gene sets are displayed with associated biological activities.
F) qRT-PCR analysis of orthotopic KI tumor tissue following treatment with vehicle or CSF1Ri
for 8 days. Graph depicts mean fold change compared to vehicle.
G) Kaplan Meier analysis of patient cohorts stratified by expression level of genes downregulated from the analysis in (B).
In all panels n=4-6 mice/group and * denotes p<0.05 (Mann-Whitney U-test), unless specified.
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Figure 2.3. CSF1/CSF1R signaling blockade reprograms TAM response.
A) Representative flow cytometry plots with gating strategy to identify mature granulocytes, GMDSCs, Mo-MDSCs, and TAM subsets.
B-D) Frequency of total, CD206Hi and CD206Low TAMs in orthotopic KI tumors treated with
aCSF1 for 6 hours–8 days. Mean percentage of macrophages over total cells is depicted.
C) Representative analysis of MHCII and CD206 expression in TAMs following 8-day treatment
with vehicle or aCSF1.
E) Analysis of dead (live/dead blue dye+) CD206Hi and CD206Low TAMs in PDAC tumors from
(B).
F) CSF1R expression by MFI in CD206Hi and CD206Low TAMs in vehicle-treated mice from (B).
G) CD206 expression by MFI and CD206Hi TAM number following 8 days of aCSF1 treatment.
H) qRTPCR analysis on CD11b+Ly6G/C-F4/80+MHCII+ TAMs sorted from KI tumors
following 8-day treatment with vehicle or aCSF1.
I) MHCII expression by MFI in TAMs from (H).
All graphs depict means values or normalized fold change +/-SEM, n=4-6 mice/group and *
denotes p<0.05 by unpaired t-test or Mann-Whitney U-test.
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Figure 2.4. CSF1/CSF1R signaling blockade enhances TAM support for CTL responses.
A) Analysis of T cell suppression by TAMs from vehicle- or aCSF1-treated mice. TAMs were
isolated by FACS and assayed for their ability to suppress splenic CD8+ T cell proliferation
following anti-CD3/CD28 stimulation. The mean number of proliferation cycles is depicted after
70 hours. Representative data from two replicate experiments (n=3 mice/group).
B) Flow cytometry analysis of tumor-derived mCherry fluorescence in tumor-infiltrating
leukocytes. Representative plots from 5 mice are depicted.
C) Frequency of CD11b+/Ly6G-/Ly6CLo/F4/80Hi/MHCII+ TAMs and CD11bLow/-/Ly6GC-/CD19/CD11c+/MHCII+ Lymphoid DCs in orthotopic KI tumors after 8 days of aCSF1 or CSF1Ri
treatment.
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D) TAMs and LyDCs were isolated by FACS from mice in (C), loaded with SIINFEKL peptide,
co-cultured with splenic OT1 cells for 18 hours. OT1 proliferation was measured by CFSE
dilution. Results reflect two triplicate experiments using 3 mice/group.
All graphs depict mean values +/- SEM. * denotes p<0.05 by unpaired t-test.
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Figure 2.5. CSF1/CSF1R blockade bolsters T cell responses.
A–C) Mice bearing established orthotopic KI or PAN02 tumors were treated with vehicle,
CSF1Ri, or aCSF1. Tumor burden is displayed as mean tumor weight (n=10–15 mice/group),
normalized to five mice sacrificed at the start of treatment (“RX Start”).
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D–E) Analysis of tumor-infiltrating CD3+CD8+CTLs, CD3+CD4+Foxp3- effector T cells, and
CD4+Foxp3+ Treg from mice in (A–B) is depicted as mean percentage over total live cells (n=6
mice/group). The mean effector (CTL + CD4+ effector)-to- TReg ratio is also depicted.
F) CD69, CD44, CTLA4, and PD1 expression in CD3+CD8+CTLs from mice in (A) is depicted
as both MFI and percentage of positive cells. Representative plots are depicted.
* denotes p<0.05 by Mann-Whitney and n=5-6 in all panels.
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Figure 2.6. CSF1/CSF1R signaling blockade elevates PDL1 expression in tumor cells.
A–B) qRT-PCR analysis of KI tumors following 8-day treatment with vehicle, CSF1Ri or aCSF1.
C) PDL1 and PDL2 expression in denoted tumor-infiltrating myeloid cells from orthotopic KI
tumors treated with vehicle or CSF1Ri. Representative FACS plots and MFI are depicted.
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D) Mean percentage of PDL1+ and PDL2+ TAMs and monocytes.
E) Mean percentage of PDL1+ PDAC cells in orthotopic KI tumors from mice treated with
vehicle, CSF1Ri, or aCSF1. PDAC cells were identified as CD45- mCherry+.
F-G) PD1 expression in tumor-infiltrating myeloid cells following vehicle or CSF1Ri treatment.
Representative expression plots, MFI and positive cells percentage data are depicted.
All graphs depict means values +/-SEM, n=3-7 mice/group. * denotes p<0.05 by unpaired t-test.
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Figure 2.7. CSF1/CSF1R signaling blockade enhances T cell checkpoint immunotherapy.
A–D) Mice bearing orthotopic KI or KC tumors were treated with vehicle, CSF1Ri, or aCSF1,
+/- GEM +/- aPD1, and +/-aCTLA4. The tumor burden is displayed as mean tumor weight
(n=10–15 mice/group), normalized to five mice sacrificed at the start of treatment (“Start”).
E) Frequency of tumor-infiltrating CD3+CD8+CTLs, CD3+CD4+Foxp3- T effectors, and Foxp3+
CD4+ TRegs from mice in (D) is depicted as mean percentage of total live cells (n=6 mice/group).
Mean effector (CTL + CD4+ effector) to TReg ratio is depicted.
F) Flow cytometric analysis of tumor-infiltrating CD11b+Ly6C/G-F4/80+MHCII+ TAMs,
CD11b+Ly6C+Ly6G- Mo-MDSCs, and CD11b+ Ly6C+Ly6G+MHCII- G-MDSCs from mice in
(D) is depicted as mean percentage of total cells (n=6 mice/group).
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G) Mice bearing orthotopic KI tumors were treated with GEM, aPD1, aCTLA4, vehicle or
aCSF1, +/- aCD4 and aCD8. The tumor burden is displayed as mean tumor weight (n=10-15
mice/group).
All graphs depict mean values +/- SEM and * denotes p<0.05 by unpaired t-test and/or MannWhitney U-test.
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Figure 2.8. Flow cytometric analysis of leukocyte infiltration in orthotopic PDAC tumors.
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A) Representative FACS plots with gating strategy to identify mature granulocytes
(CD11b+Ly6G+Ly6C-MHCII+), G-MDSCs (CD11b+Ly6G+Ly6C+), Mo-MDSCs (CD11b+Ly6GLy6C+), and CD206Lo and CD206Hi TAMs (CD11b+Ly6G/C-F4/80+MHCII+).
B) CD206 expression in TAM subsets.

	
  

91	
  

Figure 2.9. CSF1 blockade depletes CD206+ Mo-MDSCs and upregulates MHCII
expression in Lymphoid DCs.
A) Frequency of CD206Hi Mo-MDSCs in orthotopic KI tumors from mice treated with aCSF1
for 6 hours to 8 days.
B) Frequency of Mo-MDSCs, G-MDSCs, and mature granulocytes in KI tumors from (A).
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C) Flow cytometry analyses of MHCII, CD11c, and F4/80 expression in mCherryLow and
mCherryHi tumor-infiltrating LyDCs from mCherry+ KI tumor-bearing mice. Representative
plots from 6 mice are depicted.
D) Flow cytometry analyses of MHCII, CD11c, and F4/80 expression in tumor-infiltrating
LyDCs from orthotopic KI tumors following vehicle or CSF1Ri treatment.
E) MHCII expression in tumor-infiltrating LyDCs from mice in (D) is quantified as MFI.
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Figure 2.10. CSF1R signaling blockade enhances T cell checkpoint immunotherapy.
A-B) Mice bearing orthotopic KC (A) or KI (B) tumors were treated with vehicle, PLX3397,
GW2850, +/- GEM +/- aPD1 and/or aCTLA4. The tumor burden is displayed as mean tumor
weight (n=10-15) compared to that of 5 mice sacrificed at the start of treatment (“Start”).
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Chapter 3: Tissue Resident Macrophages in
Pancreatic Ductal Adenocarcinoma Originate from
Embryonic Hematopoiesis and Promote Tumor
Progression

Reference:
Zhu Y, Herndon JM, Sojka DK, Kim KW, Knolhoff BL, Zuo C, Cullinan DR, Luo J, Bearden
AR, Lavine KJ, Yokoyama WM, Hawkins WG, Fields YC, Randolph GJ, DeNardo DG.
Pancreatic cancer-associated macrophage subsets have different origin and functions. (Revision
Submitted to Immunity)
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3.1 Summary
Tumor-associated macrophages (TAMs) are essential components of the cancer
microenvironment and play critical roles in the regulation of tumor progression. Optimal
therapeutic intervention requires in-depth understanding of the sources that sustain macrophages
in malignant tissues. In this study, we investigated the ontogeny of TAMs in murine pancreatic
ductal adenocarcinoma (PDAC) models. We identified both inflammatory monocytes and tissueresident macrophages as sources of TAMs. Unexpectedly, significant portions of pancreasresident macrophages originate during embryonic development and expand through in situ
proliferation during tumor progression. While monocyte-derived TAMs play more potent roles in
antigen presentation, embryonically derived TAMs exhibit a pro-fibrotic transcriptional profile,
indicative of their role in producing and remodeling extracellular matrix molecules. Collectively,
these findings uncover the heterogeneity of TAM origin and functions, and could provide
therapeutic insight for PDAC treatment.
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3.2 Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignant diseases.
Current therapeutic interventions are extremely ineffective in PDAC treatment, partly due to
components in the microenvironment that promote tumor growth. Two hallmarks of the PDAC
microenvironment are the dense fibrotic stroma and extensive infiltration of myeloid cells,
including macrophages. Tumor-associated macrophages (TAMs) are one of the most abundant
immune cells infiltrating PDAC. TAMs promote tumor growth by releasing growth factors,
inhibiting anti-tumor adaptive immune responses, modifying angiogenesis, and promoting
fibrosis, among other mechanisms (Biswas and Mantovani, 2010; Noy and Pollard, 2014; Ruffell
and Coussens, 2015). Therefore, high numbers of TAMs correlate with poor patient outcome
(Balaz et al., 2002; Ino et al., 2013; Kurahara et al., 2011). Consequently, TAMs are considered a
highly desirable therapeutic target (Mantovani et al., 2014; Noy and Pollard, 2014).
Optimal therapeutic strategies targeting TAMs require an in-depth understanding of their
ontogeny and the mechanisms governing their homeostasis. The traditional view holds that tissue
macrophages are derived from circulating Ly6CHi monocytes. In the last few years, an increasing
amount of evidence suggests that various types of tissue-resident macrophages are established
during embryonic development, persist into adulthood, and self-maintain independently of the
adult hematopoietic system (Epelman et al., 2014; Ginhoux and Guilliams, 2016; Gomez
Perdiguero et al., 2015; Hashimoto et al., 2013; Perdiguero and Geissmann, 2016; Schulz et al.,
2012; Varol et al., 2015; Yona et al., 2013). Under homeostatic conditions, macrophages derived
from different developmental origins co-exist in many organs. Two notable exceptions are brain
microglia, the majority of which are generated during embryonic hematopoiesis at the yolk sac
stage (Ginhoux et al., 2010; Hoeffel et al., 2015), and intestinal macrophages, which rely on
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continuous replenishment by adult blood monocytes (Bain et al., 2014). Macrophages in many
other organs, including the pancreas, have mixed origins (Calderon et al., 2015). A limited
number of studies suggest that co-existing macrophages, derived from different developmental
origins, have both overlapping and distinct functions within the same tissue (Epelman et al.,
2014; Gibbings et al., 2015). However, more studies are needed to address the correlation
between the ontogeny and functionality of different macrophage subsets.
Despite the growing body of knowledge of tissue-resident macrophages, monocytes are
still often considered as the precursors of macrophages in tumors (Franklin and Li, 2016). Indeed,
multiple studies in several tumor models have demonstrated the contribution of circulating
monocytes to sustaining TAM numbers. (Franklin et al., 2014; Laoui et al., 2014; Movahedi et
al., 2010). In addition to bone marrow, spleen was also shown to serve as an extramedullary
hematopoietic site that supplies monocytes to replenish TAM pools (Cortez-Retamozo et al.,
2013). However, the contribution of tissue-resident macrophages to TAMs has largely been
understudied. Tissue-resident macrophages are known to proliferate in situ under pathological
conditions (Amano et al., 2014; Jenkins et al., 2011). In addition, in situ proliferating
macrophages have been observed in human cancers (Campbell et al., 2010). However, it is not
known whether proliferation of tissue-resident macrophages contributes to TAM numbers in
malignancies.
In this study, we document a previously unappreciated heterogeneity in the ontogeny of
TAMs in pancreatic ductal adenocarcinoma. We identify both Ly6CHi monocytes and tissueresident macrophages of embryonic origin as sources of TAMs. More importantly, TAMs
derived from different origins demonstrate distinct phenotypes and transcriptional profiles,
suggesting divergent functionality. While monocyte-derived TAMs are more potent at sampling
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tumor antigens and regulating adaptive immune responses, embryonically derived TAMs have
higher expression levels of pro-fibrotic genes that encode for extracellular matrix (ECM) and
ECM remodeling molecules. These data reveal a potential novel function of embryonically
derived macrophages, and suggest a previously unknown interaction between TAMs and the
fibrotic PDAC stroma, which could serve as a therapeutic target for PDAC treatment.
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3.3 Methods and Materials
Murine PDAC Models
KPC mice (p48-CRE/Lox-stop-Lox(LSL)-KrasG12D/p53flox/+) used in these studies have been
previously described (Hingorani et al., 2005) and were backcrossed to C57BL/6 background and
screened for C57BL/6 identity using congenic markers. KPC-1 cell line was derived from PDAC
tissues of 2.2-month-old p48-CRE+/LSL-Lox KrasG12D/p53flox/flox (KPPC); the KPC-2 cell line
was derived from tumors of 6-month-old p48-CRE+/LSL-Lox KrasG12D/p53flox/+ (KPC) mice.
Cells were grown on collagen-coated tissue culture flasks for <12 passages, and were tested for
cytokeratin-19, smooth muscle actin, vimentin, and CD45 to verify their carcinoma identity and
purity. To establish orthotopic KPC models, either 50,000 or 200,000 KPC-1 or KPC-2 cells in
50 µL of Cultrex (Trevigen) were injected into the pancreas of 6-12-week-old C57BL/6 mice
according to published protocol (Kim et al., 2009). For mCherry analyses or bioluminescence
imaging (BLI), KPC-1 or KPC-2 cells were infected with mCherry or click beetle red (CBR)GFP vector respectively. mCherryhi or GFPhi cells were selected by FACS prior to orthotopic
implantation.

Other Mouse Models
The following mouse strains were purchased from Jackson Laboratories: CCR2-/-, Nur77-/-,
Rosa26- LSL-eYFP, and Cx3cr1-CreERT2 (all on the C57BL/6 background). Csf1r-Mer-iCreMer mice were purchased from Jackson Laboratories, and were crossed to Rosa26-LSLtdTomato mice, which were a kind gift from Dr. Gregory D. Longmore; both strains are on the
FVB background. Flt3-Cretg mice were a kind gift from Dr. Thomas Boehm and were crossed to
Rosa26-LSL-eYFP or –tdTomato mice, all under the C57BL/6 background. Mice were
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maintained in the Laboratory for Animal Care barrier facility at Washington University School
of Medicine. Washington University School of Medicine Institutional Animal Studies
Committee approved all animal studies.

Labeling of Blood Ly6Chi Monocytes
To selectively label Ly6Chi monocytes, 250 uL of liposomes containing clodronate were injected
intraveneously (i.v.), followed by i.v. injection of 250 uL of FITC-conjugated plain microspheres
16-18 hours later (1.0 um, 2.5% solids [wt/vol]; Polysciences, diluted 1:4 in PBS). Tissues were
processed for flow cytometry analyses at indicated time points after bead injection.

Parabiosis
Parabiotic pairs were generated according to established protocols (Peng et al., 2013) from age(3.5-month-old) and weight-matched female CD45.2+ (KPC or wild-type C57BL/6) and CD45.1+
(C57BL/6) mice. Mice were injected with Buprenex subcutaneously after surgery. Sulfatrim was
continuously added in drinking water for 10 days post-surgery to minimize infections at surgical
wounds. Mice were separated and perfused with phosphate buffered saline (PBS) containing
0.2% heparin. Single cell suspensions from tissues were stained with antibodies for flow
cytometry analyses 2 or 6 weeks after the establishment of parabiosis.

Bone Marrow Transplantation
Three and a half-month-old C57BL/6 mice or KPC mice were exposed to γ-irradiation dosed at
1100 rads. Animals were subsequently injected with 2.5 x 106 bone marrow cells from CD45.1+
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C57BL/6 mice through i.v. injection (retro-orbital or tail vain). Leukocyte chimerism was
analyzed 6 weeks later.

Macrophage Depletion
To deplete tissue resident macrophages, 8-16-week old C57BL/6 mice were treated with 3 doses
of CSF1 neutralizing antibody (clone 5A1, BioXCell) (1 mg, 0.5 mg, 0.5 mg on Days -18, -14,
and -11, Figure 3) and 3 doses of clodronate-containing liposome (200 uL/each on Days -17, -13,
and -10). Control mice were treated with same doses/volume of IgG (clone HRPN, BioXCell)
and liposome (or phosphate buffered saline as indicated). On Day 0, Mice were implanted
orthotopically with 200,000 CBR+ KPC-2 cells or 50,000 CBR+ KPC-1 cells, and subjected to
BLI on Days 3 and 7.
Similarly, KPC and KPPC mice were treated with 2 doses of αCSF1 (0.5 mg each, Day 1 and
Day 5) and 2 doses of clodronate-loaded liposome (100 uL each, Day 3 and Day 7) starting at
2.5-month and 1-month of age, respectively. Tumor burden was analyzed when mice reached 4.5
months for KPC mice or 2.0 months for KPPC mice.
To deplete embryonically derived macrophages, C57BL/6 or Flt3-CreYFP mice were
intraperitoneally injected with 3.0 mgs of CSF1R depleting antibody (AFS98 clone, BioXCell)
on 13.5 dpc. Surviving mice were implanted with 50,000 CBR+ KPC-1 at 6 weeks of age. Mice
were sacrificed 12 days after tumor establishment for flow cytometry and tumor burden analyses.

Lineage Tracing of Embryonically Derived Macrophages
Timed breeding was set up by crossing Csf1r-Mer-iCre-Mer mice with Rosa26-LSL-tdTomato
mice (both on the FVB background). Embryonic timeline was assessed based on vaginal plug
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observation: 12pm on the day of plug formation was estimated to be 0.5 day post coitum (dpc).
Pregnant mice were treated with tamoxifen (Sigma-Aldrich) (75 µg/g) combined with
progesterone (Sigma-Aldrich) (37.5 µg/g) at one of the following time points: 8.5, 9.5, 10.5, or
13.5 dpc. To test the contribution of embryonically derived CSF1R+ cells to monocytes or
macrophages at homeostatic conditions, tumor-free F1 mice were sacrificed for fate mapping
analyses as they reached 6 weeks of age. To test the contribution of embryonically derived
CSF1R+ cells to TAMs in PDAC tumors, 50,000 syngeneic Kras-INK cells were orthotopically
implanted into F1 mice as they reached 6 weeks. Kras-INK cells were derived from p48Cre/Lox-Stop-Lox (LSL)-KrasG12D/Ink4a-Arflox/lox mice on the FVB background as previously
described. Mice were sacrificed approximately 12 days after tumor implantation for the analyses
of tdTomato signal in different leukocyte populations.
To trace CX3CR1+ cells, Cx3cr1-CreERT2 mice were crossed with Rosa26-LSL-eFYP mice
(both on the C57BL/6 background). Pregnant mice were treated with tamoxifen (75 µg/g) and
progesterone (37.5 µg/g) on 13.5 dpc. F1 neonates were fostered by lactating female mice and
then aged to 6 weeks for fate mapping analyses.

Mouse Tissue Isolation and Flow Cytometry
Mice were euthanized by intracardiac perfusion using 20 mL of PBS-heparin under isoflurane
anesthesia. Tumor tissues and colon were manually minced and digested in 25 mL of Dulbecco’s
Modified Eagle Medium (DMEM) (Thermo Fisher) containing 2 mg/mL of collagenase A
(Roche) and 1X DNase I (Sigma) for 30 minutes at 37˚C with constant stirring. Normal pancreas
was digested in the same buffer for 15 minutes at 37˚C. Digestion was quenched in 5 mL of fetal
bovine serum (FBS) (Atlanta Biologicals) and filtered through 40 µm Nylon mesh, pelleted
	
  

103	
  

through centrifugation (2000 rpm for 5 min at 4˚C), and resuspended in staining buffer (PBS
containing 1% BSA). Brain and spleen were minced and triturated through 40 µm filters.
Single cell suspensions were blocked with rat anti-mouse CD16/CD32 antibodies (eBioscience)
(1/200) for 10 minutes, pelleted by centrifugation, and subsequently labeled with 100 uL of
fluorophore-conjugated anti-mouse antibodies at recommended dilutions for 20 minutes on ice,
and washed with staining buffer. For proliferation assays, mice were injected with 5-bromo-2’deoxyuridine (BrdU, 1 mg) i.p. 3 hours prior to sacrifice. BD Bioscience Cytofix/cytoperm kit
was used to stain for BrdU. eBioscience transcription factor staining buffer set was used to stain
for Ki67. Data were acquired on LSR-II (BD Biosciences), and analyzed using FlowJo software
(Tree Star). To quantify proliferating/cycling cells in Flt3-CreYFP mice, tumors were digested as
described above, stained with fluorophore-conjugated antibodies for 20 minutes, fixed in 4%
formaldehyde for 10 minutes on ice, permeabilized in ice-cold 70% ethanol for 3 hours, stained
with Ki67 antibody diluted in staining buffer for 20 minutes on ice, pelleted and resuspended in
staining buffer, and immediately processed for data acquisition on LSR-II. To assess hypoxia,
Flt3-CreYFP mice were intraperitoneally injected with pimonidazole hydroxychloride (60 mg/kg)
1 hour prior to sacrifice (Hypoxyprobe). Single cell suspensions were stained with antibodies
against pimonidazole adducts for 20 minutes at 4˚C without fixation or permeabilization prior to
data acquisition.
To quantitate blood monocytes, 200 uL of blood was obtained by intracardiac puncture prior to
perfusion, incubated in red blood cell lysis buffer (BioLegend) for 15 minutes on ice, and stained
with fluorophore-conjugated antibodies for 20 minutes on ice. Stained cells were counted using
LSR-II. For blood analysis that does not require numeration, blood was drawn via tail vein
bleeding, followed by RBC lysis, antibody staining, and data acquisition.
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Fluorescence-Activated Cell Sorting (FACS)
Normal or tumor-bearing mice (Flt3-CreYFP, KPC, or C57BL/6 control) were perfused with 20
mL of heparin-containing PBS. Tissues were digested in 25 mL of DMEM containing 2 mg/mL
of collagenase A (Roche) and 1X DNase I (Sigma) for 30 minutes at 37˚C with constant stirring.
CD45+ cells were enriched from single cell suspensions through MACS® magnetic selection
using anti-mouse CD45 microbeads (Miltenyi). Elutes were blocked with rat anti-mouse
CD16/CD32 antibodies (eBioscience) (1/200) for 10 minutes, pelleted by centrifugation, and
labeled with fluorophore-conjugated anti-mouse antibodies at recommended dilutions for 20
minutes on ice. Cells were filtered through 40 µm Nylon mesh, and immediately sorted using
Aria-II (BD Biosciences). For microarray analyses and gene expression analyses, cells were
sorted directly into RNA lysis buffer (Omega Biotek); RNA was isolated using the EZNA kit
(Omega Biotek) according to instructions by the manufacturer. For ex vivo assays, cells were
sorted into DMEM containing 20% FBS before being pelleted and resuspended for subsequent
treatments.

Human PDAC Tissues
Human PDAC tissues were obtained from surgically resected specimens from patients diagnosed
in the Department of Pathology at Washington University (St. Louis, MO). Patients underwent
pancreaticoduodenectomy followed by adjuvant chemotherapy. Patients did not receive
neoadjuvant therapy. Tissues were embedded in paraffin blocks and processed into 6 µm-thick
sections for immunofluorescence staining.
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For gene expression profiling in PDAC patients, tissues were freshly obtained from 9 patients at
pancreaticoduodenectomy, digested into single cell suspension using the protocol described
above, stained with indicated antibodies (Table 3.4), and processed for cell isolation using AriaII (BD Biosciences). Cells were directly sorted into RNA lysis buffer (Omega Biotek). RNA was
isolated using the EZNA kit (Omega Biotek) according to instructions by the manufacturer.
cDNA was synthesized using the qScript Supermix (Quanta). cDNA targets were pre-amplified
for 12 cycles, followed by QPCR analyses (Taqman®, Thermo Fisher). Four out of the nine
patients

have

received

neoadjuvant

therapies,

including

FOLFIRINOX

or

ABRAXANE/gemcitabine prior to being scheduled for resection. All patients were off therapy
for 21 days prior to surgery. All tissues were collected under informed consent from patients.
Washington University Ethics committee approved the study under IRB protocol #201108117.

PDAC Patient Outcome Analysis
We used top 110 genes whose expressions were >10-fold higher in the mouse Flt3-CreYFP-negative
TAM subset than the Flt3-CreYFP-positive subset. Mouse gene entrez IDs were mapped to human
ortholog based on ENSEMBLE 87 annotation using Bioconductor package “biomaRt”. Genes
were queried in the cbioportal TCGA pancreatic RNA-seq data through the R package “cdgsr”
on 178 primary PDAC tumors. For association analysis with survival outcomes, we considered
the gene signature using the averaged gene expression across all mapped genes (after centering
each by their median). The gene signature was dichotomized by associated median to divide
patients into the two groups of over- and under-expression. The Kaplan-Meier method was used
to estimate empirical survival probabilities and log rank test to compare survival difference
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between patient groups. Hazard ratio from Cox proportional hazard model was reported with
95% confidence interval.

Sirius Red Staining and Immunofluorescence Staining
Tissues were isolated from perfused mice, fixed in 10% formalin overnight, incubated in graded
ethanol, embedded in paraffin, and cut into 6 µm-thick sections. To analyze tumor fibrosis, tissue
sections were deparaffinized in xylene, rehydrated in graded ethanol, and processed for PicroSirius Red staining according to instructions by the manufacturer (Sigma Aldrich). To visualize
macrophages in mouse KPC and human PDAC tissues, paraffin sections were steam heated for
antigen retrieval in citrate-based buffer (Biogenex), treated with 1% hydrogen peroxide
(Invitrogen) for 20 minutes to quench endogenous peroxidase, incubated with blocking buffer
(PBS containing 5% goat serum and 2.5% BSA) for 1 hour at room temperature (RT), blocked
for biotin/avidin according to instructions by the manufacturer (Vector Labs), and stained with
primary antibodies at recommended dilutions at 4˚C overnight (Table 3.3). Opal 4-color IHC kit
was then used according to instructions by the manufacturer (PerkinElmer). When two
antibodies were used for co-staining, FITC and Cy5 were used to minimize emission spectral
overlap. To visualize YFP-positive macrophages in Flt3-CreYFP mice, orthotopic PDAC tissues
were fixed in 4% formaldehyde at 4˚C overnight, incubated in PBS containing 30% sucrose and
0.1% sodium azide overnight at 4˚C, and embedded in OCT compound on dry ice. Frozen
sections (6 µm-thick) were air-dried, treated with blocking buffer at RT for 1 hour, and stained
with CD68 (1/200) (Abcam) overnight, followed by 1 hour incubation with goat anti-rabbitAlexa594 (1/400) (Molecular Probes) at RT. All sections were washed in PBS containing 0.05%
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Tween-20 between incubation steps, and mounted in DAPI-containing media (Vector Labs) for
imaging on Nikon 80i microscope.

Statistical Analyses
Statistical analysis was performed using Unpaired Student’s t-test, Mann-Whitney U test,
Wilcoxon matched-pairs signed rank test, or ANOVA analysis as appropriate for the data set.
Data in bar graphs are displayed as means ± SEM. Statistical significance is displayed as *
p<0.05.
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3.4 Results
3.4.1 Pancreatic Ductal Adenocarcinoma Tissues are Infiltrated with Macrophages
High levels of fibrosis and extensive inflammatory cell infiltration characterize the tumor
microenvironment of human PDAC. Among the infiltrating cells, macrophages are frequently a
dominant component. This can be readily observed by comparing the expression of panmacrophage/myeloid cell markers CD68, CD163, and CD206 in paired human pancreatic tissue
samples containing both PDAC lesions and adjacent normal tissue (Figures 3.1A-B). This
increase in macrophage number parallels the levels of tissue fibrosis. While tumor infiltration by
macrophages is well characterized, the sources of these macrophages have not been elucidated
completely.
To explore the ontogeny of TAMs in PDAC, we analyzed p48-Cre+/LSLKrasG12D/p53flox/+ (KPC) genetically engineered mouse models (GEMMs), which undergo
stepwise progression through stages of pancreatic intraepithelial neoplasia (PanIN) and
ultimately develop PDAC (Hingorani et al., 2005). The KPC model faithfully recapitulates many
pathological features of the human disease, including progressive development of stromal
fibrosis and extensive accumulation of macrophages (Figure 3.1C). By flow cytometry, we
identified CD45+CD11b+CD3-CD19-Ly6G-Ly6CLow/-F4/80+MHCII+ macrophages in normal
pancreas, autochthonous tumors in KPC mice (Figure 3.1D), and syngeneic orthotopic PDAC
tumors established using KPC-derived cancer cell lines (KPC-1) (Figure 3.8). In all cases, we
confirmed macrophage identity in our gating strategy based on the expression of CD68, MerTK,
CD64 (Gautier et al., 2012), colony-stimulating factor-1 receptor (CSF1R), and CX3C
chemokine receptor-1 (CX3CR1), but not Siglec-F (Figur2s 3.1E, 3.8C). To confirm the
exclusion of dendritic cells (DCs) in our macrophage gating, we established orthotopic tumors in
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Zbtb46gfp/+ reporter mice (Satpathy et al., 2012), and found minimal GFP signal in the
macrophage population compared to DC specific gating strategies (Figures 3.1E, 3.8D).
Furthermore, the vast majority of DCs in both normal pancreas and orthotopic PDAC (identified
by CD45+Zbtb46-GFP+) express considerably lower levels of macrophage markers, including
MerTK, CD64, F4/80, and CX3CR1 (Figure 3.8E), suggesting that pancreas-infiltrating
macrophages are phenotypically distinct from DCs. Flow cytometry analyses of tissues from the
KPC mouse model demonstrated a 24-fold increase in total number and 5-fold increase in
density of macrophages in end-point PDAC compared to normal pancreas (Figure 3.1F).
Similarly, macrophage numbers expand in orthotopic PDAC tissues as the tumors progress
(Figure 3.1G). Taken together, the dramatic upregulation of the number and density of
macrophages in KPC mouse models mimics that seen in human pancreatic cancer. However, the
sources of these macrophages are not clearly defined.

3.4.2 Subsets of Macrophages in Pancreas and PDAC Tissues Are Maintained
Independently of Blood Monocytes
To test the contribution of blood monocytes to macrophages in tumors, we first
performed parabiosis by surgically joining the CD45.2-expressing KPC mice with congenic
wild-type mice that express CD45.1. Parabiotic pairs were set up when KPC mice were 3.5
months of age. At this age, KPC mice have developed extensive PanIN lesions, with microscopic
evidence of progression to full PDAC. To study the contribution of blood monocytes to
macrophages in PDAC, we analyzed chimerism after 6 weeks (at 5 months of age), when disease
in KPC mice would have progressed to late-stage PDAC. We also evaluated chimerism in a
cohort of mice 2 weeks after the establishment of parabiosis to study the dynamics of
	
  

110	
  

macrophage turnover. We observed 28% chimerism of Ly6CHi monocytes in the blood of KPC
mice within the first 2 weeks, which did not increase further after 6 weeks of parabiosis (Figures
3.2A-3.2B). This level of chimerism was mirrored by tissue-infiltrating Ly6CHi monocytes in
both normal pancreas and KPC tumors (Figures 3.9A-B). However, tissue macrophages in
steady-state pancreas only achieved 2.5% chimerism after 6 weeks of parabiosis (Figure 3.2B),
suggesting that the majority of macrophages are maintained independently of circulating
monocytes during this time period. This level of chimerism was close to what we observed in
brain microglia (0.5%), which are known to be locally maintained (Ginhoux et al., 2010; Hoeffel
et al., 2015). Interestingly, the chimerism of macrophages present in KPC tumors was only 8.8%,
compared to 27% for Ly6CHi monocytes in the same tissue. These data suggest that while
monocytes contribute to the expansion of macrophage numbers during PDAC progression, they
might not be the sole source of macrophages in tumor tissues. Additionally, the level of
chimerism observed in macrophages in PDAC tissues was comparable after 2 and 6 weeks, in
spite of significant increases in macrophage numbers during this time period (Figure 3.2B).
These data suggest that chimerism reached equilibrium within 2 weeks of parabiosis and that the
expansion of TAMs was maintained with equal contributions from both monocytes and other
sources.
It is well appreciated that macrophages in tumors exist in subsets with distinct pro-tumor
activities. One approach to identity these TAM subsets is based on differential expression of
major histocompatibility class (MHC) II (denoted MHCIIHi and MHCIILow here-in) (Movahedi et
al., 2010; Zhu et al., 2014). To determine if monocytes replenish these subsets differentially, we
analyzed the tumor tissue following parabiosis. We found that the MHCIIHi subset constituted up
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to 80% of the donor-derived TAMs, suggesting that monocytes preferentially, but not
exclusively, replenish this population over the 6-week time course (Figure 3.2C).
To complement these parabiosis studies, we established bone marrow chimeras by
lethally irradiating wild-type CD45.2+ mice and adoptively transferring bone marrow cells from
CD45.1+ wild-type mice. Six weeks after transfer, more than 99% of the immune cells in the
blood and the bone marrow of KPC mice were CD45.1+ donor-derived (Figure 3.2D). Strikingly,
despite potential elimination of radio-sensitive tissue-resident macrophages and the influx of
Ly6CHi monocytes induced by irradiation, 30% of macrophages in the pancreas were hostderived (CD45.2+) (Figure 3.2D). In parallel, we lethally irradiated 3.5-month-old KPC mice at
the PanIN stage, adoptively transferred bone marrow cells from CD45.1+ wild-type mice, and
analyzed chimerism 6 weeks later in fully established PDAC. Similarly, a significant portion
(>15%) of TAMs in KPC tumors were host-derived, which contrasts with the >99% chimerism
detected in circulating monocytes (Figure 3.2G). These data confirmed the existence of
pancreas-resident TAMs that were not rapidly replaced by blood monocytes. Consistent with the
results of the parabiosis studies, host-derived (CD45.2+) macrophages were preferentially, but
not exclusively, MHCIILow in both normal pancreas and KPC tumor tissues (Figures 3.2E-F,
3.2H).
To further assess the short-term contribution of blood monocytes to TAM maintenance,
we used fluorescently labeled latex beads to selectively trace Ly6CHi blood monocytes in tumorbearing mice, and observed the fluorescent signals in the TAM compartments at 12, 24, 48, and
72 hours after monocyte labeling (Figure 3.9C) (Tacke et al., 2006). While fluorescent beads
labeled 25% of blood monocytes within 24 hours, which is the peak time for fluorescence
detection in blood (Tacke et al., 2006), bead signal was observed in a negligible amount of
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macrophages (<0.5%) in normal pancreas (Figure 3.2I), suggesting that the turnover of
pancreas-resident macrophages relies minimally on monocyte influx, at least short-term. In
orthotopic PDAC, a significantly larger percentage (12%) of TAMs were fluorescently labeled
(Figure 3.2I), suggesting that tumors up-regulate the recruitment of circulating Ly6CHi
monocytes to replenish a portion of TAMs. Consistent with BMT and parabiosis results, beadlabeled monocytes almost exclusively replenished the MHCIIHi TAM subset (Figures 3.2J-K),
and this replenishment persisted through 72 hours after bead injection (Figure 3.9D).

3.4.3 Impairment of Circulating Monocytes Alone Does Not Impact PDAC Progression
To determine the long-term contribution of blood monocytes to macrophages in the
pancreas, we evaluated pancreas and PDAC macrophages in CCR2- and Nur77-defficient mice,
which have impairments in circulating Ly6CHi and Ly6CLow monocytes, respectively (Hanna et
al., 2011; Serbina et al., 2008). Despite >95% reduction in the number of circulating Ly6Chi
monocytes (Figures 3.3A and 3.10A), the frequency of macrophages in steady-state pancreas
was not changed in CCR2-deficient mice (Figure 3.10B). Additionally, while in PDAC tumorbearing CCR2-/- mice, circulating Ly6CHi monocytes was still decreased by >95%, PDACinfiltrating macrophages were decreased by only 50% (Figures 3.3B and 3.10C). Consistent
with the results of the monocyte labeling experiments, CCR2 deficiency decreased MHCIIHi
TAM frequency, while MHCIILow TAMs were not affected (Figure 3.3C). Surprisingly, while
CCR2 deficiency did reduce macrophage numbers, this did not impact tumor growth in two
independent PDAC models (Figures 3.3D and 3.10D). Similar to these syngeneic PDAC models,
there were no changes in tumor burden in KPPC GEMMs treated with CCR2 inhibitors
continuously for 45 days (Figure 3.3K).
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To address the possibility that Ly6CLow monocytes might contribute to macrophages in
PDAC tissues, we analyzed Nur77-/- mice. Similar to data from a previous reports (Hanna et al.,
2011), we observed a 75% decrease in circulating Ly6CLow monocyte numbers in Nur77-/- mice,
compared to Nur77+/- littermates (Figures 3.3E and 3.10A). However, neither macrophage
numbers nor their MHCII-subset distribution was changed in either normal pancreas or
orthotopic PDAC tissues (Figures 3.3F-G). Additionally, Nur77 deficiency did not impact
PDAC tumor growth in three distinct orthotopic PDAC models (Figures 3.3H and 3.10E).
Together, these data suggest that circulating Ly6CHi monocytes are important for sustaining
MHCIIHi macrophages, but dispensable for tumor progression.

3.4.4 Tissue-Resident Macrophages Promote PDAC Progression
To determine whether tissue-resident macrophages regulate tumor growth, we treated
tumor-naïve mice with CSF1 neutralizing antibodies in combination with clodronate-loaded
liposomes, followed by a 10-day chase period to allow mice to recover circulating monocyte
numbers. Following the 10-day recovery, we found that circulating monocyte numbers in
αCSF1/clodronate-treated animals were restored to control/untreated levels (Figure 3.3I). By
contrast, pancreas-resident macrophages were depleted as early as 12 hours after injection and
remained depleted by 85-95% after 10 days of recovery (Figures 3.3I and 3.10F). These data
suggest that this regimen could allow us to test the impact of the loss of tissue-resident
macrophages without decreasing circulating inflammatory monocyte numbers. To study how
loss of resident macrophages affects tumor progression, we established orthotopic PDAC tumors
10 days after treatment with αCSF1/clodronate or IgG/PBS. We found that loss of resident
macrophages prior to tumor implantation resulted in a 50% reduction in TAMs in established
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tumors (Figures 3.3I and 3.10F). These data suggest that loss of resident macrophages is not
fully compensated for by monocyte-derived TAMs. In contrast to observations in CCR2-null
mice, depletion of pancreas-resident macrophages led to a significant reduction in tumor burden,
as measured by both bioluminescence imaging (BLI) and tumor wet-weights (Figure 3.3J).
These studies were repeated using two distinct KPC-derived PDAC models (Figure 3.10G). To
exclude the possibility that the impaired tumor progression was due to deficient tumor “seeding”
upon implantation, we treated two genetic PDAC models (KPC and KPPC mice) with
αCSF1/clodronate at the premalignant PanIN stage, and analyzed tumor burden after mice
developed fully established PDAC. In both KPC and KPPC models, depletion of resident
macrophages resulted in significant reduction in tumor burden (Figures 3.3K). By contrast,
continuous treatment of KPPC-mice with CCR2 inhibitors during the same time period, in spite
of reducing monocyte numbers, did not impact tumor burden (Figures 3.3K). More impressively,
analysis of tumor pathology in KPPC mice showed that in addition to reducing overall tumor
burden, depletion of resident macrophages dramatically reduced the development of high-grade
invasive tumors, which correlated with reduced PDAC cell proliferation (Figures 3.3L-M).
Taken together, these data suggest that pancreas-resident macrophages are more critical,
compared to monocyte-derived TAMs, in driving PDAC tumor progression.

3.4.5 Embryonically Derived Macrophages are Significant Components of Tissue-Resident
Macrophages and Expand During Tumor Progression
To determine whether tissue-resident macrophages are derived from the adult
hematopoietic system, we performed lineage tracing using Flt3-Cre+/Lox-Stop-Lox (LSL)-YFP
reporter mice (Flt3-CreYFP). Flt3 is upregulated at the multipotent progenitor stages of
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hematopoietic stem cell (HSC) differentiation (Boyer et al., 2011). HSC-derived cells that have
gone through the Flt3+ stage become labeled as YFP-positive, whereas macrophages derived
from embryonic progenitors outside HSCs are YFP-negative (Schulz et al., 2012). To validate
this model, we analyzed circulating leukocytes and found that >95.5% of leukocytes in the blood,
including both Ly6CHi and Ly6CLow monocytes, were YFP-positive in both steady-state and
tumor-bearing mice (Figure 3.4A). As controls, we analyzed colon macrophages and brain
microglia. Consistent with previous reports (Bain et al., 2014; Ginhoux et al., 2010), in adult
mice (8-10 weeks old), 93% of the macrophages in the colon were YFP-positive and 98.8% of
brain microglia were YFP-negative (Figure 3.4B). In contrast, we observed heterogeneity of
macrophage ontogeny in pancreatic tissues, with 32.4% of tissue macrophages labeled as YFPnegative. To determine if this heterogeneity is retained in aged mice, we analyzed 15-month-old
Flt3-CreYFP reporter mice and found that 30% of the macrophages in the pancreas were still
YFP-negative (Figures 3.11A-B). These data suggest that embryonically derived pancreasresident macrophages persist with age.
To determine whether these YFP-negative macrophages persist during tumor progression,
we established orthotopic KPC tumors in Flt3-CreYFP reporter mice. Surprisingly, despite the
known contribution from circulating monocytes to the tumor macrophage pool, 35.4% of the
macrophages in these KPC tumors remained YFP-negative, similar to the frequency in normal
pancreas (Figure 3.4C-D). Even more strikingly, the number of YFP-negative macrophages was
elevated

by

>29-fold

in

tumors

compared

to

normal

pancreas

(Figure

3.4E).

Immunofluorescence analysis also identified clear subsets of both YFP-positive and YFPnegative macrophages in normal pancreas and KPC-derived tumors (Figure 3.4F). These data
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suggest that a significant portion of TAMs in PDAC tumors are derived independently of the
Flt3+ progenitors, and that these TAMs expand rapidly in number during tumor progression.
The presence of large numbers of YFP-negative macrophages suggests that many TAMs
could be derived during embryonic hematopoiesis. Alternatively, these cells could have
originated from adult HSCs without going through extensive Flt3+ stages. To distinguish
between these two possibilities, we treated Flt3-CreYFP mice with one dose of a CSF1R antibody
(αCSF1R) at 13.5 days post coitum (E13.5) (Hoeffel et al., 2015) to deplete macrophages
derived from embryonic sources. We then quantified the abundance of YFP-negative
macrophages in the pancreas of F1 progenies as they reached 6 weeks of age. Treatment with
αCSF1R on embryonic day E13.5 resulted in 80% reduction in the density of YFP-negative
macrophages in steady-state pancreas (Figure 3.4G). To further confirm the contribution of
embryonically derived macrophages to TAMs in PDAC, we orthotopically implanted KPC tumor
cells in adult mice following αCSF1R treatment on E13.5. Embryonic αCSF1R treatment
resulted in a 40-60% reduction in the number of macrophages in established tumors (Figure
3.4H). Additionally, the loss of embryonically derived macrophages led to delayed tumor
progression in two distinct syngeneic PDAC models (Figure 3.4I). Taken together these data
suggest that embryonically derived macrophages facilitate PDAC progression.
To further assess the specific contribution of embryonic hematopoietic progenitors to
PDAC TAMs, we administered one dose of tamoxifen in Csf1r-mer-iCre-mer; Rosa26-LSLtdTomato mice at E8.5, E9.5, E10.5, E11.5, or E13.5 to span yolk sac and fetal liver stages.
Using this model, we observed that HSC-derived circulating monocytes were labeled at all time
points later than E9.5 (Figures 3.12A-B). Using E8.5 or E9.5 tamoxifen pulsing, we observed
labeling in 4% and 10% of macrophages, respectively, in normal pancreas retained the label as
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mice reached 6 weeks of age (Figures 3.5A-B). To confirm this, we used Cx3cr1-CreERT2;
Rosa26-LSL-eYFP reporter mice. After administration of tamoxifen on E13.5 at fetal liver stage,
the majority of Ly6CHi monocytes are not labeled (Yona et al., 2013), but we also observed
significant labeling in pancreas tissue macrophages (Figures 3.12C). To assess if the
embryonically labeled macrophages would expand during tumor progression, we established
orthotopic Kras-INK (KI)-derived PDAC tumors in Csf1r-mer-iCre-mer/ LSL-tdTomato mice.
Consistent with results in Flt3-Cre reporter mice, tdTomato+ macrophages labeled with a
tamoxifen pulse at E8.5 or E9.5 expanded in number by 6.8- or 13.5-fold, respectively, during
PDAC tumor progression (Figures 3.5C). These data suggest that yolk sac-derived macrophages
are a significant source of tissue-resident macrophages that undergo significant numerical
expansion during tumor progression.
In both CSF1R- and CX3CR1-driven lineage-tracing models, we observed higher levels
of labeling in the MHCIILow macrophage subset (Figures 3.12D-E). Similarly, in the Flt3-Cre
reporter mice, significantly larger portions of YFP-negative macrophages constitute the
MHCIILow subset in both normal pancreas and PDAC tissues (Figures 3.11C-D). These results
further confirm that embryonically derived macrophages are preferentially but not exclusively
enriched in the MHCIILow macrophages. Interestingly, we found that in both HSC-derived and
embryonically derived TAMs, the MHCIILow subset experiences higher levels of hypoxia.
However, macrophage hypoxia level was independent of origin (Figure 3.11E-F). These data
suggest that macrophage origin might drive intrinsic differences in macrophage phenotype and
function that can be further molded by conditions in the tumor microenvironment.
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3.4.6 Embryonically Derived Macrophages Expand through in situ Proliferation
To determine if tissue-resident macrophages undergo expansion through local
proliferation, we analyzed Ki67 expression and short-term 5-Bromo-2'-deoxyuridine (BrdU)
incorporation in macrophages from normal pancreas and PDAC tissues. Analyses of normal
pancreas demonstrated that <1% of macrophages incorporated BrdU following a 3-hour pulse
and <3% were Ki67+ (Figure 3.6A-D). These data suggest that pancreas-resident macrophages
in steady state are mostly quiescent. On the other hand, >15% of TAMs in either autochthonous
KPC PDAC tissues or orthotopic KPC-1 tumors were Ki67+, and 3.5-4% were labeled with
BrdU within 3 hours (Figures 3.6A-D). Of note, the 3-hour pulse resulted in no detectable BrdU
signal in circulating monocytes (Figure 3.13A), suggesting that BrdU signals in pancreatic
macrophages reflect in situ proliferation. Confirming these data, immunofluorescence staining
also identified a significant portion of Ki67+F4/80+ cells in autochthonous KPC PDAC tissues
(Figure 3.6C), but not in normal pancreas. Interestingly, the majority of these Ki67+F4/80+ cells
localized to fibrotic tumor areas, whereas F4/80+ cells in the tumor nests were mostly Ki67
negative (Figures 3.6C and 3.13C). Consistent with this, macrophages cultured on high-density
collagen I gels had higher proliferation rates compared to those cultured on low-density collagen
(Figure 3.13D), suggesting that there may be cross talks between tumor fibrosis and proliferative
expansion of macrophages. Microarray analysis of TAMs from autochthonous KPC tumors
demonstrated distinct changes in cell cycle regulatory genes when compared to macrophages in
normal pancreas (Figure 3.6E). To assess if embryonically derived TAMs proliferate at higher
rates than HSC-derived TAMs, we stained for Ki67 in tumor-bearing Flt3-CreYFP mice.
Embryonically derived TAMs had a significantly higher frequency of Ki67 positivity than their
HSC-derived counterparts (Figure 3.6F). This increased level of Ki67 in embryonic TAMs was
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independent of their MHCII status (Figure 3.13B). In addition, transcriptional profiling by QPCR also identified significantly reduced level of genes that negatively regulate cell cycle
progression, such as Mafb and c-Maf, but higher levels of cell cycle promoting genes, such as
Jun and Ets2, in the YFP-negative TAM subset (Figure 3.6G). These data suggest that
macrophages in PDAC tissues up-regulate proliferative programs, perhaps in response to fibrosis,
and that embryonically derived macrophages proliferate at high levels to keep pace with tumor
progression.
We next sought to identity what signals sustain the survival of these TAM subsets in
PDAC tissues. We took a targeted approach and treated orthotopic PDAC-bearing Flt3-CreYFP
mice with neutralizing antibodies against CSF1 and CSF2, both of which have been implicated
in macrophage survival in mouse models of cancer (Hoeffel et al., 2015; Zhu et al., 2014).
Although CSF2 signal blockade did not change the number of TAMs, inhibition of CSF1
signaling led to a 48% reduction in the YFP-positive and a 75% reduction in the YFP-negative
macrophages (Figure 3.6H). These data suggest that CSF1 is important for the survival of both
TAM subsets, but embryonically derived macrophages are more sensitive.

3.4.7 Embryonically Derived TAMs Have a Distinct Pro-fibrotic Phenotype.
Having identified both embryonically derived and HSC-derived monocytes as sources of
TAMs in PDAC, we next asked whether distinct macrophage origins correlated with phenotypic
differences. Towards that end, we first performed flow cytometry analyses to compare the
expression of a panel of cell surface markers in TAM subsets using the Flt3-CreYFP mice. Both
subsets expressed similar levels of macrophage identity markers, including CD64, CD115, and
F4/80, whereas YFP-negative TAMs expressed lower levels of CD11b (Figures 3.7A and
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3.14A), consistent with previous reports of CD11b level in embryonically derived macrophages
under homeostatic conditions (Schulz et al., 2012). YFP-negative TAMs also expressed
significantly lower levels of MHCI and MHCII (Figure 3.7A). Similar differences were also
seen between the two macrophage subsets in normal pancreas (Figure 3.14B), which suggests
possibly inherent differences in antigen presentation activities. By contrast, co-stimulatory
molecules (CD80, CD86), T cell-activating molecules (CD40), and immune checkpoint
molecules (PDL1, PDL2, PD1) were expressed at comparable levels (Figure 3.7A).
Embryonically derived TAMs also expressed significantly higher levels of CX3CR1 and lower
levels of CD11a and CD49d (Figures 3.7A and 3.14C). Interestingly, despite the lack of
CXCR4 expression in either macrophage subset in the normal pancreas, CXCR4 was
significantly upregulated in TAMs, but only in the YFP-negative population (Figure 3.7A and
3.14B). Taken together, these data suggest that TAMs derived from different origins are
phenotypically distinct.
To gain further insight into potential functional differences between embryonically
derived and HSC-derived macrophages, we performed transcriptional profiling on macrophages
sorted from Flt3-CreYFP mice (Figures 3.7B and 3.14D). Only a modest number of genes were
expressed differentially between the YFP-positive and YFP-negative macrophages in steadystate pancreas tissue. However, 660 genes were differentially expressed (>1.5 fold, p<0.05)
between the two subsets in orthotopic KPC tumors, suggesting that TAMs of different origins
may have distinct functions in PDAC tumors. Using gene set enrichment analysis, we found that
the genes enriched in embryonic-derived macrophages showed a strong trend toward poor
survival when mapped to data sets from human PDAC patients (Figure 3.14E). Analysis of gene
ontogeny demonstrated that embryonically derived macrophages had a higher expression of
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molecules involved in extracellular matrix (ECM) deposition and/or remodeling (Figure 3.7C).
Indeed, molecules on top of the list of genes that were expressed at higher levels in
embryonically derived TAMs were mostly involved in ECM organization (Table 3.1). This
included genes encoding for ECM molecules (collagen isoforms, nidogen, tenascin C, and
elastin), ECM-producing enzymes (hyaluronan synthases 2 and 3), and ECM-remodeling
molecules (lysyl oxidase), which we validated using Q-PCR analyses in two independent
experiments (Figures 3.7D and 3.14F). To test if the expression of pro-fibrotic genes is related
to functional differences in ECM production, we isolated YFP-positive and YFP-negative TAMs
from Flt3-CreYFP mice and tested their ability to produce collagen ex vivo. Correlating with their
differential expression profiles, we found that embryonically derived TAMs could produce
significantly more Collagen I and IV (Figure 3.7F). To correlate these ex vivo results to in vivo
impact, we analyzed collagen density in PDAC tissue from mice treated on E13.5 with αCSF1R
or control IgGs and compared these results to CCR2-deficient mice. We found embryonic
macrophage depletion led to reduced collagen deposition. By contrast, CCR2-deficient mice had
slightly elevated collagen levels compared to control mice (Figure 3.14G). These data suggest
that macrophages of different origins have differential impacts on fibrosis.
To rule out the possibility that the identified YFP-negative cells contained fibroblasts
instead of macrophages, we compared cancer-associated fibroblasts (CAFs) to YFP-negative
TAMs. We found that CAFs expressed platelet-derived growth factor receptor-a (PDGFRa), but
not CD45, F4/80, or CD11b, whereas YFP-negative TAMs demonstrated the opposite pattern
(Figure 3.14H). Similarly, the mRNA expression levels of macrophage/myeloid identity genes
(Emr1, Itgam, Csf1r, Csf2r, and Cx3cr1) were comparable in both YFP-positive and YFPnegative TAMs, as determined by Q-PCR analysis, and were 10- to 1000-fold higher in both
	
  

122	
  

subsets of TAMs as compared to CAFs (Figure 3.14I). These data confirm that the YFPnegative cells were not fibroblasts but were a macrophage subset with a unique pro-fibrotic
phenotype. To evaluate how the pro-fibrotic gene signature in embryonically derived TAMs
differed from that in CAFs, we compared selected fibrosis genes by Q-PCR. As expected, CAFs
were the dominant producers of several isoforms of collagens (such as Col1a2 and Col3a1),
Elastin, and Sparc (Figure 3.14J). However, mRNA for other ECM molecules, such as Col6a1,
Nidogen, and Adamts12, were expressed at comparable levels. In contrast, embryonically derived
TAMs were the more dominant expressers of Col4a4, Col10a1, Col17a1, Col18a1, and Has3
(Figure 3.14J). Taken together, these data suggest that embryonically derived TAMs may be
more involved in “fine-tuning” fibrotic responses in PDAC tumors.
In contrast to pro-fibrotic genes, the levels of mRNA involved in class I and class II
antigen presentations (Erap1, Psme1, and Ciita) were higher in HSC-derived TAMs (Figure
3.7E). To test the antigen uptake capacity in TAMs subsets in vivo, we orthotopically implanted
mCherry+ KPC-1 PDAC cells and determined the mCherry positivity in TAMs. Although both
TAM subsets demonstrated potent capacity to uptake tumor antigen, the amount of antigen
uptake was >2-fold higher in HSC-derived TAMs compared to their embryonic counterparts
(Figure 3.7G). We next tested the ability of each TAM subset to present antigen (ovalbumin) to
OT1+ CD8+ T cells and found that HSC-derived (YFP+) TAMs were far more potent at antigen
presentation compared to their embryonically derived (YFP-) counterparts. In addition, HSCderived TAMs expressed significantly higher levels of Il12a, Il4, Ccl17, and Ifnb1 compared to
their embryonic counterparts (Figure 3.7E). Taken together, these data suggest that TAMs
derived from HSCs and embryonic sources likely play more potent roles in regulating adaptive
immunity and/or driving immune tolerance. This is consistent with previous reports showing that
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monocyte-derived TAMs regulate immunosuppression in PDAC models (Beatty et al., 2015;
Mitchem et al., 2013; Sanford et al., 2013) and in early phase clinical trials (Nywening et al.,
2016).

3.4.8 Subsets of TAMs in Human PDAC Tissue Resemble Murine Embryonically Derived
TAMs
To address whether the identification and characterization of embryonic TAMs in murine
PDAC models is relevant for human cancer, we took advantage of the observation that CXCR4
was almost exclusively upregulated in murine embryonic TAMs (Figure 3.7A). We first
evaluated human PDAC tissues for CXCR4+ TAMs and found that 10-40% of TAMs expressed
high levels of CXCR4 (Figure 3.7I). We also noted that these CXCR4+ TAMs expressed lower
levels of HLA-DR in eight out of nine patients evaluated (Figure 3.7J). These results are
consistent with our observation that CXCR4+ TAMs of embryonic origin expressed lower levels
of MHCII in murine PDAC models. To determine if this subset of human PDAC TAMs shared
the pro-fibrotic gene expression profile we identified in mice, we isolated CXCR4-positive and
negative TAMs from PDAC tissues from three untreated surgical patients and performed Q-PCR
analyses. Consistent with our animal model data, we found that CXCR4+ TAMs expressed
significantly higher levels of Collagens and ECM-modulating molecules compared to their
CXCR4-negative counterparts (Figure 3.7K). Collectively, these data suggest that CXCR4+
TAMs in human PDAC resemble the ECM regulatory phenotype of murine embryonically
derived PDAC TAMs.
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3.5 Discussion
Ontological origins of tissue macrophages vary among different tissues under steady state.
With the exception of brain and intestine, many other organs contain macrophages of different
origins co-existing within the tissue context. Consistent with previous reports (Calderon et al.,
2015), our study demonstrated that pancreas-associated macrophages contain cells derived from
both adult HSCs and embryonic hematopoietic sources. The precise nature of embryonic
hematopoietic progenitors that gave rise to these macrophages needs to be defined; likely sources
include yolk sac-derived erythro-myeloid progenitors (EMPs) (Gomez Perdiguero et al., 2015)
and EMP-derived fetal monocytes (Hoeffel et al., 2015). The origin of HSC-derived
macrophages in normal pancreas is also unclear; possible sources include fetal liver HSCs and
bone marrow HSC-derived monocytes that may populate the pancreas perinatally. Regardless of
developmental origin, significant portions of macrophages in the pancreatic stroma are likely
resident in the tissue without rapid replenishment from circulating monocytes. The majority of
pancreas-resident macrophages are quiescent under steady state, suggesting that these cells may
self-maintain through longevity. It is also important to note that the ontogeny of tissue-resident
macrophages is not static. Embryonically derived macrophages in multiple organs have shown
various degrees of replacement by monocytes with different kinetics (Bain et al., 2016; Ginhoux
and Guilliams, 2016; Molawi et al., 2014). Our study using aged mice demonstrated that
embryonically derived macrophages could persist long-term in the pancreas, despite potential
slow replacement by blood monocytes that we cannot rule out. It remains to be seen if and to
what extent could embryonically derived macrophages persist in aged human patients.
Fates of tissue-resident macrophages vary under different pathological conditions. For
example, liver resident Kupffer cells undergo necroptosis during Listeria monocytogenes
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infection, which recruits monocytes to replenish macrophages (Bleriot et al., 2015). On the other
hand, tissue macrophages undergo in situ proliferation during helminth infections (Jenkins et al.,
2011). Very few studies have looked at the fate of tissue-resident macrophages during cancer
progression. One report documented a loss of resident macrophages concomitant with the
increase in monocyte-derived TAMs in a breast cancer model (Franklin et al., 2014). On the
other hand, microglia were shown to be present in brain tumor models (Bowman et al., 2016;
Hambardzumyan et al., 2016). Here, we demonstrated that in PDAC, embryonically derived
tissue-resident macrophages not only persisted in the tissue, but also underwent significant
proliferative expansion to keep pace with tumor progression. TAMs in the PDAC tissues adopted
a transcriptional program to enhance proliferation, and embryonically derived tissue-resident
macrophages further enhanced their proliferative programs compared to the monocyte-derived
counterparts. Of note, PDAC also upregulated the proliferation of monocyte-derived
macrophages, similar to what is seen in other cancers and tissue repair (Franklin et al., 2014;
Wang and Kubes, 2016); though their proliferative activities were less robust than those in the
embryonically derived macrophages. Factors that sustain and promote in situ proliferation in
different TAM subsets, as well as the cellular sources of these factors, have yet to be identified.
It also remains to been seen to what extent would these observations hold true in other tumors or
if this feature is enriched in PDAC due to its uniquely fibrotic nature. One tumor type of interest
is pancreatic neuroendocrine tumors (PNET), which originate from the islets of Langerhans.
Under steady state, macrophages in the pancreatic islets are maintained by blood monocytes,
whereas stromal macrophages are embryonically derived and locally maintained (Calderon et al.,
2015). It would be interestingly to see whether PNET contrasts with PDAC and relies on
circulating monocytes to sustain TAMs in-spite of residing in the same tissue. Answers to these
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questions could provide insights into how we can therapeutically target TAM subset-specific
pathways in order to restrain the progression of different types of tumors even within the same
organ.
A highly debated question regarding macrophage ontogeny is the functional differences
between macrophages derived from distinct origins that are located within the same tissue
context. This question remains largely unsolved. A limited number of transcriptional studies
suggest that macrophages of different ontogeny demonstrate mostly overlapping transcriptional
profiles within the same tissue, at least in non-disease settings (Gibbings et al., 2015; Gundra et
al., 2014; van de Laar et al., 2016). Upon engraftment, circulating monocytes could also
replenish the resident macrophage pool and adopt a transcriptional profile similar to their
embryonically derived counterparts (Scott et al., 2016). These studies led to the assumption that
tissue environment, as opposed to ontogeny, is the main driver of macrophage functions. Indeed,
macrophages resident in different organs or at different niches within the same organ have
distinct transcriptional profiles, supporting the concept that tissue environment could educate
macrophages to adopt distinct functionalities (Gautier et al., 2012; Mass et al., 2016; Movahedi
et al., 2010; Ojalvo et al., 2009). However, our microarray data demonstrated that although gene
expression profiles of embryonically derived and HSC-derived macrophages are fairly similar in
the normal pancreatic tissue, their expression profiles and ex vivo functions are very distinct in
PDAC tissues. As a harbinger of this dynamic, CXCR4 is largely not expressed in macrophages
of either origin in the normal pancreas, but specifically upregulated in PDAC TAMs of
embryonic origin. These data suggest that origin may epigenetically poise macrophages to
differentially respond to inflammatory insults with distinct bioactivities, such as ECM
modulation or antigen processing/presentation. Future experiments are needed to determine
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which lineage commitment factors poise macrophages for differing functional responses during
tumor progression.
Our studies also demonstrate unique fibrosis-modulating functions in embryonically
derived TAMs. Macrophages are well known for their ability to promote fibrosis in multiple
physiological and pathological conditions, such as wound healing and cancer (Wynn and
Vannella, 2016). However, such activities are thought to be indirectly executed by activating
fibroblasts to lay down and remodel ECM. Here, our data suggest that subsets of macrophages
may fine-tune fibrosis by directly depositing and/or remodeling the ECM. Fibrosis is a hallmark
of PDAC, which imposes a major physical barrier that not only inhibits endogenous anti-tumor
immune responses but also deters effective delivery of chemo- and immune-therapies (Beatty et
al., 2011; Jiang et al., 2016). Although it has been demonstrated that tumor-derived factors
promote macrophage expansion and fibrosis, the initiation of these two pathological features
were considered to be independent of each other. Our data suggest these responses may be more
integrated. Corresponding with this idea, a recent report demonstrated that TAMs directly
construct ECM in colon cancer (Afik et al., 2016). Interestingly, such activities were carried out
by monocyte-derived TAMs in their model.
Strikingly, depletion of macrophage subsets had different impacts on tumor progression
in PDAC models. Loss of monocyte-derived macrophages had limited effects on tumor
progression, whereas depletion of tissue-resident macrophages significantly reduced tumor
growth and aggressivity/grade. These observations form a nice comparison to several other
tumor models, where the depletion of monocyte-derived macrophages inhibits tumor growth and
metastasis (Afik et al., 2016; Franklin et al., 2014; Qian et al., 2011). Although we cannot rule
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out the importance of monocyte-derived TAMs in the regulation of PDAC development, our data
suggest that tissue-resident macrophages are important in PDAC progression.
In summary, our study demonstrates that PDAC contains macrophages with
heterogeneous ontological origins. In addition to Ly6CHi monocytes, tissue-resident
macrophages derived from embryonic origin are also a major source of TAMs in murine models.
Embryonically derived macrophages expand in PDAC tissues through in situ proliferation and
exhibit a pro-fibrotic transcriptional profile, suggesting a potential role in fine-tuning fibrosis in
PDAC. We provide a new paradigm of macrophage heterogeneity under the tumor setting, which
may facilitate future investigations that ultimately improve therapeutics to target the “fibroinflammatory” microenvironment of PDAC and potentially other cancers.
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3.6 Figures and Tables
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Figure 3.1. Pancreatic Ductal Adenocarcinomas Are Highly Infiltrated with Macrophages.
(A) Representative images of human PDAC and adjacent normal pancreatic tissues assessed for
macrophage density (CD68, CD206, or CD163) and fibrosis (Sirius Red). Epithelial cells were
stained by pan-Keratin (PanK).
(B) Quantitation of CD68+ cells in human PDAC tissue vs. normal adjacent tissue from the same
surgical sample.
(C) Representative images of pancreas tissue from the p48-CRE/KrasG12D/p53flox/+ (KPC) mouse
model assessing macrophage infiltration (F4/80) and collagen density (Sirius Red).
(D) Representative flow cytometry plots showing gating strategy to identify macrophages in
autochthonous KPC tumors.
(E) Measurement of listed cell surface markers analyzed by flow cytometry and pre-gated on
macrophages as shown in (D).
(F) Quantification of macrophages by flow cytometry in normal pancreas tissues and advanced
KPC PDAC tissues (n=4-8/group).
(G) Kinetics of macrophage numbers assessed by flow cytometry in syngeneic orthotopic KPC-1
tumors. (n=4/group)
Data are shown as mean ± SEM and * denotes p<0.05 by t-test or Mann-Whitney test.
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Figure 3.2. Substantial Portions of Macrophages in Steady-State Pancreas and PDAC
Maintained Independently of Blood Monocytes.
(A) 3.5-month-old homozygous CD45.1 and CD45.2 (KPC or wild-type C57BL/6) mice were
surgically joined to create parabiotic pairs. Tissues were analyzed after 2 or 6 weeks of
parabiosis. Representative plots (6 weeks) of chimerism in indicated cell types are shown.
(B) Quantification of chimerism in (A); (n=6-16/group).
(C) MHCIIHi and MHCIILow composition of CD45.1+CD45.2(-)-derived TAMs in (B).
(D) C57BL/6J mice were lethally irradiated and adoptively transferred with bone marrow cells
from homozygous CD45.1 mice. Analysis of chimerism in several tissues after 6 weeks is
depicted.
(E) Quantification of chimerism in MHCIIHi and MHCIILow macrophage subsets in normal
pancreas in (D).
(F) Representative plots of (E).
(G) Autochthonous KPC mice bearing premalignant disease (3.5-month-old) were lethally
irradiated and adoptively transferred with bone marrow cells from CD45.1 mice. Tissues were
analyzed for chimerism after 6 weeks, when disease had progressed to full PDAC. Relative
CD45.1 and CD45.2 percentages analyzed by flow cytometry are depicted.
(H) Quantification of chimerism in MHCIIHi and MHCIILow TAMs in (G).
(I) Tumor-naïve mice and orthotopic KPC tumor-bearing mice were treated with clodronateloaded liposomes followed by i.v. injection of FITC-labeled beads. Tissue macrophages were
analyzed for FITC signal by flow cytometry after 24 hours.
(J) Representative flow cytometry plots of beads+ TAMs in orthotopic PDAC from (I).
(K) MHCIIHi and MHCIILow composition of beads+ TAMs from (I).
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Data are shown as mean ± SEM and * denotes p<0.05 by t-test.
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Figure 3.3. Tissue-Resident Macrophages Promote PDAC Progression.
(A-D) KPC cells were orthotopically implanted into CCR2+/- and CCR2-/- mice. Tumors were
processed on Day 12 for flow cytometry analysis.
(A) Blood was drawn from orthotopic KPC-2-bearing mice via intracardiac puncture. Monocytes
were assessed by flow cytometry (n=3-4/group).
(B) Frequency of macrophages orthotopic KPC-2 tissues of CCR2+/- and CCR2-/- mice.
(C) Frequency of MHCIIHi and Low TAM subsets assessed by flow cytometry in orthotopic KPC2 tumors. Representative plots of TAM subsets are shown (n=3-4/group).
(D) Wet weights of KPC-2 tumors in (B).
(E-H) KPC-2 cells were orthotopically implanted into Nur77+/- and Nur77-/- mice. Tumors were
processed on Day 13 for flow cytometry analysis (n=4/group normal, n=6-8/group of tumor
bearing).
(E) Blood was drawn from orthotopic PDAC-bearing mice via intracardiac puncture. Monocytes
were quantified.
(F) Quantity of macrophages in normal pancreas and orthotopic PDAC in Nur77+/- and Nur77-/mice.
(G) Representative plots of MHCIIHi and Low TAM subsets.
(H) Wet weights of KPC-2 tumors in (F).
(I-J) KPC-2-CBRLuc+ cells were orthotopically implanted into IgG/PBS- or αCSF1/clodronatetreated mice. Bioluminescence imaging (BLI) was used to measure tumor progression. Tumors
were processed on Day 12 for flow cytometry and tumor burden analyses.
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(I) Scheme of pancreas-resident macrophage depletion followed by orthotopic PDAC of KPC-2CBRLuc+ cells. Blood monocytes and pancreatic macrophage numbers before and after PDAC
implantation are shown.
(J) Tumor burden based on BLI and wet weight measurement.
(K) 2.5-month-old KPC or 1.0-month-old KPPC mice were treated with αCSF1/clodronate.
Tumor burden was analyzed at 4.5 or 2.0 month of age.
Data are shown as mean ± SEM and * denotes p<0.05 by t-test or Mann-Whitney test.
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Figure 3.4. Embryonically Derived Macrophages are Significant Components of TissueResident TAMs and Expand During PDAC Progression.
(A-C) KPC-1 cells were orthotopically implanted into Flt3-CreYFP mice. Indicated tissues were
analyzed by flow cytometry for YFP expression. Representative flow cytometry plots of YFP
signal in leukocytes from blood (A), macrophages from colon and brain (B), and macrophages in
normal pancreas and end stage PDAC tissues (C) are depicted.
(D) Quantifications of percentage of YFP-negativity in leukocytes from (A-C; n=7-22/group).
(E) Kinetics of YFP-negative macrophages quantity and density in orthotopic KPC-1 tumors.
(F) Representative immunofluorescence images of CD68 and YFP from (C). Inlets identify YFPpositive and YFP-negative macrophages.
(G) Flt3-CreYFP reporter mice were treated with αCSF1R on E13.5. Pancreas was isolated at 6
weeks of age. Density of YFP-negative macrophages was quantified (n=3-5/group).
(H) C57BL/6 mice were treated with αCSF1R or vehicle on E13.5. Orthotopic PDAC was
established at 6 weeks of age. TAMs were quantified after 12 days (n=5-6/group).
(I) Tumor burden from (H) was analyzed (n=6-9/group).
Data are shown as mean ± SEM and * denotes p<0.05 by t-test.
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Figure 3.5. Yolk Sac-Derived Macrophages Expand during PDAC Progression.
(A) Representative flow cytometry plot of tdTomato signals in the normal pancreas and
orthotopic KI tumors of adult mice upon E8.5 or E9.5 tamoxifen pulse.
(B) Percentage of indicated leukocytes that were labeled upon E8.5 or E9.5 tamoxifen pulse
(n=3-7/group).
(C) Absolute numbers of tdTomato+ macrophages in the normal pancreas and orthotopic KI
tumors (n=3-4/group).
Data are shown as mean ± SEM and * denotes p<0.05 by t-test.

	
  

141	
  

	
  

142	
  

Figure 3.6. Embryonically Derived Macrophages in PDAC Expand through in situ
Proliferation.
(A) Analysis of autochthonous KPC PDAC and normal pancreas tissues for BrdU+ macrophages.
Animals were injected with BrdU 3 hours prior to sacrifice. Representative plots are shown.
(B) Quantification of BrdU incorporation in (A).
(C) Representative immunofluorescence images of Ki67 and F4/80 staining in autochthonous
KPC tumors.
(D) Quantification of flow cytometry data for Ki67 and BrdU positivity in macrophages in
normal pancreas and orthotopic KPC-1 tumors (n=4-5/group).
(E) Heat map of cell cycle regulation genes assessed by array on RNA in macrophages isolated
from normal pancreas and autochthonous KPC PDAC tissues (n=6/group).
(F) Orthotopic KPC-1 tumors were established in Flt3-CreYFP reporter mice. Proliferation of
TAM subsets was analyzed by flow cytometry for Ki67.
(G) TAM subsets were sorted from orthotopic KPC-1 tumors in Flt3-CreYFP mice. Q-PCR
analyses were performed to quantify transcripts of proliferation regulation genes.
(H) Orthotopic KPC-1-bearing Flt3-CreYFP reporter mice were treated with three doses of aCSF1
or αCSF2 on Days 7, 11, and 14. TAM subsets were quantified on Day 15.
Data are shown as mean ± SEM and * denotes p<0.05 by t-test.
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Figure 3.7. Embryonically Derived TAMs Have Distinct Phenotypes and Functions that are
Recapitulated by Subsets of TAMs in Human PDAC.
(A) Flow cytometry analysis of orthotopic KPC-1 PDAC tissues in Flt3-CreYFP mice stained with
indicated antibodies and gated on TAMs (gray, isotype control; blue, YFP-negative TAMs; red
YFP-positive TAMs).
(B) YFP-positive and YFP-negative macrophages were sorted from normal pancreas or latestage orthotopic KPC-1 tumors of Flt3-CreYFP mice. RNA was extracted for microarray analyses.
Hierarchical clustering of genes that were differentially expressed between macrophage subsets
either in normal pancreas or PDAC is shown.
(C) Gene ontogeny analyses of molecules expressed at higher levels in YFP-negative TAMs.
(D-E) Q-PCR analyses of gene expression for molecules involved in ECM modification (D) or
immune modulation (E). Analysis was performed on RNA from sorted YFP+ and (-) TAMs from
Flt3-CreYFP mice bearing KCP-1 tumors (n=5/group). Genes were selected from the top
candidates in (B).
(F) Analysis of collagen production ex vivo by YFP+ and (-) TAMs sorted from orthotopic KPC1 PDAC tissues in Flt3-CreYFP mice. Collagen laydown was assessed after 36 hours by
immunofluorescence intensity. Experiments are representative of three independent repeats.
(G) Orthotopic tumors were established in Flt3-CreYFP reporter mice using KPC-1-mCherry+
tumor cells. TAMs were analyzed for mCherry positivity. Representative flow plots and mean
fluorescence intensity (MFI) are depicted (n=4/group).
(H) Analysis of antigen presentation to CD8+ T cells by YFP+ and (-) TAMs sorted from Flt3CreYFP mice bearing KPC-1 tumors. Antigen presentation was assessed by the ability of TAMs to
activate OT1 cells after SIINFEKL loading and measured by CFSE-dilution and/or
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CD44+/CD69+/CD62L- expression on T cells. Three independent sorting experiments are
depicted as paired analyses.
(I) Flow cytometry analysis of human PDAC tissues from surgical resections is depicted. The
percentage of CXCR4+ TAMs of total is shown for nine patients.
(J) Analysis of HLA-DR expression in CXCR4-positive and negative TAMs using data from (I).
A representative flow plot and MFI analysis in paired samples are depicted.
(K) Q-PCR analysis of mRNA from CXCR4-positive and negative TAMs sorted from human
PDAC tissues. Pro-fibrotic genes assessed were identified in (B), and analysis of paired isolates
from three patients is depicted. All graphs depict mean values +/- SEM and * denotes p<0.05 by
t-test, Mann-Whitney test, or Wilcoxon matched pairs rank test as appropriate for the data set.
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Figure 3.8, related to Figure 3.1. Macrophage Gating Strategy in Normal Pancreas and
Orthotopic Tumors.
(A) Representative flow cytometry plots showing gating strategy to identify macrophages in
normal pancreas.
(B) Representative flow cytometry plots showing gating strategy to identify macrophages in
orthotopic tumors established using KPC-1 cells.
(C) Measurement of listed surface markers analyzed by flow cytometry and pre-gated on
macrophages in orthotopic KPC-1 tumors as shown in (B). To confirm CX3CR1 antibody
staining, orthotopic KPC-1 tumors were established in CX3CR1gfp/gfp mice; Representative flow
cytometry plot of GFP signals in TAMs is shown. (representative of n=15).
(D) Representative flow cytometry plots of Zbtb46-GFP fluorescence in TAMs of orthotopic
KPC-1 tumors, brain microglia (CD45Low/CD11bHi/F4/80+), and splenic dendritic cells (DCs)
(CD45+/CD11c+/MHCII+/B220-/CD8+ or CD11b+). Mean fluorescence intensity (MFI) for each
cell population is calculated by deducting baseline MFI of isotype staining control from the MFI
of stained samples. (n=4-5/group, mean ± SEM).
(E) Measurement of listed surface markers in pancreatic dendritic cells (DCs) and macrophages
by flow cytometry.
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Figure 3.9, related to Figure 3.2. Substantial Portions of Macrophages in Normal Pancreas
and PDAC Self-Maintain Independently of Blood Monocytes.
(A-B) 3.5-month-old homozygous CD45.1 and CD45.2 (KPC or wild-type C57BL/6) mice were
surgically joined to create parabiotic pairs. Chimerism of indicated leukocytes were analyzed 2
weeks (A) or 6 weeks (B) after the establishment of parabiosis. (n=6-16/group, mean ± SEM).
(C) KPC-1 orthotopic tumor-bearing mice were treated with clodronate i.v. to deplete circulating
Ly6CLow monocytes, followed by retro-orbital injection of FITC-labeled latex beads.
Representative flow cytometry plots showing FITC signals in blood Ly6CHi monocytes 24 hours
after bead injection.
(D) Representative flow cytometry plots of beads+ TAMs in orthotopic KPC-1 tumors at
indicated time points (n=3/time point).
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Figure 3.10, related to Figure 3.3. Deficiencies in Tissue Resident Macrophages but Not in
Blood Monocytes Impact PDAC Tumor Burden.
(A) Representative quantification of blood monocyte frequency in tumor-bearing B6, CCR2-/and Nur77-/- mice. (n=3-5/group).
(B) Representative quantification of pancreatic macrophage frequency in tumor-free CCR2+/- and
CCR2-/- mice. (n=3/group).
(C) Orthotopic tumors were established in B6, CCR2+/- or CCR2-/- mice with 200,000 or 50,000
KPC-1 or KPC-2 cells. Frequencies or quantities of TAMs from 4 independent experiments were
analyzed at indicated time points after tumor implantation. Each bar graph represents an
independent experiment.
(D) Tumor burden analysis from (C).
(E) Orthotopic tumors were established in B6, Nur77+/-, or Nur77-/- mice (numbers and cell types
indicated). Tumor weights were measured at indicated time points. Each bar graph represents an
independent experiment.
(F) 8-week old C57BL/6 (left and middle) or Flt3-CreYFP (right) mice were treated with αCSF1
combined with clodronate as described in Experimental Approach. Orthotopic tumors were
subsequently established using KPC-2 or KPC-1 cells. Quantities of macrophages prior to or
after tumor establishment were assessed by flow cytometry. (n=3-4/data point)
(G) Tumor burden from (F) were analyzed by bioluminescence imaging (BLI) or wet tumor
weight. (n=4-5/data point/group)
Data are shown as mean ± SEM and ∗ denotes p<0.05 by t-test.
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Figure 3.11, related to Figure 3.4. Embryonically Derived Macrophages are Present in the
Pancreas and PDAC of Adult Mice and are Enriched in the MHCIILow Subset.
(A) Representative flow cytometry plots of YFP signals in pancreatic macrophages of 15-monthold tumor-free Flt3-CreYFP mice.
(B) Percentage of YFP-negativity in indicated leukocytes from 15-month-old tumor-free Flt3CreYFP mice. (n=3).
(C) Representative flow cytometry plots showing YFP and MHCII signals in macrophages from
normal pancreas of orthotopic KPC-1 tumors.
(D) Percentage of YFP-negativity in MHCIIHi and MHCIILow macrophage subsets in normal
pancreas and orthotopic KPC-1 tumors.
(E) Representative flow cytometry plots of pimonidazole (PIMO) signals in indicated TAM
subsets.
(F) MFI of PIMO signals in indicated TAM subsets from (E).
Data are shown as mean ± SEM and ∗ denotes p<0.05 by t-test.
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Figure 3.12, related to Figure 3.5. Yolk Sac and Fetal Liver Derived Pancreatic
Macrophages are Present in the Pancreas and PDAC of Adult Mice and are Enriched in
the MHCIILow Subset.
(A) Csf1r-Mer-iCre-Mer; Rosa26-LSL-tdTomato mice were treated with tamoxifen at indicated
time points. Labeling efficiency in indicated leukocyte populations was analyzed by flow
cytometry. (n=3-7/group)
(B) Kinetics of labeling efficiency in brain microglia, pancreas macrophages, and PDAC TAMs
from (A).
(C) Cx3cr1-CreERT2; Rosa26-LSL-eYFP mice were treated with tamoxifen at E13.5. Labeling
efficiency in indicated leukocyte populations was analyzed by flow cytometry. Representative
flow cytometry plots of YFP signals in pancreatic macrophages are shown.
(D) Labeling efficiency of CSF1R+ cells in pancreatic macrophage subsets from (A-B).
(E) Labeling efficiency of CX3CR1+ cells in pancreatic macrophage subsets from (C).
Data are shown as mean ± SEM and ∗ denotes p<0.05 by t-test.
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Figure 3.13, related to Figure 3.6. In Situ Proliferating Macrophages Localize in Proximity
to Fibrotic Tumor Areas.
(A) Representative flow cytometry plot showing 3-hour BrdU incorporation in blood Ly6CHi
monocytes.
(B) Percentage of Ki67 positivity in indicated TAM subsets of KPC-1 tumor-bearing Flt3-CreYFP
mice.
(C) Serial sections from autochthonous KPC tumors were stained for macrophages (F4/80) and
proliferation marker Ki67. Inlets demonstrate double positive cells. Fibrosis was assessed in the
adjacent section by Sirius Red staining.
(D) Bone marrow-derived macrophages were cultured on collagen I at different densities.
Percent of Ki67 positivity were quantified by immunofluorescence staining.
Data are shown as mean ± SEM and ∗ denotes p<0.05 by t-test.
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Figure 3.14, related to Figure 3.7. Embryonically Derived TAMs Have Distinct Surface
Marker Expression and Unique Pro-fibrotic Transcriptional Profile.
(A) MFI of indicated markers in TAMs from orthotopic KPC-1 tumors in Flt3-CreYFP mice.
Value is calculated by deducting baseline MFI of isotype staining control from the MFI of
stained samples.
(B) MFI of CXCR4 and MHCII in normal pancreatic macrophages. Representative histograms
are shown.
(C) MFI of CD11a and CD49d in TAMs from orthotopic KPC-1 tumors in Flt3-CreYFP mice.
Representative histograms are shown.
(D) Representative flow cytometry plots showing gating strategies used to sort YFP-positive and
-negative TAMs from Flt3-CreYFP mice.
(E) Kaplan-Meier analysis of patient cohorts stratified by expression level of genes that are
higher in Flt3-CreYFP-negative TAMs based on analysis in Figure 3.7B.
(F) Q-PCR analyses of indicated genes in Flt3-CreYFP-positive (red) and Flt3-CreYFP-negative (blue)
TAMs in a second repeat of sorting. (n=5/group for normal pancreas macrophages, n=6/group
for TAMs).
(G) Quantification of PDAC collagen density by image analysis of Trichrome or Sirus Red
staining on orthotopic KPC-2 tumors implanted in mice treated with anti-CD115 at E13.5 or
CCR2-/- mice or control mice.
(H) Expression of listed surface markers in cancer-associated fibroblasts (CAFs) (orange) and
TAMs (pink).
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(I) Q-PCR analyses of indicated genes coding for macrophage surface identity markers in
cancer-associated fibroblasts (CAFs) (orange), Flt3-CreYFP-positive (red) and Flt3-CreYFP-negative
(blue) TAMs. (n=6/group for TAMs)
(J) Q-PCR analyses of indicated genes coding for ECM production and modification molecules
in cancer-associated fibroblasts (CAFs) (orange) and Flt3-CreYFP-negative TAMs (blue). (n=6/group
for TAMs)
Data are shown as mean ± SEM and ∗ denotes p<0.05 by t-test.
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Table 3.1, Top 40 Genes Higher in the Flt3-CreYFP-Negative TAM subset on Microarray
Entrez Gene ID

Gene Symbol

16949
20319
14125
13078
12833
14107
17022
20716
107449
21923
12834
13179
109624
20692
12945
71228
218952
12873
50781
16948
18073
13602
18028
242608
16948
170643
19662
22601
67701
12111
69675
12831
17534
18596
17153
15228
239337
12842
17112
66773

Loxl1
Sfrp2
Fcer1a
Cyp1b1
Col6a1
Fat1
Lum
Serpina3n
Unc5b
Tnc
Col6a2
Dcn
Cald1
Sparc
Dmbt1
Dlg5
Fermt2
Cpa3
Dkk3
Lox
Nid1
Sparcl1
Nfib
Podn
Lox
Kirrel
Rbp4
Yap1
Wfdc2
Bgn
Pxdn
Col5a1
Mrc2
Pdgfrb
Mal
Foxg1
Adamts12
Col1a1
Tm4sf1
Gm17019

	
  

Fold
Change
(YFPNegative vs. -Positive)
63.289225
49.434489
47.168637
46.682438
44.095025
43.982448
43.106335
42.226946
37.411451
36.737766
33.948455
32.864451
32.081952
30.158108
29.555895
28.841214
28.552239
28.488505
28.452825
28.392067
26.763409
26.16561
24.737366
23.756922
23.563272
23.48621
23.361095
22.207021
22.1382
22.120345
22.116972
22.061485
21.234791
21.193765
21.021883
21.009472
20.932199
20.290887
19.497997
19.069459
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Adjusted p-Value
0.000875412
0.002976931
0.001479908
0.000577909
0.005380821
0.00067664
0.002411298
2.36575E-06
6.02918E-05
1.75967E-05
0.0107914
0.000918713
0.009871551
0.002911626
0.002827771
0.000450364
0.000900703
0.009611972
0.000765057
2.20501E-05
0.006042784
0.02195566
0.0450516
0.001129132
0.000163479
0.004143432
0.000281845
0.001841186
0.001520571
0.004549826
0.003057716
0.004469495
0.001029897
0.003426061
0.000893123
0.000115044
0.008746559
0.000281845
0.00545794
0.000785569

Table 3.2, Mouse Antibodies for Flow Cytometry and FACS
Antigen
B220
BrdU
CD3
CD11a
CD11b
CD16/CD32
CD19
CD40
CD45
CD45.1
CD45.2
CD49d
CD64
CD68
CD80
CD86
CD115

Clone
RA3-6B2
3D4
145-2C11
M17/4
M1/70
93
eBio1D3
1C10
30-F11
A20
104
R1-2
X54-5/7.1
FA-11
16-10A1
GL1
AFS98

CD124
CD206

mIL4R-M1
MR5D3
C068C2
SA011F11
2B11
BM8
C11
SolA15
16A8
HK1.4
1A8

CX3CR1
CXCR4
F4/80
Keratin
Ki67
Ly6C
Ly6G
MerTK
MHCI
MHCII
PD1
PDGFRα
PDL1
PDL2
SiglecF
Tie2
	
  

108928
DS5MMER
34-1-2S
M5/114.15.2
J43
APA5
MIH5
122
ES22-10D8
E50-2440
TEK4

Fluorophore
APC
FITC
APC, PerCP-Cy5.5
PE
Alexa700, PE-Cy7
Unconjugated
APC
PE-Cy5
PE-Cy7, APC-Cy7
APC
FITC
PE
PE
FITC
PE-Cy5
PE-Cy5
PE
BV605
PE
FITC
PE-Cy7
PE
PerCP-eFluor710
PE-Cy5, PE
Alexa488
FITC
BV605
PerCP-Cy5.5, Alexa488
PE
APC
PE
PE-Cy7
PE
eFluor450, APC-Cy7
PE
PE
PE
PE
APC, PE-Vio770
PE
PE
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Source
BioLegend
BD Bioscience
eBioscience
BioLegend
eBioscience
eBioscience
eBioscience
eBioscience
eBioscience
eBioscience
eBioscience
BioLegend
eBioscience
eBioscience
eBioscience
eBioscience
eBioscience
BioLegend
BD Biosciences
AbD Serotec
BioLegend
BioLegend
eBioscience
eBioscience
Cell Signaling
eBioscience
BioLegend
eBioscience
eBioscience
BioLegend
R&D
eBioscience
eBioscience
eBioscience
eBioscience
eBioscience
eBioscience
eBioscience
Miltenyi
BD Biosciences
BioLegend

Table 3.3, Antibodies for Immunofluorescence Staining
Antigen
CD68
CD163
CD206
Collagen I
Collagen IV
CXCR4
F4/80
Ki67
Pan-Keratin

	
  

Clone
KP-1
Polyclonal Ab125212
EPR19518
Polyclonal Ab64693
3G3
Polyclonal Ab6586
D4Z7W
BM8
MIB-1
Polyclonal Ab15580
C11

Species
Mouse anti-human
Rabbit anti-mouse
Rabbit anti-human
Rabbit anti-human
Rabbit anti-mouse
Mouse anti-mouse
Rabbit anti-human/mouse
Rat anti-mouse
Mouse anti-human
Rabbit anti-mouse
Anti-Human/Mouse
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Source
NeoMarkers
Abcam
Abcam
Abcam
Abcam
Abcam
Cell Signaling
eBioscience
DaKo
Abcam
Cell Signaling

Table 3.4. Human Antibodies for Flow Cytometry and FACS
Antigen
CD3
CD11b
CD14
CD16
CD19
CD45
CD115
CXCR4

Clone
HIT3a
ICRF44
61D3
3G8
HIB19
2D1
12-3A3-1B10
12G5

HLA-DR

L243

	
  

Fluorophores
PE
Alexa488
Qdot605
PE
PE
APC-Cy7
PE-Cy7
Alexa488
PerCP-Cy5.5
eFluor450
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Source
BD Biosciences
BioLegend
eBioscience
BD Biosciences
BD Biosciences
BD Biosciences
eBioscience
R&D Systems
eBioscience
eBioscience

Chapter 4: Future Directions

4.1 Reprogramming myeloid responses to improve cancer immunotherapies
Therapeutics that activates anti-tumor immune responses has demonstrated significant
potential for the treatment of solid tumors. One of the most promising strategies targets immune
checkpoint molecules, such as programmed death 1 (PD1) or cytotoxic T lymphocyte-associated
antigen 4 (CTLA4) (Simpson et al., 2013). These immune checkpoint molecules counteract proinflammatory signals and block anti-tumor T cell activities. The potential of this type of
strategies was demonstrated by the efficacy of CTLA4 antagonistic antibody, ipilimumab, in the
treatment of subsets of metastatic melanoma (Hodi et al., 2010), as well as recent FDA approval
of PD1 for the same indication. Another category of immunotherapies involves tumor
vaccination through adoptive transfer of tumor antigen-specific T cells or dendritic cells
(Rosenberg et al., 2008). An example is Sipuleucel-T, an autologous dendritic cell-based
vaccination designed to activate T cells targeting a prostate cancer antigen, which significantly
improved patient overall survival in a phase III trial (Kantoff et al., 2010). Despite clear efficacy
in subsets of human cancer, these approaches are not effective in all patients or all cancer types.
For example, although ipilimumab achieved impressive response rates in melanoma patients, it
failed as a monotherapy to improve clinical outcome of patients with pancreatic cancer (Royal et
al., 2010).
One possible explanation for the lack of responses in many patients to immunotherapy is
the presence of a suppressive immune microenvironment. While tumor antigen-specific T cells
may be present in many cancers, the immune infiltrate is often dominated by various subsets of
myeloid cells. Tumor-infiltrating suppressive myeloid cells include macrophages, immature
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dendritic cells, and monocytic or granulocytic myeloid-derived suppressor cells (MDSCs). These
suppressive cells can silence adaptive immune responses by blocking the recruitment of
cytotoxic T lymphocytes (CTLs) to the tumor tissue, metabolically inhibiting CTL functions,
chemically modifying T cell receptors to hinder the recognition of tumor antigens, and/or
amplifying immune suppression via the expansion of regulatory T cells (Gabrilovich and Nagaraj,
2009; Qian and Pollard, 2010). Altogether, these myeloid cell activities can allow tumor cells to
evade endogenous and treatment-elicited immune surveillance. Therefore, these subsets of
suppressive myeloid cells could impose significant limitations on efficient immunotherapies
(Figure 4.1). Correspondingly, strategies to manipulate suppressive myeloid cells may also
provide opportunities to improve the efficacy of immunotherapy. Several recent studies
demonstrated that combining therapeutics that alleviates immune suppression by targeting
myeloid cell activities could improve the outcome of immunotherapy in mouse models.
Work from our own group assessed if targeting tumor-associated macrophages (TAMs)
could mitigate immune suppression and improve immunotherapy in pancreatic ductal
adenocarcinoma (PDAC) models (Zhu et al., 2014). We targeted TAMs through the inhibition of
macrophage colony-stimulating factor receptor (CSF1R) signaling, which plays an essential role
in macrophage differentiation, trafficking, and survival. Blockade of CSF1R signaling not only
reduced the total number of suppressive macrophages in the tumor tissue, but also reprogrammed
the remaining TAMs to support anti-tumor T cell responses, as shown by elevated interferon
expression, reduced immunosuppressive activities, and improved antigen presentation capacity
in the remaining TAMs. One unwanted consequence of CSF1R signal blockade is the
upregulation of programmed death ligand 1 (PDL1) in tumor cells and CTLA4 in T cells, which
potentially poses a significant limitation on the efficacy of CSF1R blockade. However, this may
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also provide an opportunity to convert tumors that are unresponsive to PD1/CTLA4 antagonists
to be more sensitive to checkpoint-based immunotherapeutics. Based on this rationale, we
designed a combination therapy by coupling CSF1/CSF1R signal blockade with immune
checkpoint antagonists in murine PDAC models. While checkpoint inhibitors alone achieved
limited efficacy in restraining tumor growth, the addition of CSF1R blockade markedly
improved the efficacy of PD1 and CTLA4 antagonists and led to regression of well-established
tumors (Zhu et al., 2014). These data demonstrated that CSF1R signal blockade could render
tumors more responsive to checkpoint antagonist-based therapies. Similarly, work by Mok et al.
showed that targeting TAMs through CSF1R blockade could also enhance the efficacy of
adoptive cell transfer (ACT)-based immunotherapy to reduce tumor burden in a mouse
melanoma model (Mok et al., 2014). Interestingly, these tumor restraining effects correlated with
increased expansion of adoptively transferred T cells both in the tumor and in peripheral
lymphoid tissues, suggesting that reprograming myeloid responses could lead to increased antitumor T cell function systemically. Taken together, these studies indicate that mitigation of
immune suppression through depletion or reprogramming of TAMs could enhance the clinical
outcomes of checkpoint-based therapeutics and adoptive cell transfer-based immunotherapies.
It is important to note that innate immune cells other than macrophages are also
promising targets. Examples include neutrophils, which are similarly abundant in many types of
cancers. In a syngeneic murine rhabdomyosarcoma model, Highfill et al. demonstrated that an
immunosuppressive microenvironment driven by granulocytic MDSC populations suppresses the
efficacy of anti-PD1 treatment (Highfill et al., 2014). In human sarcoma patients and mouse
models, tumor cells often overexpress a family of C-X-C motif chemokines, including CXCL1, 2,
and 8. Their predominant receptor, CXCR2, is expressed on granulocytes and promotes
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granulocytic MDSC trafficking into tumor sites. Inhibition of CXCR2 signaling blocked the
recruitment of granulocytic MDSCs to the tumor site and significantly enhanced the efficacy of
PD1 blockade. These data suggest that responses to immune checkpoint blockade are limited by
the suppressive microenvironment driven by granulocytes, and that alleviation of this
suppression could improve the efficacy of checkpoint-based therapies.
In conclusion, the suppressive tumor microenvironment driven by myeloid cells may
pose a major limitation on the efficiency of immunotherapy. Therefore, combining
immunotherapy with strategies that reprogram the suppressive tumor microenvironment holds
significant promises in cancer treatment (Figure 4.1). Development of such strategies will
require careful evaluation, as tumor cells, immune responses, and chosen therapeutic strategies
all interact in a complex and dynamic manner. Future work is needed to determine which
myeloid populations mediate suppression in specific tumor types, and what immunotherapeutic
strategies are optimal for combination.

4.2 Regulation of tissue resident macrophages
Having identified the contribution of pancreas resident macrophages to TAM populations
in PDAC, the logical next question is how we can target these cells to improve cancer treatment.
Solution to this question relies on better understanding of the basic biological activities of tissue
resident macrophages.
Tissue resident macrophages face two major challenges throughout the life of an
organism. First, they need to self-maintain long-term both during homeostatic conditions and
during aging. Second, they need to be able to expand to meet the proliferative demands upon
pathological challenges, exemplified by the case of tumor development. To persist with aging,
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tissue resident macrophages could be replenished through self-renewal. However, based on
propidium iodine staining and BrdU incorporation assays, we saw very minimal level of
apoptosis and proliferation in pancreas resident macrophages under homeostatic conditions.
While low level of “tonic” proliferation could sustain long-term self-renewal, this could also
suggest a second possibility that tissue resident macrophages persist through longevity. Further
experiments are needed to distinguish between these two possibilities. One approach would be to
perform a pulse chase experiment, such as BrdU or doxycycline-inducible H2B-GFP pulse.
During the extended pulse period in young adult mice, tissue resident cells will be labeled as
BrdU-or GFP-positive. The dilution or retention of the BrdU/GFP signals would tell us whether
proliferation or longevity is responsible for the maintenance of tissue resident macrophages
during aging.
On the other hand, embryonically derived macrophages dramatically enhance their
proliferative activities during tumor challenge. Concomitantly, molecules involved in both
extrinsic and intrinsic apoptosis pathways are upregulated, leading to elevated level of apoptosis.
This suggests that as embryonically derived macrophages expand through in situ proliferation,
these cells achieve high turnover rates at the expense of the longevity machinery. It is important
to note that we only observed proliferation in a small fraction of tumor-associated macrophages.
This leads us to ask: during tumor progression, is the proliferative activity restricted to a small
subset of macrophages with progenitor-like properties, or is the macrophage pool simply a
uniform collection of terminally differentiated cells that undergo proliferation in a stochastic
manner? The current paradigm supports the latter, despite the lack of sufficient number of
studies to support these claims. Hashimoto et al. attempted to address this question using a
combination of a diphtheria toxin (DT)-mediated macrophage double depletion model with BrdU
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pulse-chase experiment. They treated CD169-DTR (diphtheria toxin receptor) with DT to deplete
lung resident macrophages, and treated mice with daily doses of BrdU for 11 days, at the end of
which the lung macrophage numbers recovered to pre-treatment level. Following a BrdU-free
chase period, they treated mice again with one dose of DT, and analyzed cell cycle status 2 days
later based on Ki67 staining. The prediction was that if there were progenitor-like cells within
the macrophage population, the Ki67 positive cells, which indicate cell repopulation during the
second recovery, would be restricted to the BrdU-labeled subset, i.e. cells that have proliferated
during the first recovery. On contrary, if macrophages stochastically proliferate to repopulate, a
fraction of Ki67-positive cells could be observed in both the BrdU-labeled and BrdU-negative
cells. Indeed, the latter is what they observed, suggesting that lung macrophages proliferate in a
stochastic model to repopulate, at least in this model (Hashimoto et al., 2013). Similarly, in a
CX3CR1-CreER-based pulse-chase experiment, Bruttger et al. demonstrated that upon depletion
using the DTR system, microglia repopulate possibly in a stochastic manner from a pre-existing
population labeled by tamoxifen (Bruttger et al., 2015). On the contrary, in a different depletion
experiment using CSF1R blockade, Elmore et al. showed that CX3CR1+ microglia repopulate
through in situ proliferation of a CX3CR1- progenitor population (Elmore et al., 2014). Further
characterization showed the expression of Nestin and IB4 in these population, which are markers
not associated with microglia. Despite being positive for IBA1, which indicates microglia
identity, these progenitor-like cells also express c-Kit and CD34, which are expressed in
hematopoietic stem and progenitor cells. This study showed the possible existence of a
progenitor subset that is capable of sustaining tissue macrophages, at least during the recovery of
these cells.
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In murine pancreatic ductal adenocarcinoma models, not all macrophages seem to expand
during tumor progression. In the CSF1R-mer-iCre-mer; Rosa26-LSL-tdTomato lineage tracing
model, yolk sac-derived macrophages can be labeled upon tamoxifen induction on E8.5 or E9.5.
Labeled cells persist in adult mice and further expand numerically in established tumors
(Figures 3.5 and 3.12). However, in the CX3CR1-CreER; Rosa26-LSL-eYFP model, E13.5
tamoxifen treatment led to the labeling of a significant percentage of macrophages in normal
pancreas of adult mice. However, the labeled population was dramatically decreased. Similarly,
if we treat mice of this genotype in adulthood with 30 days of tamoxifen labeling followed by
tumor implantation, the number of tamoxifen labeled macrophages was decreased in established
tumors. This suggests the possibility that a population of CX3CR1Low/Neg macrophages residing
the pancreas actively proliferated during tumor progression and replaced the CX3CR1Hi subset.
Further experiments are needed to address the possibility that a macrophage progenitor subset is
responsible for the expansion of tissue resident macrophages during PDAC progression.
In order to target tissue resident macrophages, we need to understand what signals
regulate their proliferation, and what stromal components produce these signals. These signals
require tight regulation for several reasons. First, these signals need to be inhibited at steady state,
so that the cells do not prematurely exhaust their proliferative potential that precludes their
persistence with aging. Second, these signals need to be recognized to activate division cycles
before the proliferative demands are overwhelmed. Preliminary data demonstrate that loss of
microbiota induces the expansion of macrophage numbers in normal pancreas (not shown),
suggesting that signaling pathways downstream of certain pattern recognition receptors could
mediate the quiescence of tissue resident macrophages. Alternatively, microbiota could educate
some other circulating leukocytes, which then suppress the proliferative activities of pancreas
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resident macrophages. It would be interesting to see if microbiota is altered in PDAC-bearing
mice to change the in situ proliferation of embryonically derived TAMs.
Microarray analyses of embryonically derived and hematopoietic stem cell-derived
macrophages in normal pancreas and PDAC also demonstrated potential signaling pathways that
mediate macrophage proliferation. A number of receptors are upregulated in the embryonically
derived macrophages, including I-7 receptor, Frizzled B, cKit, CD44, CXCR4, CXCR7, CCR2,
Endothelin receptor A, Ephrin A2, TGF beta receptor 1, nuclear hormone receptors (NR4A1,
NR4A3, Retinoic acid receptor alpha 2), and GPR132. Comparison between embryonically
derived and HSC-derived TAMs demonstrated that embryonically derived TAMs have higher
level of TGF beta-receptor 3, FGF receptor like-1, Frizzled 1, and N-cadherin genes.
Interestingly, among the genes in the embryonic macrophages that are upregulated by the tumor,
three genes remained higher than their monocyte-derived TAM counterparts: PDGF receptor
beta, Frizzled 4, and secreted Frizzled-related protein 2 (Sfrp2). Both Frizzled 4 and Sfrp2 are
involved in Wnt signaling pathways. The identification of interesting targets suggests that we
could explore the potential relevance of PDGF and Wnt signaling pathways in the regulation of
TAM proliferation.
Lastly, it is important to note that the pathways that mediate TAM proliferation and
functionality may be uncoupled. CXCR4 is a unique marker of embryonically derived
macrophages, and its specificity is only manifested in PDAC but not normal pancreas. Treatment
of orthotopic PDAC-bearing mice did not alter TAM numbers or proliferation (data not shown).
However, it would be interesting to see if CXCR4 signaling is involved in shaping the functions
of the embryonically derived TAM subset.
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4.3 Targeting the cancer cell-macrophage-fibrosis triad
As we develop therapeutic strategies to target the cancer microenvironment, it is
important to note that not all tumor types are created equal. Each tumor has its unique stromal
structure that needs to be considered.
Two hallmarks of pancreatic ductal adenocarcinoma are the extensive myeloid infiltration
and dense desmoplastic reactions characterized by high level of fibrosis. High levels of
macrophage infiltration predict worse survival duration for PDAC patients (DeNardo et al.,
2011; Ino et al., 2013), making them a good therapeutic target. Indeed, depletion of TAMs in
murine models of PDAC decreased tumor infiltrating cells, relieved immunosuppression, and
improved responses to both chemotherapies and checkpoint-based immune therapies (Mitchem
et al., 2013; Zhu et al., 2014). On the other hand, fibrosis is considered to be another major
barrier of PDAC treatment. While fibrosis was originally considered to provide a mechanical
encapsulation that contains the primary tumor and prevents its spread, high level of fibrosis was
later found to negatively correlate with patient outcome. Excessive amount of fibrosis increases
interstitial fluid pressures, induces collapses of vasculature, and presents major physical barriers
to perfusion and diffusion of small molecule-based therapeutics (Provenzano et al., 2012).
Therefore, alleviation of fibrotic elements in the stroma, by targeting hyaluronan acid for
example, enhances the delivery of chemotherapies and improves overall survival in preclinical
mouse models. Alternatively, targeting tumor cell-intrinsic pathways, such as the focal adhesion
kinase pathway, to reduce fibrosis also improves chemotherapy and checkpoint-based and
adoptive cell transfer-based immunotherapies (Jiang et al., 2016). It is important to note that
while fibroblast cells are the major source of fibrosis, simply stripping fibroblasts may not
generate favorable outcome (Ozdemir et al., 2014). This could be due to the heterogeneity in the
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quality of fibrosis: certain configurations of extracellular matrix structure could be necessary for
anti-tumor activities. Therefore, it may be more favorable to reprogram tumor cells or fibroblasts
to alleviate fibrosis, or alter the qualities of the ECM components. It would be interesting to see
if macrophages could serve as a target during these processes. Our study demonstrated that
myeloid cells, in particular tissue resident macrophages of embryonic origin, are involved in the
modulation of fibrosis. Fibrosis, in turn, could serve as a positive feedback loop to enhance the in
situ proliferation of tissue resident macrophages. Therefore, it is possible to foresee a
combination treatment option that combines the reprogramming of macrophages with the
alleviation of desmoplasia.

4.4 Targeting the hematopoietic system to optimize tumor immunity
As we expand our knowledge of the tumor immune microenvironment, it is important to
remind ourselves that the local immune microenvironment likely results from a systemic level of
immune responses. Immune cells are not generated in isolation, but are provided by the
hematopoietic system at different stages in various lymphoid organs, such as bone marrow,
spleen, and embryonic organs including yolk sac and fetal liver. This is not only true in mouse
models but also observed in human patients: patients not only show enhanced level of immune
infiltration in the tumor tissue, but also have elevated level of circulating immune cells and
increased production in the bone marrow. Change in the qualities of systemic immune cell
production is also seen in the hematopoietic system, as shown by the expansion of myeloid
progenitors at the expense of lymphoid production (Casbon et al., 2015), which leads to
increased myeloid-mediated immunosuppression coupled with impaired adaptive T cell
cytotoxicity. Therefore, it is important to study how the hematopoietic differentiation pathways
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are skewed in tumors, and how we can target these processes to combat cancer. Interestingly,
bias towards myeloid expansion at the cost of lymphopoiesis is also seen during aging,
suggesting the possibility that this skewed hematopoiesis during aging could contribute to cancer
initiation by promoting chronic inflammation (Akunuru and Geiger, 2016; Geiger et al., 2013).
In addition, knowledge of how tumors communicate with distant sites such as the bone marrow
to modulate the immune system on an organismal level is still lacking. Such studies could
provide insights into whether we can engineer an immune system from the source, i.e.
hematopoietic stem and progenitor cells, and provide novel options that can further improve
current immunotherapeutics.
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Figure 4.1. Reprogramming of the myeloid responses to enhance anti-tumor immunity.
Tumor tissues contain extensive infiltration of suppressive myeloid cells, such as tumorassociated macrophages (TAMs), immature dendritic cells (DCs), and granulocytic myeloidderived suppressor cells (G-MDSCs), which inhibit anti-tumor activities of cytotoxic T
lymphocytes (CTLs). Strategies to alleviate immune suppression mediated by these myeloid cells,
such as using CSF1R inhibition or CXCR1/2 signal blockade, could reprogram these myeloid
cells to activate the adaptive immune system and enhance the efficacy of immunotherapeutics to
eliminate tumor cells.
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